


**Committee on Energy and Commerce**  
**U.S. House of Representatives**  
Witness Disclosure Requirement - "Truth in Testimony"  
Required by House Rule XI, Clause 2(g)(5)

1. Your Name: <b>Jeffrey A. Lieberman, M.D.</b>		
2. Your Title: <b>Chairman, Dept of Psychiatry - College of Physicians + Surgeons</b> <b>Director, NYSP / Psychiatrist in Chief, Columbia University - NY Presbyterian Hospital</b>		
3. The Entity(ies) You are Representing: <b>Columbia University / New York - Presbyterian Hospital</b>		
4. Are you testifying on behalf of the Federal, or a State or local government entity?	Yes	No <input checked="" type="checkbox"/>
5. Please list any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed.  <b>See attached</b>		
6. Please attach your curriculum vitae to your completed disclosure form.  <b>See attached</b>		

Signature: 

Date: 6/12/15

**Question 5: List any Federal grants or contracts, or contracts or payments originating with a foreign government, that you or the entity(ies) you represent have received on or after January 1, 2013. Only grants, contracts, or payments related to the subject matter of the hearing must be listed**

**Federal: Current**

Project PI:	Lieberman, J. A.	\$761,756	0.60 Calendar
Project #	HHSN27100005	9/1/14-4/30/15	
Source:	NIH-NIMH		
Title:	mGluR5 Cntnap2 Study/HHSN2712012000071 FAST-PS		
Major Goals:	This project seeks to verify overexpression of mGluR5 in Old-Order Amish individuals in a CNTNAP2 (Contactin-associated protein-like 2, also known as CASPR2) gene mutation.		

Project PI:	Lieberman, J. A.	\$1,098,271	0.60 Calendar
Project #	HHSN2710003	8/29/13-4/28/15	
Source:	NIH-NIMH		
Title:	Biomarker Validation Study Task/HHSN2712012000071 FAST-PS		
Major Goals:	Feasibility study to evaluate the ability of an mGluR2/3 agonist to reverse ketamine-induced GLX MRS, 13C MRS, Bold fMRI, and EEG alterations in healthy humans.		

Project Role:	Lieberman J. A. (Co-Investigator, Columbia University Subcontract PI)	\$312,797	0.60 Calendar
Project #	R01MH097799 (Siever)	4/1/13-2/28/18	
Source:	NIH-NIMH		
Title:	A D1 Agonist for Working Memory Enhancement in the Schizophrenia Spectrum		
Major Goals:	The aim of the study is to evaluate in a random double blind design the effectiveness of DAR-0100A to improve cognitive performance		

Project PI	Lieberman, J. A.	\$112,389	1.20 Calendar
Project #	HSS-NIH-DA-2012-242	09/24/12-09/14/15	
Source:	NIH/NIMH		
Title:	New Experimental Medicine Studies: Fast-Fail Trials in Psychotic Spectrum Disorders (FAST-PS)		
Major Goals:	Infrastructure to allow for the expeditious performance of small-scale Phase I and/or Phase IIa clinical trials (e.g., FIH, POCM, POC) to demonstrate target engagement, safety, and early signs of efficacy of promising interventions in healthy subjects and/or a well-characterized cohort of patients with clinical dimensions of psychopathology associated with traditional psychotic spectrum disorders.		

Project Role:	Lieberman, J. A. (Co-Investigator, RFMH Subcontract PI)	\$254,380	0.07 Calendar
Project #	R01NS076277 (Marshall)	4/1/12-3/31/17	
Source:	NIH-NINDS		
Title:	Blood Flow and Cognition in Asymptomatic Carotid Artery Disease		
Major Goals:	Demonstrating the link between cerebral blood flow dysregulation and cognitive impairment could lead to a major shift in the treatment algorithms of carotid artery disease affecting tens of thousands of individuals in the US each year.		

Project Role:	Lieberman J. A. (Co-Investigator)	\$2,735,154	0.60 Calendar
---------------	-----------------------------------	-------------	---------------

Project #	1R01MH093398-01A1 (Small)	09/22/11-05/31/16	
Source:	NIH/NIMH		
Title:	Longitudinal Imaging in Patients at Clinical Risk for Psychosis		
Goals:	The goal of this study is to use two variants of functional brain imaging that can detect disease-associated dysfunction in small regions of the brain and apply this to patients at clinical risk for psychosis who are followed prospectively for clinical and brain imaging outcomes. The main project goal is to definitively test the hypothesis of hippocampal hyperfunction as a pathogenic driver in schizophrenia and related disorders.		

Project PI:	Lieberman, J.A.	\$592,339	0.60 Calendar
Project #	OT-1432	02/15/11-11/30/15	
Source:	The Stanley Medial Research Institute		
Title:	BH4 Treatment in Schizophrenia		
Major Goals:	To evaluate an anticipated clinical response to BH4 treatment including negative symptoms and cognitive deficits. Evaluate the safety of 6R-BH4-treatment for patients with schizophrenia and the relationship of changes in plasma BH4 levels and efficacy outcomes.		

---

Project Role:	Lieberman, J. A. (Co-Investigator)	\$1,344,509	1.80 Calendar
Project #	1P50MH086404-01A1 (Abi-Dargham)	07/01/10-03/31/15	
Source:	NIH/NIMH		
Title:	Dopamine Dysfunction in Schizophrenia		
Major Goals:	The overall goal of this Center is to use clinical imaging, epigenetic and transgenic animal models in mice and rhesus monkeys to test the hypothesis that striatal dopaminergic hyperactivity during development leads to prefrontal cortical dopamine (DA) dysfunction in schizophrenia (SCZ) and the cognitive deficits that characterize the disorder.		

Project Role:	Lieberman, J. A. (Co-Investigator)	\$8,947,060	0.36 Calendar
Project #	HHSN-271-2009-00020C (Dixon)	07/09/09-03/31/14	
Source:	NIH/NIMH		
Title:	Recovery After an Initial Schizophrenia Episode (RAISE)		
Major Goals:	The RAISE initiative from NIMH seeks to fundamentally change the trajectory and prognosis of schizophrenia through coordinated and aggressive treatment in the earliest stages of illness.		

Project Role:	Lieberman J. A. (Co-Investigator, Subcontract with Columbia)	\$2,635,450	0.12 Calendar
Project #	7R01MH081107-02 (Stroup)	07/09/09-03/31/14	
Source:	NIH/NIMH		
Title:	A Comparison of Long-Acting Injectable Medications for Schizophrenia (ACLAIMS)		
Major Goals:	The aim of this study is to compare effectiveness, cost and tolerability of two long acting injectable antipsychotics in patients with schizophrenia or schizoaffective disorder.		

Project PI:	Lieberman, J.A.	\$468,424	2.4 Calendar
Project #	1 U01 MH076544-01	09/30/05-03/31/13	
Source:	NIH/NIMH		
Title:	Pharmacologic and Clinical testing of a D1 Agonist for Neuropsychiatric Disorders		
Major Goals:	This proposal is a joint collaboration between an academic institution, Columbia University, a pharmaceutical company, as well as many outstanding scientists from the community at large, to conduct a proof of concept study assessing the use of a selective D1 agonist, DAR-0100, in the treatment of cognitive deficit in schizophrenia.		

**Pharmaceutical: Current**

Project PI:	Lieberman, J. A.	\$7,069,092	0.12 Calendar
Source:	Sunovion	03/26/10-12/31/13	
Title:	Clinical and Biomarker Assessment of Cognitive Remediation in Patients with Schizophrenia Stabilized on Lurasidone		
Major Goals:	The primary research hypothesis for this 17-site study is that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized composite MATRICS score and UPSA-Brief)		
Project PI:	Lieberman, J.A.	\$1,028,698	0.12 Calendar
Source:	Hoffman LaRoche	05/12/11-02/15/15	
Title:	A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period.		
Major Goals:	The primary objective of the study is to evaluate efficacy, safety and tolerability of 24 weeks treatment with RO4917838 in the PANSS negative symptom factor score in patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics		
Project PI:	Lieberman, J.A.	\$959,954	0.12 Calendar
Source:	Hoffman LaRoche	05/12/11-02/15/15	
Title:	A Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo-controlled double blind treatment period.		
Major Goals:	The primary objective of the study is to evaluate the efficacy, safety and tolerability of 12 weeks of treatment with RO4917838 in the PANSS positive symptom factor score in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics.		
Project PI:	Lieberman, J.A.	\$70,874	0.12 Calendar
Source:	Psychogenics	02/2011-02/2016	
Title:	A randomized, double-blind, parallel-design trial comparing the effects of Eltoprazine (as an adjunctive treatment to anti-psychotics) with Placebo in Adults with DSM-IV-TR diagnosis of schizophrenia, in improving one or more dimensions of cognitive impairment associated with schizophrenia		
Major Goals:	The aim of the study is to: 1) compare the efficacy of eltoprazine to placebo in adults with schizophrenia using the MATRICS supplement with the Continuous Performance Test (AX version and the 2-Back) test.		
Project PI:	Lieberman, J.A.	\$522,596	0.12 Calendar
Source:	Eli Lilly	06/2011-study completion	
Title:	A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Safety and Efficacy Study of LY2140023 in Patients with DSM-IV-TR Schizophrenia		
Major Goals:	The aims of this study are to evaluate the efficacy of LY2140023 as measured by PANSS and treatment response in overall population or subgroup of patients		
Project PI:	Lieberman, JA	\$744,124	0.12 Calendar
Source:	Eli Lilly	7/2011-study completion	

**Title:** Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia  
**Major** The aims of this study are to assess time to discontinuation due to lack of tolerability among  
**Goals:** patients with schizophrenia receiving LY2140023 and further evaluate safety and tolerability of  
LY2140023

---

**CURRICULUM VITAE**  
**JEFFREY ALAN LIEBERMAN, M.D.**

*(UPDATED APRIL 2015)*

**PERSONAL INFORMATION:**

Work Address: New York State Psychiatric Institute  
Columbia University Medical Center  
1051 Riverside Drive - Unit #4  
New York, New York 10032

Birthplace: Cleveland, Ohio

**CURRENT POSITION:**

Chairman, Department of Psychiatry  
College of Physicians and Surgeons, Columbia University  
Director, New York State Psychiatric Institute  
Director, Lieber Center for Schizophrenia Research  
Psychiatrist-in-Chief, Columbia University Medical Center of the New York-Presbyterian Hospital

**EDUCATION:**

B.S.	1970	Miami University (Ohio) Athletic Scholarship (full)	Biology
M.D.	1975	George Washington University U.S. Health Professions Scholarship (partial)	Medicine

**POSTGRADUATE TRAINING:**

1975-1979	Internship and Residency St. Vincent's Hospital and Medical Center of New York, New York Medical College
1979-1980	Research Fellowship, Bronx Psychiatric Center Albert Einstein College of Medicine, Bronx, NY

## **PROFESSIONAL EXPERIENCE:**

2005-Present	Psychiatrist-in-Chief, Columbia University Medical Center of New York Presbyterian Hospital
2005-Present	Director, Lieber Center for Schizophrenia Research
2005-Present	Director, New York State Psychiatric Institute
2005-Present	Chairman, Department of Psychiatry, College of Physicians and Surgeons, Columbia University
1996-2005	Vice Chairman for Scientific Affairs Dept of Psychiatry and Director, Mental Health and Neuroscience Clinical Research Center University of North Carolina School of Medicine, Director Division of Clinical Research, Dorothea Dix Hospital, Raleigh, NC
1993-1996	Medical Staff of the Clinical Research Center, Medical Department, Brookhaven National Laboratory, Upton, NY
1990-1996	Co-Director Neuroimaging Laboratory, Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, NY
1988-1996	Director of Research, Hillside Hospital division of Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, N.Y.
1986-1996	Co-Director Mental Health Clinical Research Center, Hillside Hospital division of Long Island Jewish Medical Center, Albert Einstein College of Medicine, Glen Oaks, N.Y.
1985-1988	Assistant Director of Research, Hillside Hospital division of Long Island Jewish Medical Center, State University of New York School of Medicine, Glen Oaks, N.Y.
1982-1985	Research Psychiatrist, Hillside Hospital division of Long Island Jewish Medical Center, State University of New York School of Medicine, Glen Oaks, N.Y.
1980-1982	Director of Day Hospital Programs, Ambulatory Psychiatry Service. Mount Sinai Medical Center, Mt. Sinai School of Medicine, New York, N.Y.

## **ACADEMIC APPOINTMENTS:**

2005-Present	Lawrence C. Kolb Professor and Chairman of Psychiatry, Columbia University College of Physicians and Surgeons
2005-Present	Lieber Professor of Schizophrenia Research in Psychiatry, Columbia University College of Physicians and Surgeons
2005-Present	Adjunct Professor, Department of Psychiatry, University of North Carolina, School of Medicine
1998- Present	Adjunct Professor of Psychiatry and Radiology, Duke University School of Medicine
1996-2005	Thad and Alice Eure Distinguished Professor of Psychiatry, Pharmacology and Radiology, University of North Carolina School of Medicine
1994-1996	Professor of Neuroscience, Albert Einstein College of Medicine, Bronx, N.Y.
1992-1996	Professor of Psychiatry, Albert Einstein College of Medicine, Bronx, N.Y.
1989-1992	Associate Professor of Psychiatry, Einstein College of Medicine, Bronx, N.Y.
1986-1989	Associate Professor of Psychiatry, School of Medicine, State University of New York at Stony Brook, N.Y.
1983-1986	Assistant Professor of Psychiatry, School of Medicine, State University of New York at Stony Brook, N.Y.
1980-1982	Instructor of Psychiatry, Mount Sinai School of Medicine, City University of New York, N.Y.

## **BOARD STATUS:**

National Board of Medical Examiners, 1975

Diplomate, American Board of Psychiatry and Neurology, 1979

## **TYPE OF PRACTICE:**

Psychopharmacology and Neuropsychiatry

## **LICENSURE STATUS:**

1996-Present, North Carolina, 96-01658

1975-1996, New York State, 127547

2005-Present, New York State, 127547-1

## **HOSPITAL AND UNIVERSITY COMMITTEES:**

2007-2008	Medicine Search Committee, College of Physicians and Surgeons, Columbia University, NY, NY
2006-Present	PET Center Oversight Committee, College of Physicians and Surgeons, Columbia University, NY, NY
2006-2007	Chair of Vice Dean for Education Search, College of Physicians and Surgeons, Columbia University, NY, NY
2001-2005	Dean's Research Advisory Committee, University of North Carolina School of Medicine, Chapel Hill, NC
1998-2005	Executive Committee, Duke-UNC Brain Imaging Analysis Center, Duke University, Durham, NC, University of North Carolina School of Medicine, Chapel Hill, NC
1998-Present	Selection Committee for Jefferson-Pilot Fellow in Academic Medicine, University of North Carolina School of Medicine, Chapel Hill, NC
1998-2000	Search Committee Department of Medicine, Chairperson, University of North Carolina School of Medicine, Chapel Hill, NC
1998-1999	Search Committee Director of General Clinical Research Center, University of North Carolina School of Medicine, Chapel Hill, NC
1998-1999	Selection Committee for James W. Woods Junior Faculty Award, University of North Carolina School of Medicine, Chapel Hill, NC
1997-1998	Search Committee UNC Neuroscience Center, Director, University of North Carolina School for Medicine, Chapel Hill, NC
1996-Present	Neurobiology Curriculum Faculty, University of North Carolina School for Medicine, Chapel Hill, NC
1996-1999	Executive Committee UNC Neuroscience Center, University of North Carolina School of Medicine, Chapel Hill, NC
1990-1992	Appointments and Promotions Committee, Albert Einstein College of Medicine
1989-1996	Medical Board, Long Island Jewish Medical Center, Glen Oaks, N.Y.
1987-1994	Quality Assurance Committee, Hillside Hospital, division of Long Island Jewish Medical Center, Glen Oaks, N.Y.



1985-1989	Faculty Practice Committee, Long Island Jewish Medical Center, Glen Oaks, N.Y.
1984-1996	Research Committee, Long Island Jewish Medical Center, Glen Oaks, N.Y.

## **NATIONAL AND INTERNATIONAL PROFESSIONAL ORGANIZATIONS:**

### **AFFILIATIONS**

Dana Alliance for Brain Initiatives (DABI)  
American College of Psychiatrists, Fellow  
American Association for the Advancement of Science, Fellow  
American College of Neuropsychopharmacology, Fellow  
American Psychiatric Association, Distinguished Fellow  
American Psychopathological Association, Fellow  
Collegium Internationale NeuroPsychopharmacologicum (C.I.N.P.)  
Institute of Medicine, National Academy of Sciences  
International Society for Magnetic Resonance in Medicine  
International Society for Neuroimaging in Psychiatry  
New York Academy of Science  
Society for Biological Psychiatry  
Society for Neuroscience

## **NATIONAL AND INTERNATIONAL PROFESSIONAL ORGANIZATIONS:**

### **ACTIVITIES**

2013-2014 President, American Psychiatric Association (APA)  
2013-2014 President, American Psychopathological Association (APPA)  
2010-2013 Board of Directors, American Psychiatric Foundation, APA  
2010-2011 Vice-President, Collegium Internationale NeuroPsychopharmacologicum (C.I.N.P.)  
2009-2012 Ethics Committee, American College of Neuropsychopharmacology  
2008-Present Board of Directors, American Psychiatric Institute for Research and Education  
2008-Present Oversight Committee for DSM-V, American Psychiatric Association  
2008-Present Council, Collegium Internationale NeuroPsychopharmacologicum (C.I.N.P.)  
2006-Present Chair, Council on Research, American Psychiatric Association  
2006-Present Chair, Committee on Research of Psychiatric Treatment, American Psychiatric Association  
2004-2005 President, Society of Biological Psychiatry  
2004 Chair of Credentials Committee, American College of Neuropsychopharmacology  
2003 Co-Chair Credentials Committee, American College of Neuropsychopharmacology  
2003-2004 Vice President, Society of Biological Psychiatry  
2003-Present Scientific Council, National Association for Research in Schizophrenia and Affective Disorders  
2002-2010 Vice-President, North America, International Early Psychosis Association  
2000-2004 Chair of the Human Subjects Research Council Workgroup of the National Advisory Mental Health Council to the NIMH

2000-2004	NIMH, National Advisory Mental Health Council
1999-Present	Chair of the American Psychiatric Association Task Force on Ethics in Psychiatric Research
1999-2001	Executive Council, American College of Neuropsychopharmacology
1999	Advocacy Committee, American College of Neuropsychopharmacology
1998-2000	Chair of National Institute of Mental Health Data and Safety Monitoring Board
1998-2000	Planning Board for the Surgeon General's Report on Mental Health, U.S. Department of Health and Human Services
1997-1999	Credentials Committee, American College of Neuropsychopharmacology
1997-2000	Brain Disorders and Clinical Neuroscience Review Committee (BDCN-6), National Institutes of Health
1997	Panel Member, National Institute of Health Inter-Institute Conference on Research Involving Individuals with Questionable Capacity to Consent: Ethical Issues and Practical Considerations for IRBs
1996-2000	Stanley Foundation Awards Selection Committee
1996-2000	Treasurer, Neuroimaging Section, World Psychiatric Association
1994-Present	Advisory Board of the International Congress on Schizophrenia Research
1994-1996	Committee on Problems of Public Concern American College of Neuropsychopharmacology
1993-2002	Committee on Research on Psychiatric Treatments, American Psychiatric Association
1992-1997	American Psychiatric Association Work Group on Schizophrenia Practice Guidelines
1992-Present	Member, Scientific Advisory Board, National Alliance for the Mentally Ill
1992-1996	Treatment Assessment Review Committee, National Institute of Mental Health
1992-1996	Chairman Symposia Subcommittee, Scientific Program Committee, American Psychiatric Association
1992-Present	Organizing Committee for International Congress on Schizophrenia Research
1991-1996	Scientific Program Committee, Society for Biologic Psychiatry
1990-1996	Scientific Program Committee, American Psychiatric Association
1988-1994	Psychopharmacologic Drugs Advisory Committee, United States Food and Drug Administration
1988-1992	Advisory Group to DSM IV Task Force Committee on Schizophrenia
1987	Clinical Phenomenology Panel, National Plan on Schizophrenia for the National Institute of Mental Health
1984-1992	Special Review Committees, Office of Extramural Project Review, National Institute of Mental Health

### **EDITORIAL BOARDS:**

2010-Present	Editorial Board Shanghai Archives of Psychiatry
2008-Present	Editorial Board European Archives of Psychiatry & Clinical Neuroscience
2007-Present	Editorial Board Psychiatry and Clinical Neurosciences
2007-Present	Associate Editor of Psychiatric Quarterly
2005-Present	Editorial Board American Journal of Psychiatry
2005-Present	Editorial Board Current Psychiatry Reviews

2004-Present	Editorial Board Neuropsychopharmacology
2003-Present	Editorial Board Journal of Psychiatric Research
2003-Present	Editorial Board Current Psychosis and Therapeutics Reports
2002-2004	Section Editor of Psychiatry, Experimental Neurology
2001-Present	Editorial Board Current Opinion in Psychiatry
2001-Present	Editorial Advisory Board Psychopharmacology Bulletin
1999-Present	Editorial Board Schizophrenia Research
1998-2001	Clinical Field Editor for Neuropsychopharmacology
1997-2003	Editorial Board International Journal of Neuropsychopharmacology
1996-Present	Editorial Board Biological Psychiatry
1996-Present	Editorial Board Psychiatry Research
1996-2003	Associate Editor of ACTA Psychiatrica Scandinavica
1996-2000	Associate Editor American Journal of Psychiatry
1994-2005	Editorial Board Schizophrenia Bulletin
1994-1997	Editorial Board Neuropsychopharmacology

## **HONORS AND AWARDS:**

2012	Ed Hornick Award, New York Academy of Medicine (NYAM)
2011	Scientific Research Award, National Alliance on Mental Illness (NAMI)
2011	C. Charles Burlingame Award, The Institute of Living, Hartford Hospital
2010	Elected Fellow, American Association for the Advancement of Science (AAAS)
2007	Adolph Meyer Award, American Psychiatric Association
2007	The George Washington University's Distinguished Alumni Scholar Award, Washington, DC
2006	Eugene A. Hargrove Mental Health Research Award, North Carolina Foundation for Mental Health Research, Inc., North Carolina Psychiatric Association, NCPA
2006	Lieber Prize for Schizophrenia Research, NARSAD
2003-2009	Best Doctors in America ®
2002	Lilly Neuroscience Award, The Collegium Internationale Neuro-Psychopharmacologicum
2001	Institute of Medicine, National Academy of Sciences
2000-2003	National Advisory Mental Health Council, National Institute of Mental Health, NIMH
2000, 2001	Exemplary Psychiatrist, National Alliance for the Mentally Ill, NAMI
2000	Stanley Dean Award, Schizophrenia Research, American College of Psychiatry
2000	Ziskind-Somerfield Award, Society of Biological Psychiatry
2000	Kempf Fund Award, Research in Psychobiological Psychiatry, American Psychiatric Association
1998	Gralnick Award, Schizophrenia Research, National Association of Private Psychiatric Hospitals
1998	Edward A. Strecker Award for Psychiatric Research, University of Pennsylvania Hospital
1998	American Psychiatric Association Research Award
1997	Exemplary Psychiatrist, National Alliance for the Mentally Ill, NAMI
1996-2005	Thad & Alice Eure Award, Distinguished Professor in Psychiatry, UNC School of Medicine
1995-2000	Independent Scientist Award, National Institute of Mental Health, NIMH
1994	Kempf Fund Award, Research in Psychobiological Psychiatry, American Psychiatric Association
1994	Exemplary Psychiatrist, National Alliance for the Mentally Ill, NAMI
1993	Presidential Award, Research, National Association of Psychiatric Health Systems
1992	Gralnick Award, Schizophrenia Research, National Association of Private Psychiatric Hospitals
1990-1995	MERIT Award, National Institute of Mental Health, NIMH
1985-1995	Research Scientist Development Award, Levels I, II and Independent Scientist Award, NIMH

- 1975 Sandoz Award for outstanding achievement by medical student in psychiatry, George Washington University School of Medicine
- 1975 William S. Schafirt Award from George Washington University School of Medicine for best article on Medicine and Public Policy

## **MAJOR RESEARCH INTERESTS:**

1. Neurobiology of schizophrenia and related psychotic disorders.
2. Psychopharmacology of schizophrenia and related psychotic disorders.
3. Translational neuroscience and animal models of mental disorders.

## **GRANTS AND CONTRACTS**

### **Federal: Current**

Project PI:	Lieberman, J. A.	\$761,756	0.60 Calendar
Project #	HHSN27100005	9/1/14-4/30/15	
Source:	NIH-NIMH		
Title:	mGluR5 Cntnap2 Study/HHSN2712012000071 FAST-PS		
Major Goals:	This project seeks to verify overexpression of mGluR5 in Old-Order Amish individuals in a CNTNAP2 (Contactin-associated protein-like 2, also known as CASPR2) gene mutation.		
Project PI:	Lieberman, J. A.	\$1,098,271	0.60 Calendar
Project #	HHSN2710003	8/29/13-4/28/15	
Source:	NIH-NIMH		
Title:	Biomarker Validation Study Task/HHSN2712012000071 FAST-PS		
Major Goals:	Feasibility study to evaluate the ability of an mGluR2/3 agonist to reverse ketamine-induced GLX MRS, 13C MRS, Bold fMRI, and EEG alterations in healthy humans.		
Project Role:	Lieberman J. A. (Co-Investigator, Columbia University Subcontract PI)	\$312,797	0.60 Calendar
Project #	R01MH097799 (Siever)	4/1/13-2/28/18	
Source:	NIH-NIMH		
Title:	A D1 Agonist for Working Memory Enhancement in the Schizophrenia Spectrum		
Major Goals:	The aim of the study is to evaluate in a random double blind design the effectiveness of DAR-0100A to improve cognitive performance		
Project PI	Lieberman, J. A.	\$112,389	1.20 Calendar
Project #	HSS-NIH-DA-2012-242	09/24/12-09/14/15	
Source:	NIH/NIMH		
Title:	New Experimental Medicine Studies: Fast-Fail Trials in Psychotic Spectrum Disorders (FAST-PS)		
Major Goals:	Infrastructure to allow for the expeditious performance of small-scale Phase I and/or Phase IIa clinical trials (e.g., FIH, POCM, POC) to demonstrate target engagement, safety, and early signs of efficacy of promising interventions in healthy subjects and/or a well-characterized cohort of patients with clinical dimensions of psychopathology associated with traditional psychotic spectrum disorders.		
Project Role:	Lieberman, J. A. (Co-Investigator, RFMH Subcontract PI)	\$254,380	0.07 Calendar

Project #	R01NS076277 (Marshall)	4/1/12-3/31/17
Source:	NIH-NINDS	
Title:	Blood Flow and Cognition in Asymptomatic Carotid Artery Disease	
Major	Demonstrating the link between cerebral blood flow dysregulation and cognitive impairment	
Goals:	could lead to a major shift in the treatment algorithms of carotid artery disease affecting tens of thousands of individuals in the US each year.	

Project	Lieberman J. A. (Co-Investigator)	\$2,735,154	0.60 Calendar
Role:			

Project #	1R01MH093398-01A1 (Small)	09/22/11-05/31/16
Source:	NIH/NIMH	
Title:	Longitudinal Imaging in Patients at Clinical Risk for Psychosis	
Goals:	The goal of this study is to use two variants of functional brain imaging that can detect disease-associated dysfunction in small regions of the brain and apply this to patients at clinical risk for psychosis who are followed prospectively for clinical and brain imaging outcomes. The main project goal is to definitively test the hypothesis of hippocampal hyperfunction as a pathogenic driver in schizophrenia and related disorders.	

Project PI:	Lieberman, J.A.	\$592,339	0.60 Calendar
Project #	OT-1432	02/15/11-11/30/15	
Source:	The Stanley Medial Research Institute		
Title:	BH4 Treatment in Schizophrenia		
Major	To evaluate an anticipated clinical response to BH4 treatment including negative symptoms and cognitive deficits. Evaluate the safety of 6R-BH4-treatment for patients with schizophrenia and the relationship of changes in plasma BH4 levels and efficacy outcomes.		
Goals:			

Project	Lieberman, J. A. (Co-Investigator)	\$1,344,509	1.80 Calendar
Role:			

Project #	1P50MH086404-01A1 (Abi-Dargham)	07/01/10-03/31/15
Source:	NIH/NIMH	
Title:	Dopamine Dysfunction in Schizophrenia	
Major	The overall goal of this Center is to use clinical imaging, epigenetic and transgenic animal models in mice and rhesus monkeys to test the hypothesis that striatal dopaminergic hyperactivity during development leads to prefrontal cortical dopamine (DA) dysfunction in schizophrenia (SCZ) and the cognitive deficits that characterize the disorder.	
Goals:		

Project	Lieberman, J. A. (Co-Investigator)	\$8,947,060	0.36 Calendar
Role:			

Project #	HHSN-271-2009-00020C (Dixon)	07/09/09-03/31/14
Source:	NIH/NIMH	
Title:	Recovery After an Initial Schizophrenia Episode (RAISE)	
Major	The RAISE initiative from NIMH seeks to fundamentally change the trajectory and prognosis of schizophrenia through coordinated and aggressive treatment in the earliest stages of illness.	
Goals:		

#### **Federal: Previous**

Project	Lieberman J. A. (Co-Investigator, Subcontract with Columbia)	\$2,635,450	0.12 Calendar
Role:			

Project #	7R01MH081107-02 (Stroup)	07/09/09-03/31/14
Source:	NIH/NIMH	
Title:	A Comparison of Long-Acting Injectable Medications for Schizophrenia (ACLAIMS)	

Major Goals:	The aim of this study is to compare effectiveness, cost and tolerability of two long acting injectable antipsychotics in patients with schizophrenia or schizoaffective disorder.		
Project PI:	Lieberman, J.A.	\$468,424	2.4 Calendar
Project #	1 U01 MH076544-01	09/30/05-03/31/13	
Source:	NIH/NIMH		
Title:	Pharmacologic and Clinical testing of a D1 Agonist for Neuropsychiatric Disorders		
Major Goals:	This proposal is a joint collaboration between an academic institution, Columbia University, a pharmaceutical company, as well as many outstanding scientists from the community at large, to conduct a proof of concept study assessing the use of a selective D1 agonist, DAR-0100, in the treatment of cognitive deficit in schizophrenia.		
Project PI:	Lieberman, J.A. (subcontract to Columbia)	\$51,392	0.6 Calendar
Project #	1675	08/01/06-07/31/12	
Source:	Foundation for NIH		
Title:	Clinical Management of Metabolic Problems in Patients with Schizophrenia		
Major Goals:	The aims of the study are to (1) determine the relative effects of switching to aripiprazole, versus continued treatment with olanzapine, quetiapine, risperidone, on measures of insulin sensitivity and related metabolic parameters and (2) determine the effects of switching to aripiprazole versus continued treatment with olanzapine, quetiapine, or risperidone on the clinical stability of schizophrenic illness.		
Project PI:	Lieberman, J.A. (subcontract to Columbia)	\$2,000,000	0.6 Calendar
Project #	3R01MH080403-03S1 (Sullivan, P.F.)	06/01/10-05/31/12	
Source:	University of North Carolina – NIH/NIMH		
Title:	2/2 A Genome-wide Association Study to Detect Genetic Variation for Schizophrenia		
Major Goals:	The aim of the study is to recruit, ascertain and sample 400 clozapine-induced agranulocytosis cases. Subjects will be identified via a broad survey of colleagues, and investigators who may have samples under existing IRB-approved protocols, and clozapine registry ascertainment by contacting the treating physicians at the time CIA occurred.		
Project PI:	Lieberman, J.A. (Subcontract to RFMH)	\$411,461	0.24 Calendar
Project #	1RC1MH089084 (Smith, T.E. & Jarskog, L.F.)	09/01/09-08/31/12	
Source:	NIH/NIMH		
Title:	Using fMRI to Measure Negative Symptoms in Schizophrenia		
Major Goals:	The major goal is to use brain imaging to provide objective and biological markers of the various negative symptoms.		
Project PI:	Lieberman, J.A.	\$1,605,425	2.4 Calendar
Project #	1 P50 MH066171-01A1	09/15/04-06/30/10	
Source:	NIH/NIMH		
Title:	The Neurobiology of Dopamine in Schizophrenia		
Major Goals:	The overall goal of this Center is to combine clinical imaging with PET and epigenetic and transgenic animal models in mice and rhesus monkeys to test the hypothesis that schizophrenia is associated with an imbalance of dopamine systems.		
Project PI:	Lieberman, J.A. (subcontract/RFMH)	\$341,872	1.2 Calendar
Project #	N01-MH90001	10/01/99-12/31/09	
Source:	NIH/NIMH		
Title:	Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)		
Major Goals:	Five year clinical trial to determine the effectiveness of the new class of atypical antipsychotic		

Goals: drugs represented by clozapine, risperidone, olanzapine, and quetiapine in the treatment of schizophrenia and Alzheimer's disease.

Project PI: Lieberman, J.A.

Project # NIMH-02-DM-0006

05/03/04-07/31/09

Source: NIH/NIMH

Title: Treatment Units for Research on Neurocognition and Schizophrenia (TURNS)

Major The purpose of this contract is to establish a network of Treatment Units for Research on

Goals: Neurocognition and Schizophrenia (TURNS) that will utilize the scientific opportunity created by new insights into the neurobiology of attention, working memory, and other fundamental cognitive processes, to identify and test potential therapeutic agents targeting cognitive deficits in schizophrenia

Project PI: Lieberman, J.A.

\$9,370,669

3.6 calendar

Project # P50-MH064065-01A1

09/01/02-07/31/07

Source: NIH/NIMH

Subproject Direct Cost: \$371,819

Title: UNC-Duke Silvio O. Conte Center for Neurosciences of Mental Disorders - Prospective Studies of the Pathogenesis of Schizophrenia

Major The goal of this project is to further identify the neurodevelopmental mechanisms in the  
Goals: pathogenesis of schizophrenia by characterizing the phenotype of the disorder and its developmental trajectory in terms of susceptibility and disease related manifestations.

Project PI: Lieberman, J.A.

\$2,072,449

5%

Project # R01-MH61603

02/01/01-01/31/05

Source: NIH/NIMH

Title: Brain MRI/MRS Changes in First Episode Schizophrenia

Major Prospective longitudinal study of brain morphology and biochemistry in first episode  
Goals: schizophrenia patients using high resolution MR and spectroscopic imaging.

Project PI: Belger, A.

\$1,174,335

3%

Project # 1R01MH58251-01A3

04/01/01-03/31/06

Source: NIH/NIMH

Title: Neurobiology of Selective Attention in Schizophrenia

Goals: The clinical objective of the proposed studies is to relate selective attention deficits in schizophrenia to symptomatology and chronicity of this illness

Project PI: Lieberman, J.A. (UNC-CH subcontract)

\$212,070

1%

Project # M01 RR00827-28

09/30/02-11/30/04

Source: NIH

Title: First BIRN (Biomedical Informatics Resource Network)

Major The goal of this grant is to fund a national infrastructure for large scale, multi-center studies of  
Goals: brain functions using functional magnetic resonance imaging (fMRI).

Project PI: Pizer, S.

\$980,995

5%

Project # P01 EB002779

04/01/02-02/28/07

Source: NIH/NIBIB

Title: Medical Image Presentation

Major This research will produce methods and systems that will allow significant advances the three  
Goals: projects that include a) developing object-based image analysis at multiple scales based on medial representations, b) segmentation for radiotherapy planning, and c) shape analysis of subcortical brain structures in schizophrenia.

Project PI:	Perkins, D.	\$1,025,000	1%
Project #	U01-MH066069, Perkins (PI)	05/08/03-02/29/08	
Source:	NIH/NIMH		
Title:	Enhancing the Prospective Prediction of Psychosis		
Major Goals:	This 3-site collaborative U01 aims to improve identification of individuals who will develop schizophrenic psychosis (including brief psychotic disorder, schizophreniform disorder, schizophrenia, or schizoaffective disorder) at the initial prodromal stage of illness, prior to the onset of the full schizophrenic syndrome.		
Project PI:	Lieberman, J.A.	\$225,000	30%
Project #	P30 MH33127	07/01/79-05/31/02	
Source:	NIH/NIMH		
Title:	Mental Health Clinical Research Center: Neuroscience of Mental Disorders		
Goals:	Translational research involving basic and clinical neuroscientific disciplines of the pathogenic and pathophysiologic mechanisms of neurodevelopmental disorders.		
Project PI:	Lieberman, J.A.	\$156,844	10%
Project #	R01 MH53551	09/30/95-03/31/00	
Source:	NIH/NIMH		
Title:	Olanzapine, Risperidone and Clozapine in Chronic Schizophrenia		
Major Goals:	To determine the comparative efficacy and safety of role of atypical antipsychotic drugs in treatment of refractory schizophrenia.		
Project PI:	Lieberman, J.A.	\$89,901	80%*
Project #	K02 MH00537-10	09/01/85-11/30/00	
Source:	NIH/NIMH		
Title:	Psychobiology of Schizophrenia – RSDA Level II		
Major Goals:	Research on the psychobiology, pathophysiology and pharmacologic response in schizophrenia. *This effort subserves effort on other funded projects		
Project PI:	Lieberman, J.A.	\$95,845	5%
Project #	R03 MH47745	04/01/93-03/31/96	
Source:	NIH/NIMH		
Title:	<i>In-vivo</i> Limbic System Morphometry in Endogenous Psychosis		
Major Goals:	To compare brain morphology in magnetic resonance scans of patients suffering from schizophrenia, schizoaffective and bipolar affective disorder with and without psychotic symptoms, by characterizing brain morphology through volumetric assessment with special attention to limbic and paralimbic brain structures		
Project PI:	Lieberman, J.A.	\$1,371,866	25%
Project #	R01 MH41646	04/01/87-06/30/96	
Source:	NIH/NIMH		
Title:	Prospective Study of Psychobiology in Schizophrenia		
Major Goals:	To prospectively study a cohort of first-episode schizophrenics using clinical assessments of symptomatology, treatment response, side effects and social adjustment and biologic measures on MRI, growth hormone secretion and provocative tests with methylphenidate. To relate treatment response to clinical and biologic variables. To examine the clinical and pathophysiological progression of early phase schizophrenia. To identify and validate subtypes of schizophrenia using biologic and clinical indices of heterogeneity		



Project PI: Lieberman, J.A. (Co-PI) \$5,378,393 25%  
 Project # P30 MH-41960 09/25/86-12/31/96  
 Source: NIH/NIMH  
 Title: Clinical Research Center for the Study of Schizophrenia  
 Major Goals: To provide an infrastructure to facilitate research on the course and treatment of schizophrenia.

Project PI: Lieberman, J.A. (Co-PI) \$1,387,493 5%  
 Project # R01 MH-40015 03/01/86-01/30/95  
 Source: NIH/NIMH  
 Title: Prospective Study of Tardive Dyskinesia in the Elderly  
 Major Goals: To determine the incidence and putative risk factors for tardive dyskinesia and spontaneous dyskinesias in patients above the age of 55 determine who are about to receive neuroleptic medication.

Project PI: Lieberman, J.A. \$639,945 10%  
 Project # R01 MH45122 09/30/89-09/29/95  
 Source: NIH/NIMH  
 Title: Clozapine Treatment of Severe Tardive Dyskinesia  
 Major Goals: To study effects of clozapine treatment on symptoms of TD and psychopathology in patients with moderate to severe TD in a random assignment double-blind comparison with haloperidol. To examine the pathophysiology and biologic correlates of treatment response in patients using MRI and biochemical assays of cerebrospinal fluid.

Project PI: Lieberman, J.A. (Co-PI) \$195,645 10%  
 Project # R01 MH4702 09/30/92-08/31/95  
 Source: NIH/NIMH subcontract  
 Title: Immunopharmacogenetics of Schizophrenia  
 Major Goals: To examine the association between MHC markers and neuroleptic treatment response in patients with schizophrenia. To determine the specific MHC class II alleles involved in agranulocytosis susceptibility among Jewish and non-Jewish agranulocytosis patients

Project PI: Lieberman, J.A. \$1,290,547 25%  
 Project # R01 MH-38880 09/30/83-11/30/95  
 Source: NIH/NIMH MERIT Award  
 Title: Prediction of Outcome in Schizophrenia  
 Major Goals: To determine the predictive validity of measures of dopamine neuronal function on outcome and likelihood of relapse in schizophrenia patients undergoing maintenance treatment.

Project PI: Lieberman, J.A. (Co-PI) \$185,000 5%  
 Project # MH-39992 09/20/84-08/31/93  
 Source: NIH/NIMH  
 Title: Treatment Strategies in Schizophrenia Cooperative Agreement Program  
 Major Goals: To compare the efficacy of three forms of maintenance pharmacotherapy in schizophrenia.

Project PI: Lieberman, J.A. \$45,750 2%  
 Project # R03 MH-42271 01/01/87-02/31/89  
 Source: NIH/NIMH  
 Title: Computed Tomography in Schizophrenia

Major Goals: To examine the relationship of brain morphology to treatment outcome in the context of the Treatment Strategies in Schizophrenia Cooperative Agreement Program.

Project PI: Lieberman, J.A. (Co-PI) \$60,000  
Project # R03 MH-39309 01/01/84-12/31/84  
Source: NIH/NIMH

Title: Neuroendocrine Regulation of Cortisol in Depression

Major Goals: To characterise hypothalamic-pituitary-adrenal hormonal activity in patients with major depression using rapid serial sample collection and novel biochemical analytic methods.

#### **Foundation: Previous**

Project PI: Lieberman, J.A. \$100,000 (No Cost Extension)

Source: NARSAD 05/01/07-04/30/10

Title: A Twelve-week Double-blind Placebo-controlled Add-on-Trial of AL-108 to Ongoing Antipsychotic Treatment for Cognition-enhancement in Chronic Schizophrenia

Major Goals: Our primary hypothesis is that the antipsychotic – AL-108 group will exhibit greater cognitive improvement from baseline compared to the antipsychotic/placebo group.

Project PI: Lieberman, J.A. \$188,000

Source: Stanley Foundation 11/30/00-06/30/05

Title: Dihydroepiandrosterone (DHEA) for Persistently Symptomatic Schizophrenia Patients

Major Goals: The goal of this study is to determine whether DHEA, a compound that can enhance NMDA receptor mediated neurotransmission, will have beneficial effects for schizophrenia patients who are already receiving “optimal” treatment and remain persistently symptomatic.

Project PI: Lieberman, J.A. \$53,998

Source: NARSAD 05/01/99-04/30/02

Title: Structural and Functional Brain Markers that Identify Affected Family Members Who Are at Increased Risk to Develop Schizophrenia in Siblings

Major Goals: To determine the role genetic factors play in the pathomorphology and biochemical abnormalities in schizophrenia using MRI and MRS.

Project PI: Lieberman, J.A. \$61,009

Source: Stanley Foundation 07/01/99-05/31/02

Project Title: Dopamine Pathophysiology and Pharmacologic Response to Clozapine and Haloperidol in First Episode Schizophrenia

Major Goals: To determine if patients with schizophrenia have increase extracellular dopamine concentrations compared to healthy control subjects using PET.

#### **Pharmaceutical: Current**

Project PI: Lieberman, J. A. \$7,069,092 0.12 Calendar

Source: Sunovion 03/26/10-12/31/13

Title: Clinical and Biomarker Assessment of Cognitive Remediation in Patients with Schizophrenia Stabilized on Lurasidone

Major Goals: The primary research hypothesis for this 17-site study is that cognitive remediation will be superior to the active control group on the change from baseline to study end point of cognitive remediation phase on both co-primary outcome measures (standardized composite MATRICS score and UPSA-Brief)

Project PI:	Lieberman, J.A.	\$1,028,698	0.12 Calendar
Source:	Hoffman LaRoche	05/12/11-02/15/15	
Title:	A Phase III, multi-center, randomized, 24 week, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in stable patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics followed by a 28 week, double-blind treatment period.		
Major Goals:	The primary objective of the study is to evaluate efficacy, safety and tolerability of 24 weeks treatment with RO4917838 in the PANSS negative symptom factor score in patients with persistent, predominant negative symptoms of schizophrenia treated with antipsychotics		

Project PI:	Lieberman, J.A.	\$959,954	0.12 Calendar
Source:	Hoffman LaRoche	05/12/11-02/15/15	
Title:	A Phase III, multi-center, randomized, 12-week, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy and safety of RO4917838 in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics followed by a 40-week double-blind, parallel-group, placebo-controlled double blind treatment period.		
Major Goals:	The primary objective of the study is to evaluate the efficacy, safety and tolerability of 12 weeks of treatment with RO4917838 in the PANSS positive symptom factor score in patients with sub-optimally controlled symptoms of schizophrenia treated with antipsychotics.		

Project PI:	Lieberman, J.A.	\$70,874	0.12 Calendar
Source:	Psychogenics	02/2011-02/2016	
Title:	A randomized, double-blind, parallel-design trial comparing the effects of Eltoprazine (as an adjunctive treatment to anti-psychotics) with Placebo in Adults with DSM-IV-TR diagnosis of schizophrenia, in improving one or more dimensions of cognitive impairment associated with schizophrenia		
Major Goals:	The aim of the study is to: 1) compare the efficacy of eltoprazine to placebo in adults with schizophrenia using the MATRICS supplement with the Continuous Performance Test (AX version and the 2-Back) test.		

Project PI:	Lieberman, J.A.	\$522,596	0.12 Calendar
Source:	Eli Lilly	06/2011-study completion	
Title:	A Phase 3, Multicenter, Double-Blind, Placebo-Controlled Safety and Efficacy Study of LY2140023 in Patients with DSM-IV-TR Schizophrenia		
Major Goals:	The aims of this study are to evaluate the efficacy of LY2140023 as measured by PANSS and treatment response in overall population or subgroup of patients		

Project PI:	Lieberman, JA	\$744,124	0.12 Calendar
Source:	Eli Lilly	7/2011-study completion	
Title:	Antipsychotic Standard of Care in Patients with DSM-IV-TR Schizophrenia		
Major Goals:	The aims of this study are to assess time to discontinuation due to lack of tolerability among patients with schizophrenia receiving LY2140023 and further evaluate safety and tolerability of LY2140023		

**Pharmaceutical: Previous**

Project PI:	Lieberman, J.A.	\$5000,000
Source:	Pfizer	2008-2011

Title:	Quantitative assessment and comparison of metabolic changes in young adults taking the antipsychotic medications ziprasidone and olanzapine	
Major Goals:	To determine changes in body weight, body composition, glucose, insulin and lipid metabolism, food intake and resting metabolic rate in patients taking olanzapine or ziprasidone	
Project PI:	Lieberman, J.A.	\$75,000
Source:	GlaxoSmithKline	Inactive
Title:	A 24-week double-blind, placebo-controlled augmentation trial of lamotrigine in first episode psychosis	
Major Goals:	A randomized controlled trial of treatment augmentation of an atypical antipsychotic drug (risperidone) with lamotrigine in patients with first episode psychosis	
Project PI:	Lieberman, J.A.	\$12,000
Source:	Janssen	09/01/06-inactive
Title:	Two-year study comparing Risperidal Consta and Abilify in adults with schizophrenia	
Major Goals:	A 2-year, prospective, blinded-rater, open-label, active-controlled, multicenter, randomized study of long-term efficacy and effectiveness comparing Risperidal Consta and Abilift (aripipazole) in adults with schizophrenia	
Project PI:	Lieberman, J.A.	\$50,000
Source:	Pfizer	12/01/05-inactive
Title:	Recognition and management of depression and suicide in China	
Major Goals:	Ongoing training course in CBT; promotion activities related to World Suicide Prevention Day; national meeting on the recognition and management of depression and suicide in women	
Project PI:	Lieberman, J.A.	\$41,000
Source:	Acadia	01/06/06-08/18/06
Title:	Comparison of the safety and side-effects of different doses of ACP-104 and placebo	
Major Goals:	Q 14-day, steady-state, double blind, placebo controlled, multiple escalating dose study of the safety and tolerability of ACP-104 in subjects with chronic schizophrenia, schizoaffective disorder or chronic psychosis	
Project PI:	Lieberman, J.A.	\$2,047,976
Source:	AstraZeneca Pharmaceuticals	09/01/01-08/30/05
Title:	Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in Treatment of First Episode Psychosis: A Randomized Double Blind 52 Week Comparison	
Major Goals:	A 52-week randomized control trial, examining effectiveness of atypical antipsychotic drugs in treatment outcome of first episode psychosis.	
Project PI:	Lieberman, J.A.	\$116,420
Source:	Hoechst Marion Roussel	01/01/97-Completion
Title:	A Multicenter, Open Label, Long-Term Followup Safety Study of MDL 100 in Schizophrenic and Schizoaffective Patients in the Study	
Major Goals:	To determine the efficacy and safety of a novel (pure 5HT-2A antagonist) putative antipsychotic drug.	
Project PI:	Lieberman, J.A.	\$1,253,460
Source:	Eli Lilly & Company	04/17/97-04/16/00
Title:	The Acute and Long-Term Efficacy of Olanzapine in First-Episode Psychotic Disorder: A Randomized Double-Blind Comparison with Haloperidol	
Major Goals:	To determine the therapeutic efficacy of a novel antipsychotic drug and its potential for	

Goals: neuroprotection in first episode psychosis patients using psychopathology, neurocognition and MRI and MRS as measures of outcome.

Project PI: Lieberman, J.A. \$674,506  
Source: Janssen Pharmaceuticals 04/03/98-04/02/00  
Title: Haloperidol, Olanzapine and Risperdone in Children and Adolescents with Psychosis  
Major: To determine the efficacy and safety profiles of haloperidol, olanzapine and risperidone, in a  
Goals: double blind, parallel treatment design.

Project PI: Lieberman, J.A. (Co-PI) \$58,083  
Source: Pfizer 01/01/99-12/31/99  
Title: Atypical Pharmacologic Characteristics of Ziprasidone  
Major: To test the hypothesis that treatment with ziprasidone will antagonize alterations in regional  
Goals: brain activity induced by the NMDA receptor antagonist ketamine.

Project PI: Lieberman, J.A. (Co-PI) \$143,000  
Source: Eli Lilly 05/01/98-04/30/00  
Title: Functional and Neuroanatomical Characterization of the Effects of Chronic Olanzapine Treatment  
Major: To determine the biochemical basis for the preferential blockade of dopamine D1 receptor  
Goals: mediated behavior demonstrated for olanzapine.

Project PI: Lieberman, J.A. \$123,565  
Source: Eli Lilly 05/01/98-04/30/00  
Title: Consequences of Long-Term Antipsychotic Drug Administration on Basal Ganglia in Rats  
Major: To characterize the neuroplastic response of the basal ganglia to long-term administration of  
Goals: typical and atypical antipsychotics.

### **DISSERTATION ADVISEES:**

2001-2005	Samantha Gizerian. Neurosteroid effects on neurodevelopment; pathogenic relevance to schizophrenia
2000-2005	Mohammed El-Sayed MD. Brain Morphology and neurodevelopment in early onset psychoses.
1999-2002	Martin Styner, Ph.D. Shape analysis in clinical neurological studies using a combined boundary and medial representation approach.
1997-1999	Kah-Chan Low, Ph.D. Figural deformation approach to brain structure segmentation of magnetic resonance images.
1994-1996	Frank Tarazi, Ph.D. Localization and regulation of dopamine and glutamate receptor subtypes following chronic treatment with typical and atypical neuroleptics.

### **FELLOWSHIP ADVISEES:**

<b><u>Fellow</u></b>	<b><u>Years</u></b>	<b><u>Current Institution</u></b>
Darlene Jody MD	1986-1988	Bristol Meyers Squibb
Bruce Saltz MD	1986-1988	Private Practice
Alberto Gonzales MD	1987-1989	Universidad of Bilbao, Escuela de Medecina
David Meyerhoff MD	1987-1989	UMDNJ

<u>Fellow</u>	<u>Years</u>	<u>Current Institution</u>
Anthony Loebel MD	1988-1990	Pfizer
Farouk Amin MD	1989-1990	Emory University School of Medicine
Sally Szymanski MD	1988-1990	Johns Hopkins University, School of Medicine
Stephen Masiar MD	1989-1990	SUNY Stonybrook, School of Medicine
Miranda Chakos MD	1990-1992	State University of New York Downstate Medical Center
Raphael Munne MD	1990-1992	Private Practice
Amy Koreen MD	1991-1993	Private Practice
Dian Picou MD	1991-1993	Mount Sinai Health System of NY
Daniel Umbricht MD	1991-1993	Univeristy of Zurich, School of Medicine
Ajun Chattergee MD	1992-1994	Merck
Brian Sheitman MD	1993-1996	University of North Carolina
Heide Lee MD	1993-1995	Tulane University, School of Medicine
Julia Becker MD	1994-1996	Albert Einstein College of Medicine
Rael Strous MD	1995-1996	Hadassah Medical School
Candace Andersson PhD	1996-2000	Bristol Myers Squibb
Terri Blackmon MD	1997-1999	Carolina Health System
Chris Marx MD	1997-2001	Duke University, School of Medicine
Chistina Grobin PhD	1998-2001	University of North Carolina
Susan Siegfried MD	1998-2000	University of Kansas, School of Medicine
Seiya Miyamoto MD	1999-2001	St. Marianna School of Medicine
Kalina Boteva MD, PhD	2000-2002	University of Maryland
Daniel Bradford MD	2001-2003	Duke University
Leisa Glantz PhD	2001-2005	University of North Carolina
Sheue-mei Wu MD, PhD	2003-2005	University of North Carolina
Ragy Girgis MD	2005-Present	Columbia University
Scott Schobel MD	2007-2012	L. Hoffman-La Roche, Inc.
David Kimhy PhD	2007-Present	Columbia University
Tiziano Colibazzi MD	2007-Present	Columbia University
Nehal Vadhan MD	2007-2014	Stony Brook University
Jacob Seth Ballon MD	2009-2014	Stanford University
Sander Markx MD	2013-Present	Columbia University

## **PEER-REVIEW JOURNAL PUBLICATIONS:** (UPDATED APRIL 2015)

### **Pre-publication: In Preparation, Submitted, and In Press**

- Corcoran C, Schobel S, Birnbaum M, **Lieberman JA**: A review of treatment trials in cohorts identified as at heightened clinical risk or putatively prodromal to psychosis, *In Prep*.
- Rosenheck RA, Davis VG, Davis SM, Stroup TS, McEvoy J, **Lieberman JA**: Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial. *In Prep*.
- Vetsa YSK, Styner M, Pizer SM, McClure RK, **Lieberman JA**, Gerig G: Localized differences in caudate size and shape in schizophrenia associated with typical versus atypical antipsychotic treatment. *In Prep*.
- Addington J, **Lieberman JA**, et al: Impact of extrapyramidal symptoms on depression in a randomized trial of treatment for chronic schizophrenia. *Psychiatric Quarterly*, Submitted.

- Davis SN, Stroup TS, Koch GG, Davis CE, Rosenheck R, **Lieberman JL**: Time to all-cause treatment discontinuation as the primary outcome in the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia study. *Statistics in Biopharmaceutical Research*, Submitted.
- Müller DJ, **Lieberman JA**, et al: Investigation of melancortin-system gene variants in antipsychotic induced weight gain. *The World Journal of Biological Psychiatry*, Submitted.
- Zipursky RB, Gu H, Charles C, Sharma T, Green AI, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Keefe R, Hamer R, Tohen MF, **Lieberman JA**, for the HGDH Study Group: Clinical correlates of MRI brain volumes in first episode psychosis. *Biological Psychiatry*, Submitted.
- Shi X, Zhu H, Ibrahim JG, Laing F, **Lieberman JA**, Styner M: Intrinsic regression models for medical representation of subcortical structures. *JAMA*, In Press.
- Sikich L, McClellan JM, Frazier JA, Findling RL, Johnson JL, Ambler D M-L, Bethea TC, Hlastala S, Noyes N, Kaufman EM, McNamara NK, Faber J, Maloney AE, Anderson R, Hamer RM, **Lieberman JA**: Acute and maintenance open ziprasidone treatment of early-onset schizophrenia spectrum disorders: ZEOSS results. *J Am Acad Child and Adolescent Psychiatry*, In Press.
- Slifstein M, **Lieberman JA**, et al: Characterization of *in vivo* pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [(11)C]NNC112 raclopride. *Journal of Cerebral Blood Flow and Metabolism*, In Press.
- Van den Oord E, Adkins D, McClay J, **Lieberman JA**, Sullican P: A systematic method for estimating individual responses to treatment with antipsychotics in CATIE. *Schizophrenia Bulletin*, In Press.
- Van der Stelt O, Frye J, **Lieberman JA**, Belger A: Visual and auditory event-related brain potentials in schizophrenia. *Archives of General Psychiatry*, In Press.

### Published

2015

- Andreassen OA, Harbo HF, Wang Y, Thompson WK, Schork AJ, Mattingsdal M, Zuber V, Bettella F, Ripke S, Kelsoe JR, Kendler KS, O'Donovan MC, Sklar P; The Psychiatric Genomics Consortium (PGC) Bipolar Disorder and Schizophrenia Work Groups; The International Multiple Sclerosis Genetics Consortium (IMSGC), McEvoy LK, Desikan RS, Lie BA, Djurovic S, Dale AM: Genetic pleiotropy between multiple sclerosis and schizophrenia but not bipolar disorder: differential involvement of immune-related gene loci. *Mol Psychiatry* 2015; 20(2):207-214.
- DeVylder JE, Lukens EP, Link BG, **Lieberman JA**: Suicidal ideation and suicide attempts among adults with psychotic experiences: data from the collaborative psychiatric epidemiology surveys. *JAMA Psychiatry* 2015; 72(3):219-225.
- Dixon LB, Goldman HH, Bennett ME, Wang Y, McNamara KA, Mendon SJ, Goldstein AB, Choi CW, Lee RJ, **Lieberman JA**, Essock SM: Implementing coordinated speciality care for early psychosis: the RAISE Connection program. *Psychiatr Serv* 2015 PMID: 25772764 [Epub ahead of print as of April 28, 2015].
- Fonseka TM, Tiwari AK, Gonçalves VF, **Lieberman JA**, Meltzer HY, Goldstein BI, Kennedy JL, Kennedy SH, Müller DJ: The role of genetic variation across IL-1 $\beta$ , IL-2, IL-6, and BDNF in antipsychotic-induced weight gain. *World J Biol Psychiatry* 2015; 16(1):45-56.
- Graham KA, Keefe RS, **Lieberman JA**, Calikoglu AS, Lansing KM, Perkins DO: Relationship of low vitamin D status with positive, negative and cognitive symptom domains in people with first-episode schizophrenia. *Early Interv Psychiatry* 2015 PMID: 24612563 [Epub ahead of print as of April 28, 2015].
- Jarskog LF, Lowy MT, Grove RA, Keefe RS, Horrigan JP, Ball MP, Breier A, Buchanan RW, Carter CS, Csernansky JG, Goff DC, Green MF, Kantrowitz JT, Keshavan MS, Laurelle M, **Lieberman JA**, Marder SR, Maruff P, McMahon RP, Seidman LJ, Peykarnian MA: a Phase II study of a histamine H<sub>3</sub> receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. *Schizophr Res* 2015; 164(1-3):136-142.

- Maier R, Moser G, Chen GB, Ripke S; Cross-Disorder Working Group of the Psychiatric Genomics Consortium, Coryell W, Potash JB, Scheftner WA, Shi J, Weissman MM, Hultman CM, Landén M, Levinson DF, Kendler KS, Smoller JW, Wray NR, Lee SH; Cross-Disorder Working Group of the Psychiatric Genomics Consortium: Joint analysis of psychiatric disorders increases accuracy of risk prediction for schizophrenia, bipolar disorder, and major depressive disorder. *Am J Hum Genet* 2015; 96(2): 283-294.
- Network and Pathway Analysis Subgroup of Psychiatric Genomics Consortium. *Nat Neurosci* 2015; 18(2):199-209.
- Pouget JG, Gonçalves VF, Nurmi EL, P Laughlin C, Mallya KS, McCracken JT, Aman MG, McDougale CJ, Scahill L, Misener VL, Tiwari AK, Zai CC, Brandl EJ, Felsky D, Leung AQ, **Lieberman JA**, Meltzer HY, Potkin SG, Niedling C, Steimer W, Leucht S, Knight J, Müller DJ, Kennedy JL: Investigation of TSPO variants in schizophrenia and antipsychotic treatment outcomes. *Pharmacogenomics* 2015; 16(1):5-22.
- Rosell DR, Zaluda LC, McClure MM, Perez-Rodriguez MM, Strike KS, Barch DM, Harvey PD, Girgis RR, Hazlett EA, Mailman RB, Abi-Dargham A, **Lieberman JA**, Siever LJ: Effects of the D1 dopamine receptor agonist dihydrexidine (DAR-0100A) on working memory in schizotypal personality disorder. *Neuropsychopharmacology* 2015; 40(2):446-453.
- Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, **Lieberman JA**: Placebo response in antipsychotic clinical trials: a meta-analysis. *JAMA Psychiatry* 2015; 71(12):1409-1421.
- Slifstein M, van de Giessen E, Van Snellenberg J, Thompson JL, Narendran R, Gil R, Hackett E, Girgis R, Ojeil N, Moore H, D'Souza D, Malison RT, Huang Y, Lim K, Nabulsi N, Carson RE, **Lieberman JA**, Abi-Dargham A: Defects in prefrontal cortical and extrastriatal dopamine release in schizophrenia: a positron emission tomographic functional magnetic resonance imaging study. *JAMA Psychiatry* 2015; 72(3):316-324.
- Zai CC, Tiwari AK, Chowdhury NI, Brandl EJ, Shaikh SA, Freeman N, **Lieberman JA**, Meltzer HY, Müller DJ, Kennedy JL: Association study of GABAA  $\alpha 2$  receptor subunit gene variants in antipsychotic-associated weight gain. *J Clin Psychopharmacol* 2015; 35(1):7-12.

## 2014

- Ballon JS, Pajvani U, Freyberg Z, Leibel RL, **Lieberman JA**: Molecular pathophysiology of metabolic effects of antipsychotic medications. *Trends Endocrinol Metab* 2014; 25(11):593-600.
- Bargmann CI, **Lieberman JA**: What the BRAIN initiative means for psychiatry. *Am J Psychiatry* 2014; 171(10):1038-1040.
- Brandl EJ, **Lieberman JA**, et al: Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain. *Pharmacogenomics* 2014; 15(4):423-431.
- Brandl EJ, Tiwari AK, Zai CC, Chowdhury NI, **Lieberman JA**, Meltzer HY, Kennedy JL, Müller DJ: No evidence for a role of the peroxisome proliferator-activated receptor gamma (PPARG) and adiponectin (ADIPOQ) genes in antipsychotic-induced weight gain. *Psychiatry Res* 2014; 219(2):255-260.
- Chowdhury NI, Souza RP, Tiwari AK, Brandl EJ, Sicard M, Meltzer HY, **Lieberman JA**, Kennedy JL, Müller DJ: Investigation of melancortico system gene variants in antipsychotic-induced weight gain. *World J Biol Psychiatry* 2014; 15(3):251-258.
- DuPont RF, **Lieberman JA**: Young brains on drugs. *Science* [Editorial] 2014; 344(6184):557.
- Gagliano SA, Tiwari AK, Freeman N, **Lieberman JA**, Meltzer HY, Kennedy JL, Knight J, Müller DJ: Protein kinase cAMP-dependent regulatory type II beta (PRKAR2B) gene variants in antipsychotic-induced weight gain. *Hum Psychopharmacol* 2014; 29(4):330-335.
- Goldstein JI, Jarskog LF, Hilliard C, Alfirevic A, Duncan L, Fourches D, Huang H, Lek M, Neale BM, Ripke S, Shianna K, Szatkiewicz JP, Tropsha A, van den Oord EJ, Cascorbi I, Dettling M, Gazit E, Goff DC, Holden AL, Kelly DL, Malhotra AK, Nielsen J, Pirmohamed M, Rujescu D, Werge T, Levy DL, Josiassen RC, Kennedy JL, **Lieberman JA**, Daly MJ, Sullivan PF: Clozapine-induced agranulocytosis is associated with rare HLA-DQB1 and HLA-B alleles. *Nat Commun* 2014; 5:4757.



- Gonçalves VF, Zai CC, Tiwari AK, Brandl EJ, Derkach A, Meltzer HY, **Lieberman JA**, Müller DJ, Sun L, Kennedy JL: A hypothesis driven association study of 28 nuclear-encoded mitochondrial genes with antipsychotic-induced weight gain in schizophrenia. *Neuropsychopharmacology* 2014; 39(6):1347-1354.
- Kao AC, Rojnic Kuzman M, Tiwari AK, Zivkovic MV, Chowdhury NI, Medved V, Kekin I, Zai CC, **Lieberman JA**, Meltzer HY, Bozina T, Bozina N, Kennedy JL, Sertic J, Müller DJ: Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances. *J Psychiatry Res* 2014; 54:36-42.
- Lieberman LA**: Our future is now. *Am J Psychiatry* 2014; 171(7):733-737.
- Nicodemus KK, Hargreaves A, Morris D, Anney R, Gill M, Corvin A, Donohoe G; Schizophrenia Psychiatric Genome-wide Association Study (GWAS) Consortium; Wellcome Trust Case Control Consortium 2: Variability in working memory performance explained by epistasis vs polygenic scores in the ZNF804A pathway. *JAMA Psychiatry* 2014; 71(7):778-785.
- Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, **Lieberman JA**, Abi-Dargham A, Girgis RR: Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. *Mol Psychiatry* 2014; 19(1):20-29.
- Poels EM, Kegeles LS, Kantrowitz JT, Javitt DC, **Lieberman JA**, Abi-Dargham A, Girgis RR: Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings. *Schizophr Res* 2014; 152(2-3):325-332.
- Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, **Lieberman JA**: Placebo response in antipsychotic clinical trials: a meta-analysis. *JAMA Psychiatry* 2014; 71(12):1409-1421.
- Shing EC, Tiwari AK, Brandl EJ, Zai CC, **Lieberman JA**, Meltzer HY, Kennedy JL, Müller DJ: Fat mass- and obesity-associated (FTO) gene and antipsychotic-induced weight gain: an association study. *Neuropsychobiology* 2014; 69(1):59-63.

## 2013

- Andreassen OA, Djurovic S, Thompson WK, Schork AJ, Kendler KS, O'Donovan MC, Rujescu D, Werge T, van de Bunt M, Morris AP, McCarthy MI; International Consortium for Blood Pressure GWAS; Diabetes Genetics Replication and Meta-analysis Consortium; Psychiatric Genomics Consortium Schizophrenia Working Group, Roddey JC, McEvoy LK, Desikan RS, Dale AM: Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. *Am J Hum Genet* 2013; 92(2):197-209.
- Brandl EJ, Tiwari AK, Lett TA, Shaikh SA, **Lieberman JA**, Meltzer HY, Kennedy JL, Müller DJ: Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain. *Human Psychopharmacol* 2013; 28(2):183-187.
- Chowdhury NI, Tiwari AK, Souza RP, Zai CC, Shaikh SA, Chen S, Liu F, **Lieberman JA**, Meltzer HY, Malhotra AK, Kennedy JL, Müller DJ: Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene. *Pharmacogenomics J* 2013; 13(3):272-279.
- Colibazzi T, Wexler B, Bansal R, Hao X, Liu J, Sanchez-Peña J, Corcoran, C, **Lieberman JA**, Peterson BS: Anatomical abnormalities in gray and white matter of the cortical surface in persons with schizophrenia. *PLoS One* 2013; 8(2):e55783.
- Cross-Disorder Group of the Psychiatric Genomics Consortium, Smoller JW, Craddock N, Kendler K, Lee PH, Neale BM, Nurnberger JI, Ripke S, Santangelo S, Sullivan PF: Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. *Lancet* 2013; 381(9875):1371-1379. Erratum in: *Lancet* 2013; 381(9875):1360.
- Crowley JJ, Hilliard CE, Kim Y, Morgan MB, Lewis LR, Muzny DM, Hawes AC, Sabo A, Wheeler DA, **Lieberman JA**, Sullivan PF, Gibbs RA: Deep resequencing and association analysis of schizophrenia candidate genes. *Mol Psychiatry* 2013; 18(2):138-140.
- Fisher CE, **Lieberman JA**: Getting the facts straight about gun violence and mental illness: putting compassion before fear. *Ann Intern Med* 2013; 159(6):423-424.
- Hasan A, Falkai P, Wobrock T, **Lieberman JA**, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task

force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 2: Update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World J Biol Psychiatry* 2013; 14(1):2-44.

- Jarskog LF, Dong Z, Kangarlou A, Colibazzi T, Girgis RR, Kegeles LS, Barch DM, Buchanan RW, Csernansky JG, Goff DC, Harms MP, Javitt DC, Keefe RS, McEvoy JP, McMahon RP, Marder SR, Peterson BS, **Lieberman JA**: Effects of davunetide on N-acetylaspartate and choline in dorsolateral prefrontal cortex in patients with schizophrenia. *Neuropsychopharmacology* 2013; 38(7):1245-1252.
- Jarskog LF, Hamer RM, Catellier DJ, Stewart DD, Lavange L, Ray N, Golden LH, **Lieberman JA**, Stroup TS, METS Investigators: Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. *Am J Psychiatry* 2013 170(9):1032-1040.
- Lee SH, Ripke S, Neale BM, Faraone SV, Purcell SM, Perlis RH, Mowry BJ, Thapar A, Goddard ME, Witte JS, Absher D, Agartz I, Akil H, Amin F, Andreassen OA, Anjorin A, Anney R, Anttila V, Arking DE, Asherson P, Azevedo MH, Backlund L, Badner JA, Bailey AJ, Banaschewski T, Barchas JD, Barnes MR, Barrett TB, Bass N, Battaglia A, Bauer M, Bayés M, Bellivier F, Bergen SE, Berrettini W, Betancur C, Bettecken T, Biederman J, Binder EB, Black DW, Blackwood DH, Bloss CS, Boehnke M, Boomsma DI, Breen G, Breuer R, Bruggeman R, Cormican P, Buccola NG, Buitelaar JK, Bunney WE, Buxbaum JD, Byerley WF, Byrne EM, Caesar S, Cahn W, Cantor RM, Casas M, Chakravarti A, Chambert K, Choudhury K, Cichon S, Cloninger CR, Collier DA, Cook EH, Coon H, Cormand B, Corvin A, Coryell WH, Craig DW, Craig IW, Crosbie J, Cuccaro ML, Curtis D, Czamara D, Datta S, Dawson G, Day R, De Geus EJ, Degenhardt F, Djurovic S, Donohoe GJ, Doyle AE, Duan J, Dudbridge F, Duketis E, Ebstein RP, Edenberg HJ, Elia J, Ennis S, Etain B, Fanous A, Farmer AE, Ferrier IN, Flickinger M, Fombonne E, Foroud T, Frank J, Franke B, Fraser C, Freedman R, Freimer NB, Freitag CM, Friedl M, Frisén L, Gallagher L, Gejman PV, Georgieva L, Gershon ES, Geschwind DH, Giegling I, Gill M, Gordon SD, Gordon-Smith K, Green EK, Greenwood TA, Grice DE, Gross M, Grozeva D, Guan W, Gurling H, De Haan L, Haines JL, Hakonarson H, Hallmayer J, Hamilton SP, Hamshire ML, Hansen TF, Hartmann AM, Hautzinger M, Heath AC, Henders AK, Herms S, Hickie IB, Hipolito M, Hoefels S, Holmans PA, Holsboer F, Hoogendijk WJ, Hottenga JJ, Hultman CM, Hus V, Ingason A, Ising M, Jamain S, Jones EG, Jones I, Jones L, Tzeng JY, Kähler AK, Kahn RS, Kandaswamy R, Keller MC, Kennedy JL, Kenny E, Kent L, Kim Y, Kirov GK, Klauck SM, Klei L, Knowles JA, Kohli MA, Koller DL, Konte B, Korszun A, Krabbendam L, Krasucki R, Kuntsi J, Kwan P, Landén M, Långström N, Lathrop M, Lawrence J, Lawson WB, Leboyer M, Ledbetter DH, Lee PH, Lencz T, Lesch KP, Levinson DF, Lewis CM, Li J, Lichtenstein P, **Lieberman JA**, Lin DY, Linszen DH, Liu C, Lohoff FW, Loo SK, Lord C, Lowe JK, Lucae S, MacIntyre DJ, Madden PA, Maestrini E, Magnusson PK, Mahon PB, Maier W, Malhotra AK, Mane SM, Martin CL, Martin NG, Mattheisen M, Matthews K, Mattingsdal M, McCarroll SA, McGhee KA, McGough JJ, McGrath PJ, McGuffin P, McInnis MG, McIntosh A, McKinney R, McLean AW, McMahon FJ, McMahon WM, McQuillin A, Medeiros H, Medland SE, Meier S, Melle I, Meng F, Meyer J, Middeldorp CM, Middleton L, Milanova V, Miranda A, Monaco AP, Montgomery GW, Moran JL, Moreno-De-Luca D, Morken G, Morris DW, Morrow EM, Moskvina V, Muglia P, Mühleisen TW, Muir WJ, Müller-Myhsok B, Murtha M, Myers RM, Myin-Germeys I, Neale MC, Nelson SF, Nievergelt CM, Nikolov I, Nimgaonkar V, Nolen WA, Nöthen MM, Nurnberger JI, Nwulia EA, Nyholt DR, O'Dushlaine C, Oades RD, Olincy A, Oliveira G, Olsen L, Ophoff RA, Osby U, Owen MJ, Palotie A, Parr JR, Paterson AD, Pato CN, Pato MT, Penninx BW, Pergadia ML, Pericak-Vance MA, Pickard BS, Pimm J, Piven J, Posthuma D, Potash JB, Poustka F, Propping P, Puri V, Quested DJ, Quinn EM, Ramos-Quiroga JA, Rasmussen HB, Raychaudhuri S, Rehnström K, Reif A, Ribasés M, Rice JP, Rietschel M, Roeder K, Roeyers H, Rossin L, Rothenberger A, Rouleau G, Ruderfer D, Rujescu D, Sanders AR, Sanders SJ, Santangelo SL, Sergeant JA, Schachar R, Schalling M, Schatzberg AF, Scheftner WA, Schellenberg GD, Scherer SW, Schork NJ, Schulze TG, Schumacher J, Schwarz M, Scolnick E, Scott LJ, Shi J, Shilling PD, Shyn SI, Silverman JM, Slager SL, Smalley SL, Smit JH, Smith EN, Sonuga-Barke EJ, St Clair D, State M, Steffens M, Steinhausen HC, Strauss JS, Strohmaier J, Stroup TS, Sutcliffe JS, Szatmari P, Szelinger S, Thirumalai S, Thompson RC,

Todorov AA, Tozzi F, Treutlein J, Uhr M, van den Oord EJ, Van Grootheest G, Van Os J, Vicente AM, Vieland VJ, Vincent JB, Visscher PM, Walsh CA, Wassink TH, Watson SJ, Weissman MM, Werge T, Wienker TF, Wijsman EM, Willemsen G, Williams N, Willsey AJ, Witt SH, Xu W, Young AH, Yu TW, Zammit S, Zandi PP, Zhang P, Zitman FG, Zöllner S; International Inflammatory Bowel Disease Genetics Consortium (IIBDGC), Devlin B, Kelsoe JR, Sklar P, Daly MJ, O'Donovan MC, Craddock N, Sullivan PF, Smoller JW, Kendler KS, Wray NR, Cross-Disorder Group of the Psychiatric Genomics Consortium: Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. *Nat Genet* 2013; 45(9):984-994.

**Lieberman JA**: Response to the presidential address. *Am J Psychiatry* 2013; 170(10):1106-1107.

**Lieberman JA**, Dixon LB, Goldman HH: Early detection and intervention in schizophrenia: a new therapeutic model. *JAMA* 2013; 310(7):689-690.

**Lieberman JA**, Dunbar G, Segreti AC, Girgis RR, Seoane F, Beaver JS, Duan N, Hosford DA: A randomized exploratory trial of an alpha-7 nicotinic receptor agonist (TC-5619) for cognitive enhancement in schizophrenia. *Neuropsychopharmacology* 2013; 38(6):968-975.

Lett TA, Chakavarty MM, Felsky D, Brandl EJ, Tiwari AK, Gonçalves VF, Rajji TK, Daskalakis ZJ, Meltzer HY, **Lieberman JA**, Lerch JP, Mulsant BH, Kennedy JL, Voineskos AN: The genome-wide supported microRNA-137 variant predicts phenotypic heterogeneity within schizophrenia. *Mol Psychiatry* 2013; 18(4):443-450.

McClure RK, Styner MA, Maltbie E, **Lieberman JA**, Gouttard S, Gerig G, Shi X, Zhu H: Localized differences in caudate and hippocampal shape are associated with schizophrenia but not antipsychotic type. *Psychiatry Res* 2013; 211(1):1-10.

Schobel SA, Chaudhury NH, Khan UA, Paniagua B, Styner MA, Asllani I, Inbar BP, Corcoran CM, **Lieberman JA**, Moore H, Small SA: Imaging patients with psychosis and a mouse model establishes a spreading pattern of hippocampal dysfunction and implicates glutamate as a driver. *Neuron* 2013; 78(1):81-93.

Schork AJ, Thompson WK, Pham P, Torkamani A, Roddey JC, Sullivan PF, Kelsoe JR, O'Donovan MC, Furberg H; Tobacco and Genetics Consortium; Bipolar Disorder Psychiatric Genomics Consortium; Schizophrenia Psychiatric Genomics Consortium, Schork NJ, Andreassen OA, Dale AM: All SNPs are not created equal: genome-wide association studies reveal a consistent pattern of enrichment among functionally annotated SNPs. *PLoS Genet* 2013; 9(4):e1003449.

Terwisscha van Scheltinga AF, Bakker SC, van Haren NE, Derks EM, Buizer-Voskamp JE, Boos HB, Cahn W, Hulshoff Pol HE, Ripke S, Ophoff RA, Kahn RS; Psychiatric Genome-wide Association Study Consortium: Genetic schizophrenia risk variants jointly modulate total brain and white matter volume. *Biol Psychiatry* 2013 73(6):525-531.

Tiwari AK, Brandl EJ, Weber C, Likhodi O, Zai CC, Hahn MK, **Lieberman JA**, Meltzer HY, Kennedy JL, Müller DJ: Association of a functional polymorphism in neuropeptide Y with antipsychotic-induced weight gain in schizophrenia patients. *J Clin Psychopharmacol* 2013; 33(1):11-17.

Zai CC, Tiwari AK, Mazzoco M, de Luca V, Müller DJ, Shaikh SA, Lohoff FW, Freeman N, Voineskos AN, Potkin SG, **Lieberman JA**, Meltzer HY, Remington G, Kennedy JL: Association study of the vesicular monoamine transporter gene SLC18A2 with tardive dyskinesia. *J Psychiatr Res* 2013; 47(11):1760-1765.

## 2012

Aberg K, Adkins DE, Liu Y, McClay JL, Bukszá J, Jia P, Zhao Z, Perkins DO, Stroup TS, **Lieberman JL**, Sullivan PF, van den Oord EJ: Genome-wide association study of antipsychotic-induced QTc interval prolongation. *Pharmacogenomics J* 2012; 12(2):165-172.

Brandl EJ, Frydrychowicz C, Tiwari AK, Lett TA, Kitzrow W, Büttner S, Erlich S, Meltzer HY, **Lieberman JA**, Kennedy JL, Müller DJ, Puls I: Association study of polymorphisms in leptin and leptin receptor genes with antipsychotic-induced body weight gain. *Prog Neuropsychopharmacol Biol Psychiatry* 2012; 38(2): 134-141.

- Derks EM, Vorstman JA, Ripke S, Kahn RS; Schizophrenia Psychiatric Genomic Consortium, Ophoff RA: Investigation of the genetic association between qualitative measures of psychosis and schizophrenia: a polygenic risk score analysis. *PLoS One* 2012; 7(6):e37852.
- Frazier JA, Guiliano AJ, Johnson JL, Yakutis L, Youngstrom EA, Breiger D, Sikich L, Findling RL, McClellan J, Hamer RM, Vitiello B, **Lieberman JA**, Hooper SR: Neurocognitive outcomes in the treatment of early-onset schizophrenia spectrum disorders study. *J Am Acad Child Adolesc Psychiatry* 2012; 51(5):496-505.
- Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, Thibaut F, Möller HJ; WFSBP Task force on Treatment Guidelines for Schizophrenia: World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Schizophrenia, Part 1: Update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World J Biol Psychiatry* 2012; 13(5):318-178.
- Hirata Y, Zai CC, Souza RP, **Lieberman JA**, Meltzer HY, Kennedy JL: Association study of GRIK1 gene polymorphism in schizophrenia: case-control and family-based studies. *Hum Psychopharmacol* 2012; 27(4):345-351.
- Huey ED, **Lieberman JA**: From known to unknown; old to new: can lesion studies inform psychiatry about mental illness in the 21<sup>st</sup> century? *Neuropsychiatry* 2012; 2(5):369-372.
- Hwang R, Tiwari AK, Zai CC, Felsky D, Remington E, Wallace T, Tong RP, Souza RP, Oh G, Potkin SG, **Lieberman JA**, Meltzer HY, Kennedy JL: Dopamine D4 and D5 receptor gene variant effects on clozapine response in schizophrenia: replication and exploration. *Prog Neuropsychopharmacol Biol Psychiatry* 2012; 37(1):62-75.
- Javitt D, Buchanan RW, Keefe RS, Kern R, McMahon RP, Green MF, **Lieberman JA**, Goff DC, Csernansky JG, McEvoy JP, Jarskog LF, Seidman LJ, Gold JM, Kimhy D, Nolan KS, Barch DS, Ball MP; Robinson J, Marder SJ: Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia. *Schizophrenia Res* 2012; 136(1-3):25-31.
- Keller MC, Simonson MA, Ripke S, Neale BM, Gejman PV, Howrigan DP, Lee SH, Lencz T, Levinson DF, Sullivan PF (Collaborators 114): Schizophrenia Psychiatric Genome-Wide Association Study Consortium: Runs of homozygosity implicate autozygosity as a schizophrenia risk factor. *PLoS Genet* 2012; 8(4):e1002656.
- Malhotra AK, Correll CU, Chowdhury NI, Müller DJ, Gergersen PK, Lee AT, Tiwari AK, Kane JM, Fleischhacker WW, Kahn RS, Ophoff RA, **Lieberman JA**, Meltzer HY, Lencz T, Kennedy JL: Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. *Arch Gen Psychiatry* 2012; 69(9):904-912.
- Mamah D, Harms MP, Barch D, Styner M, **Lieberman JA**, Wang L: Hippocampal shape and volume changes with antipsychotics in early stage psychotic illness. *Front Psychiatry* 2012; 3:96.
- Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, **Lieberman JA**: Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents. [Feature Review] *Mol Psychiatry* 2012; 12:1206-1227.
- Müller DJ, Brandl EJ, Hwang R, Tiwari AK, Sturgess JE, Zai CC, **Lieberman JA**, Kennedy JL, Richter MA: The amplichip CYP450® test and response to treatment in schizophrenia and obsessive-compulsive disorder: a pilot study and focus on cases with abnormal CYP2D6 drug metabolism. *Genet Test Mol Biomarkers* 2012; 16(8):891-903.
- Müller DJ, Zai CC, Sicard M, Remington E, Souza RP, Tiwari AK, Hwang R, Likhodi O, Shaikh S, Freeman N, Arenovich T, Heinz A, Meltzer HY, **Lieberman JA**, Kennedy JL: Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain. *Pharmacogenomics J* 2012; 12(2):156-164.
- Sherer EA, Sale ME, Pollock BG, Belani CP, Egorin MJ, Ivy PS, **Lieberman JA**, Manuck SB, Marder SR, Muldoon MF, Scher HI, Solit DB, Bies RR: Application of a single-objective, hybrid genetic algorithm approach to pharmacokinetic model building. *J Pharmacokinet Pharmacodyn* 2012; 39(4):393-414.
- Souza RP, Tiwari AK, Chowdhury NI, Ceddia RB, **Lieberman JA**, Meltzer HY, Kennedy JL, Müller DJ:

- Association study between variants of AMP-activated protein kinase catalytic and regulatory subunit genes with antipsychotic-induced weight gain. *J Psychiatr Res* 2012; 46(4):462-468.
- Tamburello AC, **Lieberman JA**, Baum RM, Reeves R: Successful removal of quetiapine from a correctional formulary. *J Am Acad Psychiatry Law* 2012; 40(4):502-508.
- Tiwari AK, Zai CC, Likhodi O, Voineskos AN, Meltzer HY, **Lieberman JA**, Potkin SG, Remington G, Müller DJ, Kennedy JL: Association study of cannabinoid receptor 1 (CNR1) gene in tardive dyskinesia. *Pharmacogenomics* 2012; 12(3):260-266.
- Zai GC, Zai CC, Chowdury NI, Tiwari AK, Souza RP, **Lieberman JA**, Meltzer HY, Potkin SG, Müller DJ, Kennedy JL: The role of brain-derived neurotrophic factor (BDNF) gene variants in antipsychotic response and antipsychotic-induced weight gain. *Prog Neuropsychopharmacol Biol Psychiatry* 2012; 39(1):96-101.
- 2011**
- Addington DE, Mohamed S, Rosenheck RA, Davis SM, Stroup TS, McEvoy JP, Swartz MS, **Lieberman JA**: Impact of second-generation antipsychotics and perphenazine on depressive symptoms in a randomized trial of treatment for chronic schizophrenia. *J Clin Psychiatry* 2011; 72(1):75-80.
- Adkins DE, Åberg K, McClay JL, Bukszár J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, **Lieberman JA**, Sullivan PF, van den Oord JCG: Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. *Mol Psychiatry* 2011; 16(3): 321-332.
- Buchanan RW, Keefe RSE, **Lieberman JA**, Barch DM, Csernansky JG, Goff DC, Gold JM, Green MF, Jarskog LF, Javitt DC, Kimhy D, Kraus MS, McEvoy JP, Mesholam-Gately RI, Seidman LJ, Ball MP, McMahon RP, Kern RS, Robinson J, Marder SR: A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia. *Biol Psychiatry* 2011; 69(5):442-449.
- Caroff SN, Davis VG, Miller DD, Davis SM, Rosenheck RA, McEvoy JP, Campbell EC, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, **Lieberman JA**, for the CATIE Investigators: Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia. *J Clin Psychiatry* 2011; 72(3):295-303.
- De Luca V, Souza RP, Viggiano E, Sickert L, Teo C, Zai C, Tiwari AK, Müller DJ, **Lieberman JA**, Volavka J, Meltzer HY, Kennedy JL: Genetic interactions in the adrenergic system genes: analysis of antipsychotic-induced weight gain. *Hum Psychopharmacol* 2011; 26(6):386-391.
- Girgis RR, Merrill DB, Vorel SR, Kim E, Portland K, You M, Pikalov A, Whitehead R, **Lieberman JA**: Aripiprazole versus haloperidol in early-stage schizophrenia. *J Psychiatr Res* 2011; 45(6):756-762.
- Girgis RR, Phillips MR, Li X, Li K, Jiang H, Wu C, Duan N, Niu Y, **Lieberman JA**: Clozapine v. chlorpromazine in treatment-naïve, first-episode schizophrenia: 9 year follow-up results from a randomized clinical trial. *Br J Psychiatry* 2011; 199(4):281-288.
- Hermes E, Nasrallah H, Davis V, Mayer J, McEvoy J, Goff D, Davis S, Stroup TS, Swartz M, **Lieberman JA**, Rosenheck R: The association between weight change and symptom reduction in the CATIE schizophrenia trial. *Schizophr Res* 2011; 128:166-170.
- Hwang R, Souza RP, Tiwari AK, Zai CC, Müller DJ, Potkin SG, **Lieberman JA**, Meltze HY, Kennedy JL: Gene-gene interaction analyses between NMDA receptor subunit and dopamine receptor gene variants and clozapine response. *Pharmacogenomics* 2011; 12(2):277-291.
- Lett TA, Tiwari AK, Meltzer HY, **Lieberman JA**, Potkin SG, Voineskos AN, Kennedy JL, Müller DJ: The putative functional rs10045881 marker of neurexin-1 in schizophrenia and clozapine response. *Schizophr Res* 2011; 132(2-3):121-124.
- Lieberman JA**, Stroup TS: The NIMH-CATIE schizophrenia study: what did we learn? *Am J Psychiatry* 2011; 168(8):770-775.
- Lyon GJ, Abi-Dargham A, Moore H, **Lieberman JA**, Javitch JJ, Sulzer D: Presynaptic regulation of dopamine transmission in schizophrenia. *Schizophr Bull* 2011; 37(1):108-117.
- Marder SR, Roth B, Sullivan PF, Scolnick EM, Nestler EJ, Geyer MA, Welnberger DR, Karayiorgou M,

- Guidotti A, Gingrich J, Akbarian S, Buchanan RW, **Lieberman JA**, Conn PJ, Haggarty SJ, Law AJ, Campbell B, Krystal JH, Moghaddam B, Saw A, Caron MG, George SR, Allen JA, Solis M: Advancing drug discovery for schizophrenia. *Ann NY Acad Sci* 2011; 1236(1):30-43.
- Marx CE, Bradford DW, Hamer RM, Naylor JC, Allen TB, **Lieberman JA**, Strauss JL, Kilts JD: Pregnenolone as a novel therapeutic candidate in schizophrenia: emerging preclinical and clinical evidence. *Neuroscience* 2011; 191:78-90.
- McClay JL, Adkins DE, Aberg K, Bukszár J, Khachane AN, Keefe RS, Perkins DO, McEvoy JP, Stroup TS, Vann RE, Beardsley PM, **Lieberman JA**, Sullivan PF, van den Oord EJ: Genome-wide pharmacogenomics study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia. *Neuropsychopharmacology* 2011; 36(3):616-626.
- McClay JL, Adkins DE, Aberg K, Stroup TS, Perkins DO, Vladimirov VI, **Lieberman JA**, Sullivan PF, van den Oord EJ: Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics. *Mol Psychiatry* 2011; 16(1):76-85.
- Olfson M, Gerhard T, Huang C, **Lieberman JA**, Bobo WV, Crystal S: Comparative effectiveness of second generation antipsychotic medications in early onset schizophrenia. *Schizophr Bull* 2011; 36(4):723-731.
- Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA, Lin DY, Duan J, Ophoff RA, Andreassen OA, Scolnick E, Cichon S, St Clair D, Corvin A, Gurling H, Werge T, Rujescu D, Blackwood DH, Pato CN, Malhotra AK, Purcell S, Dudbridge F, Neale BM, Rossin L, Visscher PM, Posthuma D, Ruderfer DM, Fanous A, Stefansson H, Steinberg S, Mowry BJ, Golimbet V, De Hert M, Jönsson EG, Bitter I, Pietiläinen OP, Collier DA, Tosato S, Agartz I, Albus M, Alexander M, Amdur RL, Amin F, Bass N, Bergen SE, Black DW, Børglum AD, Brown MA, Bruggeman R, Buccola NG, Byerley WF, Cahn W, Cantor RM, Carr VJ, Catts SV, Choudhury K, Cloninger CR, Cormican P, Craddock N, Danoy PA, Datta S, de Haan L, Demontis D, Dikeos D, Djurovic S, Donnelly P, Donohoe G, Duong L, Dwyer S, Fink-Jensen A, Freedman R, Freimer NB, Friedl M, Georgieva L, Giegling I, Gill M, Glenthøj B, Godard S, Hamshire M, Hansen M, Hansen T, Hartmann AM, Henskens FA, Hougaard DM, Hultman CM, Ingason A, Jablensky AV, Jakobsen KD, Jay M, Jürgens G, Kahn RS, Keller MC, Kenis G, Kenny E, Kim Y, Kirov GK, Konnerth H, Konte B, Krabbendam L, Krasucki R, Lasseter VK, Laurent C, Lawrence J, Lencz T, Lerer FB, Liang KY, Lichtenstein P, **Lieberman JA**, Linszen DH, Lönngqvist J, Loughland CM, Maclean AW, Maher BS, Maier W, Mallet J, Malloy P, Mattheisen M, Mattingsdal M, McGhee KA, McGrath JJ, McIntosh A, McLean DE, McQuillin A, Melle I, Michie PT, Milanova V, Morris DW, Mors O, Mortensen PB, Moskvina V, Muglia P, Myin-Germeys I, Nertney DA, Nestadt G, Nielsen J, Nikolov I, Nordentoft M, Norton N, Nöthen MM, O'Dushlaine CT, Olincy A, Olsen L, O'Neill FA, Orntoft TF, Owen MJ, Pantelis C, Papadimitriou G, Pato MT, Peltonen L, Petursson H, Pickard B, Pimm J, Pulver AE, Puri V, Quedsted D, Quinn EM, Rasmussen HB, Réthelyi JM, Ribble R, Rietschel M, Riley BP, Ruggeri M, Schall U, Schulze TG, Schwab SG, Scott RJ, Shi J, Sigurdsson E, Silverman JM, Spencer CC, Stefansson K, Strange A, Strengman E, Stroup TS, Suvisaari J, Terenius L, Thirumalai S, Thygesen JH, Timm S, Toncheva D, van den Oord E, van Os J, van Winkel R, Veldink J, Walsh D, Wang AG, Wiersma D, Wildenauer DB, Williams HJ, Williams NM, Wormley B, Zammit S, Sullivan PF, O'Donovan MC, Daly MJ, Gejman PV, The Schizophrenia Psychiatric Genome-Wide Association Study (GWAS) Consortium: Genome-wide association study identifies five new schizophrenia loci. *Nat Genet* 2011; 43(10):969-976.
- Roberts CE, Mortenson LY, Merrill DB, Rafizadeh N, Smith TE, **Lieberman JA**: Successful re-challenge with clozapine after eosinophilia. *Am J Psychiatry* 2011; 168(11):1147-1151.
- Rosenfeld AJ, **Lieberman JA**, Jarskog LF: Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. *Schizophr Bull* 2011; 37(5):1077-1087.
- Shi X, Ibrahim JG, **Lieberman JA**, Styner M, Li Y, Zhu H: Two-stage empirical likelihood for longitudinal neuroimaging data. *Annals of Applied Statistics* 2011; 5(2B):1132-1158.
- Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, **Lieberman JA**, Kennedy JL, Müller DJ: Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. *Pharmacogenomics* 2011; 11(11):1561-1571.
- Souza RP, Meltzer HY, **Lieberman JA**, Le Foll B, Kennedy JL: Influence of neurexin 1 (NRXN1)

- polymorphisms in clozapine response. *Hum Psychopharmacol* 2011; 25(7-8):582-585.
- Souza RP, Meltzer HY, **Lieberman JA**, Voineskos AN, Remington G, Kennedy JL: Prolactin as a biomarker for treatment response and tardive dyskinesia in schizophrenia subjects: old thoughts revisited from a genetic perspective. *Hum Psychopharmacol* 2011; 26(1):21-17.
- Souza RP, Rosa DV, Romano-Silva MA, Zhen M, Meltzer HY, **Lieberman JA**, Remington G, Kennedy JL, Wong AH: Lack of association of NALCN genetic variants with schizophrenia. *Psychiatry Res* 2011; 185(3):450-452.
- Stauffer VL, Case M, Kinon BJ, Conley R, Ascher-Svanum H, Kollack-Walker S, Kane J, McEvoy J, **Lieberman JA**: Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. *Psychiatry Res* 2011; 187(1-2):42-48.
- Stroup TS, Appelbaum PS, Gu H, Hays S, Swartz MS, Keefe RS, Kim SY, Manschreck TC, Boshes RA, McEvoy JP, **Lieberman JA**: Longitudinal consent-related abilities among research participants with schizophrenia: results from the CATIE study. *Schizophr Res* 2011; 130(1-3):47-52.
- Stroup TS, McEvoy JP, Ring KD, Hamer RH, Lavange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, **Lieberman JA**: The Schizophrenia Trials Network: A randomized trial examining the effectiveness of switching from olanzapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). *Am J Psychiatry* 2011; 168(9):947-956.
- Tiwari HK, Patki A, **Lieberman JA**, Stroup TS, Allison DB, Leibel RL, Chung WK: Association of allelic variation in genes mediating aspects of energy homeostasis with weight gain during administration of antipsychotic drugs (CATIE study). *Front Genet* 2011; 2(56) doi:pii:00056.
- Wessels AM, Bies RR, Pollock BG, Schneider LS, **Lieberman JA**, Stroup TS, Li CH, Coley K, Kirshner MM, Marder SR: Population pharmacokinetic modeling of ziprasidone in patients with schizophrenia from the CATIE study. *J Clin Pharmacol* 2011; 51(11):1587-1591.
- Yolken RH, Torrey EF, **Lieberman JA**, Yang S, Dickerson FB: Serological evidence of exposure to Herpes Simplex Virus type 1 is associated with cognitive deficits in the CATIE schizophrenia sample. *Schizophr Res* 2011; 128(1-3):61-65.

## 2010

- Aberg K, Adkins DE, Bukszár J, Webb BT, Caroff SN, Miller DD, Sebat J, Stroup TS, Fanous AH, Vladimirov VI, McClay JL, **Lieberman JA**, Sullivan PF, van den Oord EJC: Genome-wide association study of movement-related adverse antipsychotic effects. *Biol Psychiatry* 2010; 67(3):279-282.
- Ballon JS, **Lieberman JA**: Advances in the management of treatment resistant schizophrenia. *Focus: Journal of Lifelong Learning in Psychiatry* 2010; 8:475-487.
- El-Sayed M, Steen RG, Poe MD, Bethea TC, Gerig G, **Lieberman JA**, Sikich L: Brain volumes in psychotic youth with schizophrenia and mood disorders. *J Psychiatry Neurosci* 2010; 35(4):229-236.
- Findling RL, Johnson JL, McClellan J, Frazier JA, Vitiello B, Hamer RM, **Lieberman JA**, Ritz L, McNamara NK, Lingler J, Hlastala S, Pierson L, Puglia M, Maloney AE, Kaufman EM, Noyes N, Sikich L: Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) Study. *J Am Acad Child & Adolesc Psychiatry* 2010; 49(6):583-594.
- Gilmore JH, Kang C, Evans DD, Wolfe HM, Smith MD, **Lieberman JA**, Lin W, Hamer RM, Styner, M, Gerig G: Prenatal and neonatal brain structure and white matter maturation in children at high risk for schizophrenia. *Am J Psychiatry* 2010; 167(9):1083-1091.
- Glantz LA, Gilmore JH, Overstreet DH, Salimi K, **Lieberman JA**, Jarskog LF: Pro-apoptotic Par-4 and dopamine D2 receptor in temporal cortex in schizophrenia, bipolar, disorder and major depression. *Schizophr Res* 2010; 118(1-3):292-299.
- Hirata Y, Souza RP, **Lieberman JA**, Meltzer HY, Kennedy JL: Lack of association between HTR4 gene polymorphisms and schizophrenia in case-control and family-based samples. *Psychiatry Res* 2010; 175(1-2):176-178.
- Hooper SR, Giliano AJ, Youngstrom E, Brieger D, Sikich L, Frazier JA, Findling RL, McClellan J, Hamer RM,



- Vitiello B, **Lieberman JA**: Neurocognition in early-onset schizophrenia and schizoaffective disorders. *J Am Acad Child & Adolesc Psychiatry* 2010; 49(1):52-60.
- Huang J, Perlis RH, Lee PH, Rush AJ, Fava M, Sachs GS, **Lieberman JA**, Hamilton SP, Sullivan P, Sklar P, Purcell S, Smoller JW: Cross-disorder genomewide analysis of schizophrenia, bipolar disorder, and depression. *Am J Psychiatry* 2010;167(10):1254-1263.
- Hwang R, Zai CC, Tiwari AK, Müller DJ, Arranz MJ, Morris AG, McKenna PJ, Munro J, Potkin SG, **Lieberman JA**, Meltzer HY, Kennedy JL: Effect of dopamine D3 receptor gene polymorphisms and clozapine treatment response: exploratory analysis of nine polymorphisms and meta-analysis of the Ser9Gly variant. *Pharmacogenomics J* 2010; 10(3):200-218.
- Karam CS, Ballon JS, Bivens NM, Freyberg Z, Girgis RR, Lizardi-Ortiz JE, Markx S, **Lieberman JA**, Javitch JA: Signaling pathways in schizophrenia: emerging targets and therapeutic strategies. *Trends in Pharmacol Sci* 2010; 31(8):381-390.
- Kimhy D, Delespaul P, Ahn H, Cai S, Shikhman M, **Lieberman JA**, Malaspina D, Sloan RP: Concurrent measurement of "Real-World" stress and arousal in individuals with psychosis: assessing the feasibility and validity of a novel methodology. *Schizophr Bull* 2010; 36(6):1131-1139.
- Konneker TI, Crowley JJ, Quackenbush CR, Keefe RS, Perkins DO, Stroup TS, **Lieberman JA** van den Oord E, Sullivan PF: No association of the serotonin transporter polymorphisms 5-HTTLPR and RS25531 with schizophrenia or neurocognition. *Am J Genet B Neuropsychiatr Genet* 2010; 153B(5):1115-1117.
- Merrill DB, Girgis RR, Bickford LC, Vorel SR, **Lieberman JA**: Teaching trainees to negotiate research collaborations with industry: a mentorship model. *Am J Psychiatry* 2010; 167(4):381-386.
- Novak G, Gallo A, Zai CC, Meltzer HY, **Lieberman JA**, Potkin SG, Voineskos AN, Remington G, Kennedy JL, Levesque D, Le Foll B: Association of the orphan nuclear receptor NR4A1 with tardive dyskinesia. *Psychiatr Genet* 2010; 20(1):39-43.
- Novak G, Zai CC, Mirkhani M, Shaikh S, Vincent JB, Meltzer H, **Lieberman JA**, Strauss J, Lévesque D, Kennedy JL, Foll BL: Replicated association of the NR4A3 gene with smoking behavior in schizophrenia and in bipolar disorder. *Genes Brain Behav* 2010; 9(8): 910-917.
- Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, **Lieberman JA**: Impact of antipsychotic medication on family burden in schizophrenia: longitudinal results of CATIE trial. *Schizophr Res* 2010; 116(2-3):118-125.
- Rodriguez-Murillo L, **Lieberman JA**: Una firma genética para las enfermedades psiquiátricas complejas (A genetic signature for complex psychiatric diseases). *Revista de Psiquiatría y Salud Mental* 2010; 3(3):75-78.
- Sicard MN, Zai CC, Tiwari AK, Souza RP, Meltzer HY, **Lieberman JA**, Kennedy JL, Müller DJ: Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis. *Pharmacogenomics J* 2010; 11(11):1561-1571.
- Souza RP, de Luca V, Meltzer HY, **Lieberman JA**, Kennedy JL: Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. *Int J Neuropsychopharmacol* 2010; 13(6):793-798.
- Souza RP, de Luca V, Meltzer HY, **Lieberman JA**, Kennedy JL: Influence of serotonin 3A and 3B receptor genes on clozapine treatment response in schizophrenia. *Pharmacogenet Genomics* 2010; 20(4):274-276.
- Souza RP, de Luca V, Remington G, **Lieberman JA**, Meltzer HY, Kennedy JL, Wong AH: Glial cell line-derived neurotrophic factor receptor alpha 2 (GFRA2) gene is associated with tardive dyskinesia. *Psychopharmacology (Berl)* 2010; 210(3):347-354.
- Souza RP, Remington G, Chowdhury NI, Lau MK, Voineskos AN, **Lieberman JA**, Meltzer HY, Kennedy JL: Association study of the GSK-3B gene with tardive dyskinesia in European caucasians. *Eur Neuropsychopharmacol* 2010; 20(10):688-694.
- Souza RP, Remington G, Meltzer HY, **Lieberman JA**, Kennedy JL, Wong AH: Phosphodiesterase 4B genetic variants are not associated with antipsychotic-induced tardive dyskinesia. *Int Clin Psychopharmacol* 2010; 25(5):264-269.
- Souza RP, Romano-Silva MA, **Lieberman JA**, Meltzer HY, Macneil LT, Culotti JG, Kennedy JL, Wong AH:



- Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response. *J Psychiatr Res* 2010; 44(11):700-706.
- Tiwari AK, Rodgers JB, Sicard M, Zai CC, Likhodi O, Freeman N, Meltzer HY, **Lieberman JA**, Kennedy JL, Müller DJ: Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; 34(8):1484-1490.
- Tiwari AK, Zai CC, Likhodi O, Lisker A, Singh D, Souza RP, Batra P, Zaidi SH, Chen S, Liu F, Puls I, Meltzer HY, **Lieberman JA**, Kennedy JL, Müller DJ: A common polymorphism in the Cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in schizophrenia. *Neuropsychopharmacology* 2010; 35(6):1315-1324.
- Tiwari AK, Zai CC, Meltzer HY, **Lieberman JA**, Müller DJ, Kennedy JL: Association study of polymorphisms in insulin induced Gene 2 (INSIG2) with antipsychotic-induced weight gain in European and African-American schizophrenia patients. *Hum Psychopharmacol: Clin & Exp* 2010; 25(3):253-259.
- Tsai H-T, Caroff SN, Miller DD, McEvoy J, **Lieberman JA**, North KE, Stroup TS, Sullivan PF: A candidate gene study of tardive dyskinesia in the CATIE schizophrenia trial. *Am J Med Genet B Neuropsychiatr Genet* 2010; 153B(1):336-340.
- Wessels AM, Pollock BG, Anyama NG, Schneider LS, **Lieberman JA**, Marder SR, Bies RR: Association of 9-hydroxy risperidone concentrations with risk of switching or discontinuation in the clinical antipsychotic trial of intervention effectiveness-Alzheimer's disease trial. *J Clin Psychopharmacol* 2010; 30(6): 683-687.
- Zai CC, Tiwari AK, Basile V, de Luca V, Müller DJ, Voineskos AN, Remington G, Meltzer HY, **Lieberman JA**, Potkin SG, Kennedy JL: Oxidative stress in tardive dyskinesia: genetic association study and meta-analysis of NADPH quinone oxidoreductase 1 (NQO1) and superoxide dismutase 2 (SOD2, MnSOD) genes. *Prog Neuropsychopharmacol Biol Psychiatry* 2010; 34(1):50-56.
- Zai CC, Tiwari AK, Müller DJ, de Luca V, Shinkai T, Shaikh S, Ni X, Sibony D, Voineskos AN, Meltzer HY, **Lieberman JA** Potkin SG, Remington G, Kennedy JL: The catechol-O-methyl-transferase gene in tardive dyskinesia. *World J Biol Psychiatry* 2010; 11(6):803-812.

## 2009

- Chwastiak LA, Rosenheck RA, McEvoy JP, Stroup TS, Swartz MS, Davis SM, **Lieberman JA**: The impact of obesity on health care costs among persons with schizophrenia. *Gen Hosp Psychiatry* 2009; 31(1):1-7.
- Cox ET, Brennaman LH, Gable KL, Hamer RM, Glantz LA, Lamantia AS, **Lieberman JA**, Gilmore JH, Maness PF, Jarskog LF: Developmental regulation of neural cell adhesion molecule in human prefrontal cortex. *Neuroscience* 2009; 162(1):96-105.
- De Luca V, Souza RP, Viggiano E, Zai CC, Shinkai T, **Lieberman JA**, Potkin SG, Meltzer HY, Remington G, Kennedy JL: MDR1 gene in tardive dyskinesia scale scores: comparison of strategies for quantitative trait haplotype analysis. *Schizophr Res* 2009; 110(1-3):200-201.
- Essock SM, Covell NH, Leckman-Westin E, **Lieberman JA**, Sederer LI, Kealey E, Finnerty MT, and members of the Scientific Advisory Committee: Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. *Psychiatric Serv* 2009; 60(12):1595-1602.
- Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA, Andreasen NC, Brady KT, Brent DA, Brzustowicz L, Carter CS, Eisenberg L, Goldman H, Javitt DC, Leibenluft E, **Lieberman JA**, Milrod B, Oquendo MA, Rosenbaum JF, Rush AJ, Siever LJ, Suppes P, Weissman MM, Roy MD, Scully JH Jr, Yager J: Conflict of interest – an issue for every psychiatrist. *Am J Psychiatry* 2009; 166(3):274.
- Kleinman L, **Lieberman JA**, Dube S, Kinon B, Mohs R, Zhao Y, Kinon B, Carpenter W, Harvey PD, Green MF, Keefe RSE, Frank L, Bowman L, Revicki DA: Development and psychometric performance of the schizophrenia objective functioning instrument: an interviewer administered measure of function. *Schizophrenia Res* 2009; 107(2-3):275-285.

- Lieberman JA**, Papadakis K, Csernansky J, Litman R, Volavka J, Jia X-D, Gage A, for the [MEM-MD-29 Study Group]: A randomized, placebo-controlled study of memantine as adjunctive treatment in patients with schizophrenia. *Neuropsychopharmacology* 2009; 34(5):1322-1329.
- Marx CE, Keefe RS, Buchanan RW, Hamer RM, Kiltz JD, Bradford DW, Strauss JL, Naylor JC, Payne VM, **Lieberman JA**, Savitz AJ, Leimone L, Dunn L, Porcu P, Morrow L, Shampine LJ: Proof-of-concept trial with the neurosteroid pregnenolone targeting cognitive and negative symptoms in schizophrenia. *Neuropsychopharmacology* 2009; 34(8):1885-1903.
- McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, Zackai EH, Kaplan P, Ganesh J, Krantz ID, Spinner NB, Roccanova P, Bhandari A, Pavon K, Lakshmi B, Leotta A, Kendall J, Lee YH, Vacic V, Gary S, Iakoucheva LM, Crow TJ, Christian SL, **Lieberman JA**, Stroup TS, Lehtimäki T, Puura K, Halderman-Engliert C, Pearl J, Goodell M, Willour VL, Derosse P, Steele J, Kassem L, Wolff J, Chitkara N, McMahon FJ, Malhotra AK, Potash JB, Schulze TG, Nöthen MM, Cichon S, Rietschel M, Leibenluft E, Kustanovich V, Lajonchere CM, Sutcliffe JS, Skuse D, Gill M, Gallagher L, Mendell NR; Wellcome Trust Control Consortium, Craddock N, Owen MJ, O'Donovan MC, Shaikh TH, Susser E, Delisi LE, Sullivan PF, Deutsch CK, Rapoport J, Levy DL, King MC, Sebat J: Microduplications of 16p11.2 are associated with schizophrenia. *Nat Gen* 2009; 41(11):1223-1227.
- Meyer JM, McEvoy JP, Davis VG, Goff DC, Nasrallah HA, Davis SM, Hsiao JK, Swartz MS, Stroup TS, **Lieberman JA**: Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE). *Biol Psychiatry* 2009; 66(11):1013-1022.
- Mohamed S, Rosenheck R, McEvoy J, Swartz M, Stroup S, **Lieberman JA**: Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia. *Schizophr Bull* 2009; 35(2):336-346.
- Patel JK, Buckley PF, Woolson S, Hamer RM, McEvoy JP, Perkins DO, **Lieberman JA**, for the CAFE investigators: Metabolic profiles of second generation antipsychotics in early psychosis: findings from the CAFE study. *Schizophr Res* 2009; 111(1-3):9-16.
- Penn DL, Keefe RS, Davis SM, Meyer PS, Perkins DO, Losardo D, **Lieberman JA**: The effects of antipsychotic medications on emotion perception in patients with chronic schizophrenia in the CATIE trial. *Schizophr Res* 2009; 115(1):17-23.
- Reaven GM, **Lieberman JA**, Sethuraman G, Kraemer H, Davis JM, Blasey C, Tsuang MT, Schatzberg, AF: In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. *J Psychiatr Res* 2009; 43(11):997-1002.
- Salimi K, Jarskog LF, **Lieberman JA**: Antipsychotic drugs for first-episode psychosis: a comparative review. *CNS Drugs* 2009; 23(10):837-855.
- Shi X, Styner M, **Lieberman JA**, Ibrahim JG, Lin W, Zhu H: Intrinsic regression models for manifold-valued data. *J Am Stat Assoc* 2009; 1;5762:192-199.
- Shi X, Styner M, **Lieberman JA**, Ibrahim JG, Lin W, Zhu H: Intrinsic regression models for manifold-valued data. *Med Image Comput Comput Assist Interv* 2009; 12(Pt2):192-199.
- Sickert L, Müller DJ, Tiwari AK, Shaikh S, Zai C, De Souza R, De Luca V, Meltzer HY, **Lieberman JA**, Kennedy JL: Association of the alpha2A adrenergic receptor -1291C/G polymorphisms and antipsychotic-induced weight gain in European-Americans. *Pharmacogenomics* 2009; 10(7):1169-1176.
- Souza RP, Tampakeras M, Basile V, Shinkai T, Rosa DV, Potkin S, Meltzer HY, **Lieberman JA**, Romano-Silva MA, Kennedy JL: Lack of association of GPX1 and MnSOD genes with symptom severity and response to clozapine treatment in schizophrenia subjects. *Hum Psychopharmacol* 2009; 24(8):676-679.
- Stroup TS, **Lieberman JA**, McEvoy JP, Davis SM, Swartz MS, Keefe RS, Miller AL, Rosenheck RA, Hsiao JK, for the CATIE Investigators: Results of phase 3 of the CATIE schizophrenia trial. *Schizophr Res* 2009; 107(1):1-12.
- Smith TE, Weston CA, **Lieberman JA**: Schizophrenia (maintenance treatment). *Clin Evid* (Online) 2009; PMID 19445748: Apr 16, pii:1007.
- Thompson PM, Bartzokis G, Hayashi KM, Klunder AD, Lu PH, Edwards N, Hong MS, Yu M, Geaga JA, Toga

- AW, Charles C, Perkins DO, McEvoy J, Hamer RM, Tohen M, Tollefson GD, **Lieberman JA**, for the HGDH Study Group: Time-lapse mapping of cortical changes in schizophrenia with different treatments. *Cerebral Cortex* 2009; 19(5):1107-1123.
- Zai CC, Tiwari AK, Basile V, De Luca V, Müller DJ, King N, Voineskos AN, Remington G, Meltzer HY, **Lieberman JA**, Potkin SG, Kennedy JL: Association study of tardive dyskinesia and five DRD4 polymorphisms in schizophrenia patients. *Pharmacogenomics J* 2009; 9(3):168-174.
- Zai CC, Tiwari AK, De Luca V, Müller DJ, Bulgin N, Hwang R, Zai GC, King N, Voineskos AN, Meltzer HY, **Lieberman JA**, Potkin SG, Remington G, Kennedy JL: Genetic study of BDNF, DRD3, and their interaction in tardive dyskinesia. *Eur Neuropsychopharmacol* 2009; 19(5):317-328.
- Zai CC, Tiwari AK, King N, De Luca V, Müller DJ, Shaikh S, Wong GW, Meltzer HY, **Lieberman JA**, Kennedy JL: Association study of the gamma-aminobutyric acid type A receptor gamma2 subunit gene with schizophrenia. *Schizophr Res* 2009; 114(1-3):33-38.
- Zhu H, Zhou H, Chen H, Li Y, **Lieberman JA**, Styner M: Adjusted exponentially tilted likelihood with applications to brain morphology. *Biometrics* 2009; 65(3):919-927.

## 2008

- Campbell DB, Ebert PJ, Skelly T, Stroup TS, **Lieberman JA**, Levitt P, Sullivan PF: Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia. *Biol Psychiatry* 2008; 63(1):32-42.
- Campbell D, Lange LA, Skelly T, **Lieberman JA**, Levitt P, Sullivan PF: Association of RGS2 and RGS5 variants with schizophrenia symptom severity. *Schizophr Res*, 2008; 101(1-3):67-75.
- Crowley JJ, Keefe RSE, Perkins PO, Stroup TS, **Lieberman JA**, Sullivan PF: The neuregulin 1 promoter RS6994992 is not associated with chronic schizophrenia or neurocognition. *Am J Med Genet B Neuropsychiatr Genet* 2008; 147B(7):1298-1300.
- Daumit GL, Goff DC, Meyer JM, Davis VG, Nasrallah HA, McEvoy JP, Rosenheck R, Davis SM, Hsiao JK, Stroup TS, **Lieberman JA**: Antipsychotic effects on estimate 10-year coronary heart disease risk in the CATIE schizophrenia study. *Schizophr Res* 2008; 105(1-3):175-187.
- Davis SM, Hsiao JK, **Lieberman JA**, for the CATIE Investigators: The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. *Schizophr Res* 2008 100(1-3):39-52.
- Fleischhacker WW, Cetkovic-Bakmas M, De Hert M, Hennekens CH, Lambert M, Leucht S, Maj M, McIntyre RS, Naber D, Newcomer JW, Olfson M, Osby U, Sartorius N, **Lieberman JA**: Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy and research challenges. *J Clin Psychiatry* 2008; 69:514-519.
- Girgis RR, Javitch JA, **Lieberman JA**: Antipsychotic drug mechanisms: links between therapeutic effects, metabolic side effects and the insulin signaling pathway. *Mol Psychiatry* 2008; 13(10):918-929.
- Hill SK, Sweeney JA, Hammer RM, Keefe RS, Perkins DO, Gu H, McEvoy JP, **Lieberman JA**: Efficiency of the CATIE and BACS neuropsychological batteries in assessing cognitive effects of antipsychotic treatments in schizophrenia. *J Int Neuropsychol Soc* 2008; 14(2):209-221.
- Kinon BJ, Volavka J, Stauffer V, Edwards SE, Liu-Seifert H, Chen L, Adams DH, Lindenmayer JP, McEvoy, JP, Buckley PF, **Lieberman JA**, Meltzer HY, Wilson DR, Citrome L: Standard and higher dose of olanzapine in patients with schizophrenia or schizoaffective disorder: A randomized, double-blind, fixed dose study. *J Clin Psychopharmacol* 2008; 28(4):392-400.
- Krystal JH, Carter CS, Geschwind D, **Lieberman JA**, et al.: It is time to take a stand for medical research and against terrorism targeting medical scientists. *Biol Psychiatry* 2008; 63(8):725-727. Erratum in *Biol Psychiatry* 2008 15; 63(10):1001.
- Lewis S, **Lieberman JA**: CATIE and CUTLASS: Can we handle the truth? *Br J Psych* 2008; 192:161-163 [Editorial].
- Lieberman JA**, Bymaster FP, Meltzer HY, Deutch AY, Duncan, Marx CE, Aprille JR, Dwyer DS, Li X-M, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG: Antipsychotic

- drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection. *Pharmacol Rev* 2008; 60(3):358-403 [Review]. Erratum in: *Pharmacol Rev* 2008; 60(4):582.
- Lieberman JA**, Drake RE, Sederer LI, Belger A, Keefe R, Perkins D, Stroup TS: Science and recovery in schizophrenia. *Psychiatric Services* 2008; 59:487-496 [Review].
- Lieberman JA**, Javitch JA, Moore H: Cholinergic agonists as novel treatment for schizophrenia: the promise of rational drug development for Psychiatry. *Am J Psychiatry* 2008; 165(8):931-936 [Editorial].
- Maynard TM, Meechen DW, Dudevoir ML, Gopalakrishna D, Peters AZ, Heindel CC, Sugimoto TJ, Wu Y, **Lieberman JA**, Lamantia AS: Mitochondrial localization and function of a subset of 22q11 deletion syndrome candidate genes. *Mol Cell Neurosci* 2008; 39(3):439-451.
- Meyer JM, Davis VG, Goff DC, Hsiao JK, Swartz MS, Stroup TS, **Lieberman JA**: Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from Phase 1. *Schizophr Res* 2008; 101:273-286.
- Meyer JM, Davis VG, McEvoy JP, Goff DC, Nasrallah HA, Davis SM, Daumit GL, Hsiao JK, Swartz MS, Stroup TS, **Lieberman JA**: Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE schizophrenia trial phase 1. *Schizophr Res* 2008; 103(1-3):104-109.
- Miller del D, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, Riggio S, Chakos MH, Swartz MS, Keefe RS, Stroup TS, **Lieberman JA**, for the Clinical Antipsychotic Trials Intervention Effectiveness (CATIE) Investigators: Extrapyramidal side-effects of antipsychotics in a randomized trial. *Br J Psych* 2008; 193(4):279-288.
- Mohamed S, Rosenheck R, Swartz M, Stroup S, **Lieberman JA**, Keefe RS: Relationship of cognition and psychopathology to functional impairment in schizophrenia. *Am J Psych* 2008; 165(8): 978-987.
- Morey RA, Mitchell TV, Inan S, **Lieberman JA**, Belger A: Neural correlates of automatic and controlled auditory processing in schizophrenia. *J Neuropsychiatry Clin Neurosci* 2008; 29(4):419-430.
- Naylor JC, Hulette CM, Steffens DC, Shampine LJ, Ervin JF, Payne VM, Massing MW, Kilts JD, Strauss JL, Calhoun PS, Calnaido RP, Blazer DG, **Lieberman JA**, Madison RD, Marx CE: Cerebrospinal fluid dehydroepiandrosterone levels are correlated with brain dehydroepiandrosterone levels, elevated in Alzheimer's disease, and related to neuropathological disease stage. *J Clin Endocrinol Metab* 2008; 93(8):3173-3178.
- Perkins DO, Gu H, Weiden PJ, McEnvoy JP, Hamer RM, **Lieberman JA**; on behalf of the Comparison of Atypicals in First Episode (CAFÉ) study group: Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. *J Clin Psychiatry* 2008; 69(1):106-113.
- Resnick SG, Rosenheck RA, Canive JM, DeSouza C, Stroup TS, McEvoy J, Davis S, Keefe RS, Swartz M, **Lieberman JA**: Employment outcomes in a randomized trial of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. *J Behav Health Res* 2008; 35(2):215-225.
- Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, Ambler D, Puglia M, Maloney AE, Michael E, De Jong S, Slifka K, Noyes N, Hlastala S, Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM, **Lieberman JA**: Double-blind comparison of first- and second-generation antipsychotics in early onset schizophrenia and schizoaffective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. *Am J Psychiatry* 2008; 165(11):1420-1431. Erratum in *Am J Psychiatry* 2008; 165(11):1495.
- Souza RP, Romano-Silva MA, **Lieberman JA**, Meltzer HY, Wong AHC, Kennedy JL: Association study of GSK3 gene polymorphisms with schizophrenia and clozapine response. *Psychopharmacology (Berl)* 2008 200(2):177-186.
- Sullivan PF, Lin D, Tzeng J-Y, van den Oord E, Perkins D, Stroup TS, Wagner M, Lee S, Wright FA, Zou F, Liu W, Downing AM, **Lieberman JA**, Close SL: Genomewide association for schizophrenia in the CATIE study: results of Stage 1. *Mol Psychiatry* 2008; 13(6):570-584 [Corrigenda 2009; 14:1144].
- Sultzer DL, Davis SM, Tariot PN, Dagerman KS, Lebowitz BD, Lyketsos CG, Hsiao JK, **Lieberman JA**, Schneider LS, for the CATIE-AD Study Group: Clinical symptom responses to atypical medications in

- Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial. *Am J Psychiatry* 2008; 165(7):844-854.
- Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, **Lieberman JA**, on behalf of the CATIE Investigators: Comparison of antipsychotic medication effects on reducing violence in persons with schizophrenia. *Br J Psychiatry* 2008; 193:37-43.
- Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, Miller DD, McGee M, Khan A, Canive JM, Davis SM, Hsiao JK, **Lieberman JA**; for the CATIE Investigators: The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. *Schizophr Res* 2008; 100(1-3): 39-52.
- Swartz M, Stroup TS, McEvoy JP, Davis SM, Rosenheck RA, Keefe RSE, Hsiao JK, **Lieberman JA**: What CATIE found: results from the schizophrenia trial. *Psychiatric Services* 2008; 59:500-506.
- Zai CC, Romano-Silva MA, Hwang R, Zai GC, DeLuca V, Müller DJ, King N, Voineskos AN, Meltzer HY, **Lieberman JA**, Potkin SG, Remington G, Kennedy JL: Genetic study of eight *AKT1* gene polymorphisms and their interaction with *DRD2* gene polymorphisms in tardive dyskinesia. *Schizophr Res* 2008; 106(2-3):248-252.

## 2007

- Buchanan, RW, Freedman R, Javitt DC, Abi-Dargham A, **Lieberman JA**: Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. *Schizophr Bull* 2007; 33(5):1120-1130.
- Corcoran C, **Lieberman JA**: The impossible dream: can psychiatry prevent psychosis? *Early Intervention in Psychiatry* 2007; 1:219-221[Editorial].
- De Luca V, Müller DJ, Hwang R, **Lieberman JA**, Volavka J, Meltzer HY, Kennedy JL: HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis. *Hum Psychopharmacol* 2007; 22(7):463-467.
- Frazier JA, McClellan J, Finding RL, Vitiello B, Anderson R, Zablotsky B, Williams E, McNamara NK, Jackson JA, Ritz L, Hlastala SA, Pierson L, Varley JA, Puglia M, Maloney AE, Ambler D, Hunt-Harrison T, Hamer RM, Noyes N, **Lieberman JA**, Sikich L: Treatment of early-onset schizophrenia spectrum disorders (TEOSS): demographic and clinical characteristics. *J Am Acad Child Adolesc Psychiatry* 2007; 46(8):979-988.
- Gilmore JH, Lin W, Prastawa MW, Looney CB, Vetsa YS, Knickmeyer RC, Evans DD, Smith JK, Hamer RM, **Lieberman JA**, Gerig G: Regional gray matter growth, sexual dimorphism, and cerebral asymmetry in the neonatal brain. *J Neurosci* 2007; 27(6):1255-1260.
- Gilmore JH, Lin W, Corouge I, Vesta YS, Smith JK, Kang C, Gu H, Hamer RM, **Lieberman JA**, Gerig G: Early postnatal development of corpus callosum and corticospinal white matter assessed with quantitative tractography. *Am J Neuroradiol* 2007; 28(9):1789-1795.
- Glantz LA, Gilmore JH, Hamer RM, **Lieberman JA**, Jarskog LF: Synaptophysin and postsynaptic density protein 95 (PSD-95) in the human prefrontal cortex from mid-gestation into early adulthood. *Neuroscience* 2007; 149(3):582-591.
- Hwang R, Shinkai T, De Luca V, Ni X, Potkin SG, **Lieberman JA**, Meltzer HY, Kennedy JL: Association study of four dopamine D1 receptor gene polymorphisms and clozapine treatment response. *J Psychopharmacol* 2007; 21(7):718-727.
- Jarskog LF, Gilmore JH, Glantz LA, Gable KL, German TT, Tong RI, **Lieberman JA**: Caspase-3 Activation in Rat Frontal Cortex Following Treatment with Typical and Atypical Antipsychotics. *Neuropsychopharmacology* 2007; 32(1):95-102.
- Jarskog LF, Miyamoto S, **Lieberman JA**: Schizophrenia: new pathological insights and therapies. *Annu Rev Med* 2007; 58:49-61 [Review].

- Keefe RS, Bilder RM, Davis SM, Harvey PD, Palmer BW, Gold JM, Meltzer HY, Green MF, Capuano G, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Davis CE, Hsiao JK, **Lieberman JA**, for the CATIE Investigators and the Neurocognitive Working Group: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. *Arch Gen Psychiatry* 2007; 64(6):633-647.
- Keefe RS, Sweeney JA, Gu H, Hamer RM, Perkins DO, McEvoy JP, **Lieberman JA**: Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. *Am J Psychiatry* 2007; 164(7):1061-1071.
- Lieberman JA**: An interview with Jeffrey A. Lieberman: Tardive Dyskinesia [interview by Sussman Norman]. *CNS Spectr* 2007; 12(10):747-750.
- Lieberman JA**: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. *J Clin Psychiatry* 2007; 68(2):e04 [Review].
- Lieberman JA**, Buckley PF, Perkins DO: Neuroprotection: a new strategy in the treatment of schizophrenia. *CNS Spectr* 2007; 12(Suppl 18):1-16.
- Lieberman JA**, First M: Renaming Schizophrenia. *British Medical Journal* 2007; 334(7585):108 [Editorial].
- Lieberman JA**, Perkins DO, Jarskog LF: Neuroprotection: a therapeutic strategy to prevent deterioration associated with schizophrenia. *CNS Spectr* 2007 12(3 Suppl 4):1-13.
- McClellan J, Sikich L, Findling RL, Frazier JA, Vitiello B, Hlastala SA, Williams E, Ambler D, Hunt-Harrison T, Maloney AE, Ritz L, Anderson R, Hamer RM, **Lieberman JA**: The treatment of early onset schizophrenia spectrum disorders (TEOSS): rationale, design and methods. *J Am Acad Child Adolesc Psychiatry* 2007; 46(8):969-978.
- McEvoy JP, **Lieberman JA**, Perkins DO, Hamer RM, Gu H, Lazarus A, Sweitzer D, Olexy C, Weiden P, Strakowski SD: Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind, 52-week comparison. *Am J of Psychiatry* 2007; 167(7):1050-1060.
- Newcomer JW, **Lieberman JA**: Comparing safety and tolerability of antipsychotic treatment. *J Clin Psychiatry* 2007; 68(3):e07 [Review].
- Pinheiro AP, Keefe RS, Skelly T, Olarte M, Leviel K, Lange LA, Lange EM, Stroup TS, **Lieberman JA**, Sullivan PF: AKT1 and neurocognition in schizophrenia. *Australian and New Zealand Journal of Psychiatry* 2007; 41(2):169-177.
- Renou J, De Luca V, Zai CC, Bulgin N, Remington G, Meltzer HY, **Lieberman JA**, Le Foll B, Kennedy JL: Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. *Mol Psychiatry* 2007; 12(12): 1058-1060.
- Rosenheck RA, **Lieberman JA**: Cost-effectiveness measures, methods, and policy implications from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) for schizophrenia. *J Clin Psychiatry* 2007; 68(2):e05.
- Rosenheck RA, Leslie DL, Sindelar JL, Miller EA, Tariot PN, Dagerman KS, Davis SM, Lebowitz BD, Rabins P, Hsiao JK, **Lieberman JA**, Schneider LS, for the Clinical Antipsychotic Trials of Intervention Effectiveness – Alzheimer's Disease (CATIE-AD) investigators: Cost-benefit analysis of second generation antipsychotics and placebo in a randomized trial of the treatment of psychosis and aggression in Alzheimer disease. *Arch Gen Psychiatry* 2007; 64(11):1259-1268.
- Sartorius N, Baghai TC, Baldwin DS, Barrett B, Brand U, Fleischhacker W, Goodwin G, Grunze H, Knapp M, Leinard BE, **Lieberman JA**, Nakane Y, Pinder RM, Shatzberg AF, Svestka J, Bauman P, Ghalib K, Markowitz JC, Padberg F, Fink M, Furukawa T, Fountoulakis KN, Jensen P, Kanba S, Riecher-Rossler A: Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. *Int J Neuropsychopharmacol*. 2007; 10 Suppl 1:S1-207.
- Steen RG, Hamer RM, **Lieberman JA**: Measuring brain volume by magnetic resonance imaging: the impact of measurement precision and natural variation on sample size requirements. *Am J of Neuroradiology*, 2007, 28(6):1119-1125.
- Stroup TS, **Lieberman JA**, McEvoy JP, Swartz MS, Davis SM, Capuano GA, Rosenheck RA, Keefe RSE, Miller AL, Belz I, Hsiao JK, for the CATIE Investigators: Effectiveness of olanzapine, quetiapine, and

- risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. *Am J Psychiatry* 2007; 164(3):415-427.
- Sullivan PF, Keefe RSE, Lange LA, Lange EM, Stroup TS, **Lieberman JA**, Maness PF: NACMI and neurocognition in schizophrenia. *Biol Psychiatry* 2007; 61(7):902-910.
- Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe RSE, McEvoy JP, Hsiao JK, **Lieberman JA**, for the CATIE Investigators: Effects of antipsychotic medications on psychosocial functioning from the NIMH CATIE study. *Am J Psychiatry* 2007; 164(3):428-436.
- Zai CC, Hwang RW, De Luca V, Müller DJ, King N, Zai GC, Remington G, Meltzer HY, **Lieberman JA**, Potkin SG, Kennedy JL: Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. *Int J Neuropsychopharmacol* 2007; 10(5):639-651.
- 2006**
- Bilder RM, Reiter G, Bates J, Lencz T, Szeszko P, Goldman RS, Robinson D, **Lieberman JA**, Kane JM: Cognitive development in schizophrenia: follow-back from the first episode. *J Clin Exp Neuropsychol* 2006; 28(2):270-282.
- Chwastiak LA, Rosenheck RA, McEvoy JP, Keefe RS, Swartz MS, **Lieberman JA**: Interrelationships of psychiatric symptom severity, medical comorbidity, and functioning in schizophrenia. *Psychiatr Serv* 2006; 57(8):1102-1109.
- Councill JH, Tucker ES, Haskell GT, Maynard TM, Meechan DW, Hamer RM, **Lieberman JA**, LaMantia AS: Limited influence of olanzapine on adult forebrain neural precursors in vitro. *Neuroscience* 2006; 140(1):111-122.
- Duncan GE, Moy SS, **Lieberman JA**, Koller BH: Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. *Psychopharmacology (Berl)* 2006; 184(2):190-200.
- Duncan GE, Moy SS, **Lieberman JA**, Koller BH: Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. *Pharmacol Biochem Behav* 2006; 85(3):481-491.
- Essock SM, Covell NH, Davis SM, Stroup TS, Rosenheck RA, **Lieberman JA**: Effectiveness of switching antipsychotic medications. *American Journal of Psychiatry* 2006; 163(12):2090-2095.
- Falkai P, Wobrock T, **Lieberman J**, Glenthøj B, Gattaz WF, Möller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: long-term treatment of schizophrenia. *World J Biol Psychiatry* 2006; 7(1):5-40.
- Gizerian SS, Moy SS, **Lieberman JA**, Grobin AC: Neonatal neurosteroid administration results in development-specific alterations in prepulse inhibition and locomotor activity: neurosteroids alter prepulse inhibition and locomotor activity. *Psychopharmacology (Berl)* 2006; 186(3):334-342.
- Glantz LA, Gilmore JH, **Lieberman JA**, Jarskog LF: Apoptotic mechanisms and the synaptic pathology of schizophrenia. *Schizophr Res* 2006; 81(1):47-63 [Review].
- Green AI, **Lieberman JA**, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB: Olanzapine and haloperidol in first episode psychosis: Two-year data. *Schizophr Res* 2006 86(1-3):234-243.
- Grobin AC, Gizerian S, **Lieberman JA**, Morrow AL: Perinatal allopregnanolone influences prefrontal cortex structure, connectivity and behavior in adult rats. *Neuroscience* 2006; 138(3):809-819.
- Hoptman MJ, Volavka J, Czobor P, Gerig G, Chakos M, Blocher J, Citrome LL, Sheitman B, Lindenmayer JP, **Lieberman JA**, Bilder RM: Aggression and quantitative MRI measures of caudate in patients with chronic schizophrenia or schizoaffective disorder. *The Journal of Neuropsychiatry and Clinical Neurosciences* 2006; 18(4):509-515.
- Jarskog LF, **Lieberman JA**: Neuroprotection in schizophrenia. *J Clin Psychiatry* 2006 67(9):e09.
- Keefe RS, Bilder RM, Harvey PD, Davis SM, Palmer BW, Gold JM, Meltzer HY, Green MF, Miller



- DD, Canive JM, Adler LW, Manschreck TC, Swartz M, Rosenheck R, Perkins DO, Walker TM, Stroup TS, McEvoy JP, **Lieberman JA**: Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial. *Neuropsychopharmacology* 2006; 31(9):2033-2046.
- Keefe RS, Perkins DO, Gu H, Zipursky RB, Christensen BK, **Lieberman JA**: A longitudinal study of neurocognitive function in individuals at-risk for psychosis. *Schizophr Res* 2006; 88(1-3):26-35.
- Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Rock SL, Woolson S, Tohen M, Tollefson GD, Sanger TM, **Lieberman JA**: Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. *Biol Psychiatry* 2006; 59(2):97-105.
- Lieberman JA**, Malaspina D, Jarskog LF: Preventing clinical deterioration in the course of schizophrenia: the potential for neuroprotection. *CNS Spectr* 2006; 11(4):suppl 1-13.
- Lieberman JA**: Neurobiology and the natural history of schizophrenia. *J Clin Psychiatry* 2006 67(10):e14.
- Marx CE, Shampine LJ, Duncan GE, Vandoren MJ, Grobin AC, Massing MW, Madison RD, Bradford DW, Butterfield MI, **Lieberman JA**, Morrow AL: Clozapine markedly elevates pregnenolone in rat hippocampus, cerebral cortex, and serum: candidate mechanism for superior efficacy? *Pharmacol Biochem Behav* 2006 84(4):598-608.
- Marx CE, Shampine LJ, Khisti RT, Trost WT, Bradford DW, Grobin AC, Massing MW, Madison RD, Butterfield MI, **Lieberman JA**, Morrow AL: Olanzapine and fluoxetine administration and coadministration increase rat hippocampal pregnenolone, allopregnanolone and peripheral deoxycorticosterone: implications for therapeutic actions. *Pharmacol Biochem Behav* 2006; 84(4):609-617.
- Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, **Lieberman JA**: Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. *Neuropsychopharmacology* 2006; 31(6):1249-1263.
- Marx CE, Trost WT, Shampine LJ, Stevens RD, Hulette CM, Steffens DC, Ervin JF, Butterfield MI, Blazer DG, Massing MW, **Lieberman JA**: The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease. *Biol Psychiatry* 2006; 60(12):1287-1294.
- Maynard TM, Meechan DW, Heindel CC, Peters AZ, Hamer RM, **Lieberman JA**, LaMantia AS: No evidence for parental imprinting of mouse 22q11 gene orthologs. *Mamm Genome* 2006; 17(8):822-832.
- McEvoy JP, Johnson J, Perkins D, **Lieberman JA**, Hamer RM, Keefe RS, Tohen M, Glick ID, Sharma T: Insight in first-episode psychosis. *Psychol Med* 2006; 36(10):1385-1393.
- McEvoy JP, **Lieberman JA**, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. *Am J Psychiatry* 2006; 163(4):600-610.
- Meechan DW, Maynard TM, Wu Y, Gopalakrishna D, **Lieberman JA**, Lamantia AS: Gene dosage in the developing and adult brain in mouse model of 22q11 deletion syndrome. *Mol Cell Neuroscience* 2006; 33(4):412-428.
- Merrill DB, Ahmari SE, Bradford JM, **Lieberman JA**: Myocarditis during clozapine treatment. *Am J Psychiatry* 2006; 163(2):204-208.
- Nasrallah HA, Meyer JM, Goff DC, McEvoy JP, Davis SM, Stroup TS, **Lieberman JA**: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline. *Schizophr Res* 2006; 86(1-3):15-22.
- Nolan KA, Czobor P, Citrome LL, Krakowski M, Lachman HM, Kennedy JL, Ni X, **Lieberman J**, Chakos M, Volavka J: Catechol-O-methyltransferase and monoamine oxidase-A polymorphisms and treatment response to typical and atypical neuroleptics. *J Clin Psychopharmacol* 2006; 26(3):338-340.
- Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, **Lieberman JA**: Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. *Schizophr Res* 2006; 83(1):53-63.
- Perlick DA, Rosenheck RA, Kaczynski R, Swartz MS, Canive JM, **Lieberman JA**: Components and correlates of family burden in schizophrenia. *Psychiatr Serv* 2006; 57(8):1117-1125.
- Rosenheck R, Leslie D, Keefe R, McEvoy J, Swartz M, Perkins D, Stroup S, Hsiao JK, **Lieberman J**: Barriers



- to employment for people with schizophrenia. *Am J Psychiatry* 2006; 163(3):411-417.
- Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, **Lieberman JA**, CATIE-AD Study Group: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. *N Engl J Med* 2006; 355(15):1525-1538.
- Steen RG, Mull C, McClure R, Hamer RM, **Lieberman JA**: Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. *Br J Psychiatry* 2006; 188:510-518 [Review].
- Stroup TS, Alves WM, Hamer RM, **Lieberman JA**: Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. *Nat Rev Drug Discov* 2006; 5(2):133-146.
- Stroup TS, **Lieberman JA**, McEvoy JP, Swartz MS, Davis SM, Rosenheck RA, Perkins DO, Keefe RS, Davis CE, Severe J, Hsiao JK: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. *Am J Psychiatry* 2006; 163(4):611-622.
- Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, **Lieberman JA**: A national study of violent behavior in persons with schizophrenia. *Arch Gen Psychiatry* 2006; 63(5):490-499.
- Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Canive JM, Miller del D, Reimherr F, McGee M, Khan A, Van Dorn R, Rosenheck RA, **Lieberman JA**: Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. *J Nerv Ment Dis* 2006; 194(3):164-172.
- Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, McGee M, Miller del D, Reimherr F, Khan A, Canive JM, **Lieberman JA**: Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. *Psychiatr Serv* 2006; 57(8):1110-1116.
- Umbrecht DS, Bates JA, **Lieberman JA**, Kane JM, Javitt DC: Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia. *Biol Psychiatry* 2006; 59(8):762-772.
- Van der Stelt O, **Lieberman JA**, Belger A: Attention modulation of early-stage visual processing in schizophrenia. *Brain Res* 2006; 1125(1):194-198.
- Venkatraman TN, Hamer RM, Perkins DO, Song AW, **Lieberman JA**, Steen RG: Single-voxel 1H PRESS at 4.0 T: precision and variability of measurements in anterior cingulate and hippocampus. *NMR Biomed* 2006; 19(4):484-491.
- Zai G, Müller DJ, Volavka J, Czobor P, **Lieberman JA**, Meltzer HY, Kennedy JL: Family and case-control association study of the tumor necrosis factor-alpha (TNF-alpha) gene with schizophrenia and response to antipsychotic medication. *Psychopharmacology (Berl.)* 2006; 188(2):171-182.
- Zhong KX, Sweitzer DE, Hamer RM, **Lieberman JA**: Comparison of Quetiapine and Risperidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Flexible-Dose, 8-Week Study. *J Clin Psychiatry* 2006; 67(7):1093-1103.

## 2005

- Chakos MH, Schobel SA, Gu H, Gerig G, Charles C, **Lieberman JA**: Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia. *British Journal of Psychiatry*, 2005; 186: 26-31.
- De Luca V, Vincent JB, Müller DJ, Hwang R, Shinkai T, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, **Lieberman JA**, Kennedy JL: Identification of a naturally occurring 21bp deletion in alpha2c noradrenergic receptor gene and cognitive correlates to antipsychotic treatment. *Pharmacological Research* 2005; 51(4):381-384.

- Falkai P, Wobrock T, **Lieberman JA**, Glenthøj B, Gattaz, WF, Møller HJ: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia. *World J Biol Psychiatry* 2005; 6(3):132-191.
- Goff DC, Sullivan LM, McEvoy JP, Meyer JM, Nasrallah HA, Daumit GL, Lambert S, D'Agostino RB, Stroup TS, Davis S, **Lieberman JA**: A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. *Schizophrenia Research* 2005; 80(1):45-53.
- Graham KA, Gu H, **Lieberman JA**, Harp JB, Perkins DO: Double-blind, placebo-controlled investigation of amantadine for weight loss in subjects who gained weight with olanzapine. *American Journal of Psychiatry* 2005; 162(9):1744-1746.
- Graham KA, Perkins DO, Edwards LJ, Barrier RC, Jr., **Lieberman JA**, Harp JB: Effect of olanzapine on body composition and energy expenditure in adults with first-episode psychosis. *Am J Psychiatry* 2005; 162(1):118-123.
- Gunduz-Bruce H, McMeniman M, Robinson DG, Woerner MG, Kane JM, Schooler NR, **Lieberman JA**: Duration of untreated psychosis and time to treatment response for delusions and hallucinations. *American Journal of Psychiatry* 2005; 162(10):1966-1969.
- Hoptman MJ, Volavka J, Weiss EM, Czobor P, Szeszko PR, Gerig G, Chakos M, Blocher J, Citrome LL, Lindenmayer JP, Sheitman B, **Lieberman JA**, Bilder RM: Quantitative MRI measures of orbitofrontal cortex in patients with chronic schizophrenia or schizoaffective disorder. *Psychiatry Research* 2005; 140(2):133-145.
- Hwang R, Shinkai T, De L, V, Müller DJ, Ni X, Macciardi F, Potkin S, **Lieberman JA**, Meltzer HY, Kennedy JL: Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations. *Psychopharmacology (Berl)* 2005; 181(1):179-187.
- Jarskog LF, Glantz LA, Gilmore JH, **Lieberman JA**: Apoptotic mechanisms in the pathophysiology of schizophrenia. *Progress in Neuro-Psychopharmacology and Biological Psychiatry* 2005; 29(5):846-858 [Review].
- Kraus JE, Sheitman BB, Cook A, Reviere R, **Lieberman JA**: Olanzapine versus risperidone in newly admitted acutely ill psychotic patients. *J Clin Psychiatry* 2005; 66(12):1564-1568.
- Lieberman JA**, Greenhouse J, Hamer RM, Krishnan KR, Nemeroff CB, Sheehan DV, Thase ME, Keller MB: Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. *Neuropsychopharmacology* 2005; 30(3):445-460.
- Lieberman JA**, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New England Journal of Medicine* 2005; 353(12):1209-1223.
- Lieberman JA**, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M: Antipsychotic drug effects on brain morphology in first-episode psychosis. *Archives of General Psychiatry* 2005; 62(4):361-370.
- McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott ST, **Lieberman JA**: Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. *Schizophrenia Research* 2005; 80(1):19-32.
- Meyer JM, Nasrallah HA, McEvoy JP, Goff DC, Davis SM, Chakos M, Patel JK, Keefe R, Stroup TS, **Lieberman JA**: The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome. *Schizophrenia Research* 2005; 80(1):9-18.
- Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, **Lieberman JA**: Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. *Schizophrenia Research* 2005; 80(1):33-43.

- Miyamoto S, Duncan GE, Marx CE, **Lieberman JA**: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. *Molecular Psychiatry* 2005; 10(1):79-104.
- Morey RA, Inan S, Mitchell TV, Perkins DO, **Lieberman JA**, Belger A: Imaging fronto-striate function in the prodrome of schizophrenia. *Archives of General Psychiatry* 2005; 62(3):254-262.
- Müller DJ, De Luca V, Sicard T, King N, Hwang R, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, **Lieberman JA**, Meltzer HY, Kennedy JL: Suggestive association between the C825T polymorphism of the G-protein beta3 subunit gene (GNB3) and clinical improvement with antipsychotics in schizophrenia. *European Neuropsychopharmacology* 2005; 15(5):525-531.
- Müller DJ, Klempan TA, De L, V, Sicard T, Volavka J, Czobor P, Sheitman BB, Lindenmayer JP, Citrome L, McEvoy JP, **Lieberman JA**, Honer WG, Kennedy JL: The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. *Neurosci Lett* 2005; 379(2):81-89.
- Nemeroff CB, **Lieberman JA**, Weiden PJ, Harvey PD, Newcomer JW, Schatzberg AF, Kilts CD, Daniel DG: From clinical research to clinical practice: a 4-year review of ziprasidone. *CNS Spectr* 2005; 10(11):s1-20.
- Nolan KA, Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome LL, McEvoy J, **Lieberman JA**: Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. *Journal of Psychiatric Research* 2005; 39(1):109-115.
- Penn DL, Waldheter EJ, Perkins DO, Mueser KT, **Lieberman JA**: Psychosocial treatment for first-episode psychosis: a research update. *American Journal of Psychiatry* 2005; 162(12):2220-2232 [Review]
- Perkins DO, Gu H, Boteva K, **Lieberman JA**: Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. *American Journal of Psychiatry* 2005; 162(10):1785-1804 [Review].
- Pinkham A, Penn D, Wangelin B, Perkins D, Gerig G, Gu H, **Lieberman J**: Facial emotion perception and fusiform gyrus volume in first episode schizophrenia. *Schizophrenia Research* 2005; 79(2-3):341-343
- Roesnheck R, Stroup S, Keefe RS, McEvoy J, Swartz M, Perkins D, Hsiao J, Shumway M, **Lieberman J**: Measuring outcome priorities and preferences in people with schizophrenia. *British Journal of Psychiatry* 2005; 187:529-536.
- Shinkai T, Luca VD, Hwang R, Matsumoto C, Hori H, Ohmori O, Remington G, Meltzer HY, **Lieberman JA**, Potkin SG, Nakamura J, Kennedy JL: Association study between a functional glutathione S-transferase (GSTP1) gene polymorphism (Ile105Val) and tardive dyskinesia. *Neuroscience Letters* 2005; 388(2):116-120.
- Steen RG, Hamer RM, **Lieberman JA**: Measurement of Brain Metabolites by (1)H Magnetic Resonance Spectroscopy in Patients with Schizophrenia: A Systematic Review and Meta-Analysis. *Neuropsychopharmacology* 2005; 30:1949-1962.
- Strakowski SM, Johnson JL, Delbello MP, Hamer RM, Green AI, Tohen M, **Lieberman JA**, Glick I, Patel JK: Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. *Schizophrenia Research* 2005; 78(2-3):161-169.
- Stroup S, Appelbaum P, Swartz M, Patel M, Davis S, Jeste D, Kim S, Keefe R, Manschreck T, McEvoy J, **Lieberman JA**: Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial. *Schizophrenia Research* 2005; 80(1):1-8.
- Styner M, **Lieberman JA**, McClure RK, Weinberger DR, Jones DW, Gerig G: Morphometric analysis of lateral ventricles in schizophrenia and healthy controls regarding genetic and disease-specific factors. *Proc Natl Acad Sci U S A* 2005; 102(13):4872-4877.
- Van der Stelt O, **Lieberman JA**, Belger A: Auditory P300 in high-risk, recent-onset and chronic schizophrenia. *Schizophrenia Research* 2005; 77(2-3):309-320.

- Van der Stelt O, Belger A, **Lieberman JA**: Macroscopic fast neuronal oscillations and synchrony in schizophrenia. *PNAS* 2005; 101(51):17567-17568.
- Volavka J, Nolan KA, Kline L, Czobor P, Citrome L, Sheitman B, Lindenmayer JP, McEvoy J, **Lieberman JA**: Efficacy of clozapine, olanzapine, risperidone, and haloperidol in schizophrenia and schizoaffective disorder assessed with nurses observation scale for inpatient evaluation. *Schizophrenia Research* 2005; 76(1):127-129.
- Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, **Lieberman JA**: Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. *British Journal of Psychiatry* 2005; 187:537-543.

## 2004

- Alamy SS, Jarskog LF, Sheitman BB, **Lieberman JA**: Secretin in a patient with treatment-resistant schizophrenia and prominent autistic features. *Schizophrenia Research* 2004; 66(2-3):183-186.
- Duncan GE, Moy SS, Perez A, Eddy DM, Zinzow WM, **Lieberman JA**, Snouwaert JN, Koller BH: Deficits in sensorimotor gating and tests of social behavior in a genetic model of reduced NMDA receptor function. *Behav Brain Research* 2004; 153(2):507-519.
- Gizerian SS, Morrow AL, **Lieberman JA**, Grobin AC: Neonatal neurosteroid administration alters parvalbumin expression and neuron number in medial dorsal thalamus of adult rats. *Brain Research* 2004; 1012(1-2):66-74.
- Green AI, Tohen MF, Hamer RM, Strakowski SM, **Lieberman JA**, Glick I, Clark WS; HGDH Research Group: First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. *Schizophrenia Research* 2004; 66(2-3):125-135.
- Grobin AC, **Lieberman JA**, Morrow AL: Perinatal flunitrazepam exposure causes persistent alterations in parvalbumin-immunoreactive interneuron localization. *Neuroscience Letters* 2004; 359(1-2):9-12.
- Jarskog LF, Selinger ES, **Lieberman JA**, Gilmore JH: Apoptotic proteins in the temporal cortex in schizophrenia: High Bax/Bcl-2 ratio without caspase-3 activation. *American Journal of Psychiatry* 2004; 161(1):109-115.
- Keefe RSE, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, Lewine RRJ, Yurgelun-Todd DA, Gur RC, Tohen M, Tollefson GD, Sanger TM, **Lieberman JA** and the HGDH Research Group: Comparative Effect of Atypical and Conventional Antipsychotic Drugs on Neurocognition in First-Episode Psychosis: A Randomized Double-Blind Trial of Olanzapine Versus Low Doses of Haloperidol. *American Journal of Psychiatry* 2004; 161(6):985-995.
- Lehman AF, **Lieberman JA**, Dixon LB, McGlashan TH, Miller AL, Perkins DO, Kreyenbuhl J; American Psychiatric Association; Steering Committee on Practice Guidelines: Practice guideline for the treatment of patients with schizophrenia, second edition. *American Journal of Psychiatry* 2004; 161(2 Suppl):1-56.
- Lieberman JA**: Dopamine Partial Agonists: A New Class of Antipsychotic. *CNS Drugs* 2004; 18(4):251-67.
- Lindenmayer J-P, Czobor P, Volavka J, **Lieberman JA**, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M: Effects of Atypical Antipsychotics on the Syndromal Profile in Treatment-Resistant Schizophrenia. *Journal of Clinical Psychiatry* 2004; 65(4):551-556.
- Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, **Lieberman JA**, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S: Physical health monitoring of patients with schizophrenia. *American Journal of Psychiatry* 2004; 161(8):1334-1349.
- Miyamoto S, Snouwaert JN, Koller BH, Moy SS, **Lieberman JA**, Duncan GE: Amphetamine-induced Fos is reduced in limbic cortical regions but not in the caudate or accumbens in a genetic model of NMDA receptor hypofunction. *Neuropsychopharmacology* 2004; 29(12):2180-2188.
- Perkins DO, Gu H, **Lieberman JA**, Tohen M, Green A, and the HGDH Research Group: Predictors of antipsychotic treatment response in patients with first episode schizophrenia, schizoaffective, and

- schizophreniform disorders. *British Journal of Psychiatry* 2004; 185:18-24.
- Sheitman BB, Knable MB, Jarskog LF, Chakos M, Boyce LH, Early J, **Lieberman JA**: Secretin for refractory schizophrenia. *Schizophrenia Research* 2004; 66(2-3):177-181.
- Sikich L, Hamer RM, Bashford RA, Sheitman BB, **Lieberman JA**: A Pilot Study of Risperidone, Olanzapine, and Haloperidol in Psychotic Youth: A double-blind, randomized, 8-week trial. *Neuropsychopharmacology* 2004; 29(1):133-145.
- Stroup TS, McEvoy JP, **Lieberman JA**: Revised PORT recommendations. *Schizophrenia Bulletin* 2004; 30(3):609-611.
- Strous RD, Alvir JMJ, Robertson D, Sheitman B, Chakos M, **Lieberman JA**: Premorbid Functioning in Schizophrenia: Relation To Baseline Symptoms, Treatment Response And Medication Side Effects. *Schizophrenia Bulletin* 2004; 30:265-278.
- Styner M, **Lieberman JA**, Pantazis D, Gerig G: Boundary and Medial Shape Analysis of the Hippocampus in Schizophrenia. *Medical Image Analysis* 2004; 8:197-203.
- Van der Stelt O, Belger A, **Lieberman JA**: Macroscopic fast neuronal oscillations and synchrony in schizophrenia. *Proceedings National Academy of Science U S A* 2004; 101(51):17567-17568.
- Van der Stelt O, Frye J, **Lieberman JA**, Belger A: Impaired P3 Generation Reflects High-Level and Progressive Neurocognitive Dysfunction in Schizophrenia. *Archives of General Psychiatry* 2004; 61:237-248.
- Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy JP, **Lieberman JA**: Prolactin Levels in Schizophrenia and Schizoaffective Disorder Patients Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol. *Journal of Clinical Psychiatry* 2004; 65(1):57-61.
- Volavka J, Czobor P, Nolan K, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy JP, Cooper TB, **Lieberman JA**: Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. *Journal of Clinical Psychopharmacology* 2004; 24(2):225-228.
- Volavka J, Kennedy JL, Ni X, Czobor P, Nolan K, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, **Lieberman JA**: COMT158 Polymorphism and Hostility. *American Journal of Medical Genetics* 2004; 127B(1):28-29.

## 2003

- Boteva K, **Lieberman J**: Reconsidering the Classification of Schizophrenia and Manic Depressive Illness-A Critical Analysis and New Conceptual Model. *World Journal of Biological Psychiatry* 2003; 4(2): 81-92.
- Bradford D, Perkins DO, **Lieberman JA**: Pharmacological Management of First Episode Schizophrenia and Related Nonaffective Psychoses. *Drugs* 2003; 63(21):2265-2283.
- Duncan GE, Miyamoto S, **Lieberman JA**: Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. *Journal of Pharmacology and Experimental Therapeutics* 2003; 305(3):999-1005.
- Grobin AC, Heenan EJ, **Lieberman JA**, Morrow AL: Perinatal neurosteroid levels influence GABAergic interneuron localization in adult rat prefrontal cortex. *The Journal of Neuroscience* 2003; 23(5):1832-1839.
- Lencz T, Bilder RM, Turkel E, Goldman RS, Robinson D, Kane JM, **Lieberman JA**: Impairments in Perceptual Competency and Maintenance on a Visual Match-to-Sample Delayed Test in First-Episode Schizophrenia. *Archives of General Psychiatry* 2003; 60(3): 238-243.
- Lieberman J**, Phillips M, Gu H, Stroup S, Zhang P, Kong L, Ji Z, Koch G, Hamer R: Atypical and Conventional Antipsychotic Drugs in Treatment Naïve First-Episode Schizophrenia: A 52 Week Randomized Trial of Clozapine versus Chlorpromazine. *Neuropsychopharmacology* 2003; 28(5):995-1003.

- Lieberman JA**, Stroup TS: Schizophrenia, VI: Treatments. *American Journal of Psychiatry* 2003; 160(10):1748 [Essay].
- Lieberman JA**, Stroup TS: What Can Large Pragmatic Clinical Trials Do for Public Mental Health Care? *Schizophrenia Bulletin* 2003; 29:15:1-6.
- Lieberman JA**, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM, HGDH Study Group: Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized double-blind trial of Olanzapine Vs Haloperidol. *American Journal of Psychiatry* 2003; 160(8):1396-1404.
- Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, **Lieberman JA**: Changes in Glucose and Cholesterol Levels in Patients with Schizophrenia Treated with Typical or Atypical Antipsychotics. *American Journal of Psychiatry* 2003; 160(2): 291-296.
- Marx CE, VanDoren MJ, Duncan GE, **Lieberman JA**, Morrow AL: Olanzapine and Clozapine increase the GABAergic neuroactive steroid Allopregnanolone in rodents: Clinical Implications. *Neuropsychopharmacology* 2003; 28(1):1-13.
- Maynard TM, Haskell GT, Peters AZ, Sikich L, **Lieberman JA**, LaMantia A-S: A Comprehensive Analysis of 22q11 Gene Expression in the Developing and Adult Brain. *Proceedings of the National Academy of Sciences* 2003; 100(24):14433-14438.
- Miyamoto S, LaMantia AS, Duncan GE, Gilmore JH, Sullivan P, **Lieberman JA**: Recent Advances in the Neurobiology of Schizophrenia. *Molecular Interventions* 2003; 3(1):27-39.
- Phillips PE, Johns JM, Lubin DA, Budygin EA, Gainetdinov RR, **Lieberman JA**, Wightman RM: Presynaptic dopaminergic function is largely unaltered in mesolimbic and mesostriatal terminals of adult rats that were prenatally exposed to cocaine. *Brain Research* 2003; 961(1); 63-72.
- Pinkham AE, Penn DL, Perkins DO, **Lieberman J**: Implications of the Neural Basis of Social Cognition for the Study of Schizophrenia. *American Journal of Psychiatry* 2003; 160(5):815-824.
- Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, **Lieberman JA**: The National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development. *Schizophrenia Bulletin* 2003; 29(1):15-31.
- Styner M, Gerig G, **Lieberman J**, Jones D, Weinberger D: Statistical shape analysis of neuroanatomical structures based on medial models. *Medical Image Analysis* 2003; 7:207-220.
- Szeszko P, Gunning-Dixon F, Goldman R, Bates J, Ashtari M, Snyder PJ, **Lieberman JA**, Bilder RM: Lack of Normal Association Between Cerebellar Volume and Neuropsychological Functions in First-Episode Schizophrenia. *American Journal of Psychiatry* 2003; 160(10):1884-1887.
- Szeszko PR, Gunning-Dixon F, Ashtari M, Snyder PJ, **Lieberman JA**, Bilder RM: Reversed Cerebellar Asymmetry in Men with First-Episode Psychosis. *Biological Psychiatry* 2003; 53(5):450-459.
- Woerner MG, Robinson DG, Alvir JMJ, Sheitman BB, **Lieberman JA**, Kane JM: Clozapine as a First Treatment for Schizophrenia. *American Journal of Psychiatry* 2003; 160(8):1514-1516.

## 2002

- Andersson C, Hamer R, Lawler C, Mailman R, **Lieberman J**: Striatal volume changes in the rat following long-term administration of typical and atypical antipsychotic drugs. *Neuropsychopharmacology* 2002; 27(2):143-151.
- Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, Horowitz TL, **Lieberman JA**: Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. *American Journal of Psychiatry* 2002; 159(6):1018-1028.
- Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X, Goldman, Hoptman MJ, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Kunz M, Chakos M, Cooper TB, **Lieberman JA**:

- Neurocognitive Correlates of the COMT Val<sup>158</sup> Met Polymorphism in Chronic Schizophrenia. *Biological Psychiatry* 2002; 52(7):701-707.
- Czobor P, Volavka J, Sheitman B, Lindenmayer J, Citrome L, McEvoy J, Cooper TB, Chakos M, **Lieberman JA**: Antipsychotic-induced weight gain and therapeutic response: A Differential Association. *Journal of Clinical Psychopharmacology* 2002; 22(3): 244-251.
- Duncan GE, Miyamoto S, Gu H, **Lieberman JA**, Koller BH, Snouwaert J: Alterations in Regional Brain Metabolism in Genetic and Pharmacological Models of Reduced NMDA Receptor Function. *Brain Research* 2002; 951(2):166.
- Goldstein RZ, Giovannetti T, Schullery M, Zuffante PA, **Lieberman JA**, Robinson DG, Barr WB, Bilder RM: Neurocognitive correlates of response to treatment in formal thought disorder in first-episode schizophrenia. *Neuropsychiatry* 2002; 15(2):88-98.
- Johns JM, Lubin DA, **Lieberman JA**, Lauder JM: Developmental effects of prenatal cocaine exposure on 5-HT1A receptors in male and female rat offspring. *Developmental Neuroscience* 2002; 24(6):522-530.
- Lieberman JA**, Stroup S, Schneider L: Prevention of relapse in schizophrenia. *New England Journal of Medicine* 2002; 346(18):1412-1413.
- Lieberman JA**, Perkins DO: Introduction, Quetiapine: A 5-Year Update. *Journal of Clinical Psychiatry*, 2002; 63(suppl 13): 3-4.
- Lieberman JA**: Pathogenesis, Pathophysiology, and Therapeutic Approaches to Schizophrenia. *Masters in Psychiatry* 2002; Summer.
- Lindenmayer JP, Czobor P, Volavka J, **Lieberman JA**, Citrome L, Sheitman B, Chakos M, McEvoy JP: Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. *Journal of Clinical Psychiatry* 2002; 63(10): 931-935.
- Marder S, Essock S, Miller A, Buchanan R, Davis K, Kane J, **Lieberman JA**, Schooler N: The Mount Sinai Conference on the pharmacotherapy of schizophrenia. *Schizophrenia Bulletin* 2002; 28(1):5-16.
- Maynard TM, Haskell GT, Bhasin N, Lee JM, Gassman AA, **Lieberman JA**, LaMantia AS: RanBP1, a velocardiofacial/DiGeorge syndrome candidate gene, is expressed at sites of mesenchymal/epithelial induction. *Mechanisms of Development* 2002; 111:177-180.
- Maynard TM, Haskell GT, **Lieberman JA**, LaMantia AS: 22q11 DS: genomic mechanisms and gene function in DiGeorge/velocardiofacial syndrome. *International Journal of Developmental Neuroscience* 2002; 20:764:1-13.
- Robinson D, Woerner M, Alvir J, Bilder R, Hinrichsen G, **Lieberman JA**: Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder. *Schizophrenia Research* 2002; 57(2-3):209.
- Spivak B, Alamy SS, Jarskog LF, Sheitman BB, **Lieberman JA**: Ziprasidone alternative for olanzapine-induced hyperglycemia. *American Journal of Psychiatry* 2002; 159(9):1606.
- Szeszko PR, Strous R, Goldman RS, Ashtari M, Knuth KH, **Lieberman JA**, Bilder RM: Neuropsychological correlates of hippocampal volumes in patients experiencing first-episode schizophrenia. *American Journal of Psychiatry* 2002; 159(2):217-226.
- Volavka J, Czobor P, Sheitman B, Lindenmayer JP, Citrome L, McEvoy J, Cooper T, Chakos M, **Lieberman JA**: Clozapine, Olanzapine, Risperidone, and Haloperidol in patients with chronic schizophrenia and schizoaffective disorder. *American Journal of Psychiatry* 2002; 159(2):255-262.

## 2001

- Basile VS, Masellis M, McIntyre RS, Meltzer HY, **Lieberman JA**, Kennedy JL: Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle. *Journal of Clinical Psychology* 2001; 62 (Suppl 23):45-66.
- Basile VS, Ozdemir V, Masellis M, Meltzer HY, **Lieberman JA**, Potkin SG, Macciardi FM, Petronis A, Kennedy JL: Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. *Molecular Psychiatry* 2001; 6(2): 230-234.

- Chakos M, **Lieberman JA**, Hoffman E, Bradford D, Sheitman B: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials. *American Journal of Psychiatry* 2001; 158:518-526.
- Citrome L, Volavka J, Czobor P, Sheitman B, Lindenmayer J, McEvoy J, Cooper T, Chakos M, **Lieberman JA**: Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol on hostility in patients with schizophrenia and schizoaffective disorder. *Psychiatric Services* 2001; 52(11):1510-1514.
- Lieberman JA**, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D, Bilder R: Longitudinal study of brain morphology in first episode schizophrenia. *Biological Psychiatry* 2001; 49(6): 487-499.
- Lieberman JA**, Perkins D, Belger A, Chakos M, Jarskog F, Boteva K, Gilmore J: The early stages of schizophrenia: Speculations on pathogenesis, pathophysiology and therapeutic approaches. *Biological Psychiatry* 2001; 50(11):884-897.
- Lieberman JA**: Starting a career in psychiatric research: The Lessons of Experience. *Academic Psychiatry* 2001; 25:28-30.
- Lieberman JA**: Hypothesis and hypothesis testing in the clinical trial. *Journal of Clinical Psychiatry* 2001; 62[suppl 9]: 5-8.
- Lindenmayer, JP, Volavka J, **Lieberman J**, Sheitman B, Citrome L, Chakos M, Czobor P, Parker B, Iskander A: Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label prospective trial. *J Clin Psychopharmacol* 2001; 21(4): 448-453.
- Marx CE, Jarskog LF, Lauder JM, **Lieberman JA**, Gilmore JH: Cytokine regulation of embryonic cortical neuron survival: Implications of schizophrenia. *Biological Psychiatry* 2001; 50(10):743-749.
- Masellis M, Basile VS, Meltzer HY, **Lieberman JA**, Sevy S, Goldman DA, Hamblin MW, Macciardi, FM, Kennedy JL: Lack of association between the T→C 267 serotonin 5-HT<sub>6</sub> receptor gene (HTR6) polymorphism and prediction of response to clozapine in schizophrenia. *Schizophrenia Research* 2001; 47:49-58.
- Maynard T, Sikich L, **Lieberman J**, LaMantia A: Neural Development , Cell-Cell signaling, and the "Two Hit" hypothesis of schizophrenia. *Schizophrenia Bulletin* 2001; 27(3):457-476.
- Miyamoto S, Mailman RB, **Lieberman JA**, Duncan GE: Blunted brain metabolic response to ketamine in mice lacking D1A dopamine receptors. *Brain Research* 2001; 894:167-180.
- Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Small GW, Lebowitz B, **Lieberman JA**: National Institute of Mental Health Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. *American Journal of Geriatric Psychiatry* 2001; 9(4):346-360.
- Sevy S, Robinson DG, Holloway S, Alvir JM, Woener MG, Bilder R, Goldman R, **Lieberman J**, Kane J: Correlates of substance misuse in patients with first-episode schizophrenia and schizoaffective disorder. *Acta Psychiatr Scand* 2001; 104(5):367-374.
- Strous RD, Pllack S, Robinson D, Sheitman B, **Lieberman JA**: Seasonal admission patterns in first episode psychosis, chronic schizophrenia, and nonschizophrenic psychosis. *Journal of Nervous Mental Disorders* 2001; 189(9):642-644.
- Stroup TS, **Lieberman JA**, Swartz MS, McEvoy JP: Comparative effectiveness of antipsychotic drugs in schizophrenia. Dialogues in Clinical Neuroscience. *Schizophrenia: General Findings* 2001; 2(4):373-380.
- Urakubo A, Jarskog LF, **Lieberman JA**, Gilmore JH: Prenatal exposure to maternal infection alters cytokine expression in the placenta, amniotic fluid, and fetal brain. *Schizophrenia Research* 2001; 47:27-36.

## 2000

- Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, **Lieberman JA**, Potkin SG, Kalow W, Macciardi FM, Kennedy JL: A functional polymorphism of the Cytochrome P450 1A2 (CYP1A2) gene: Association with tardive dyskinesia in schizophrenia. *Molecular Psychiatry* 2000; 5:410-417.



- Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, Pappadopulos E, Wilson DF, Alvir JM, Woerner MG, Geisler S, Kane JM, **Lieberman JA**: Neuropsychology of first-episode schizophrenia: Initial characterization and clinical correlates. *American Journal of Psychiatry* 2000; 157(4):549-559.
- Duncan GE, Miyamoto S, Leipzig JN, **Lieberman JA**: Comparison of the effects of Clozapine, Risperidone, and Olanzapine on ketamine-induced alterations in regional brain metabolism. *Journal of Pharmacology and Experimental Therapeutics* 2000; 293(1):8-14.
- Jarskog LF, Gilmore JH, Selinger ES, **Lieberman JA**: Cortical BCL-2 protein expression and apoptotic regulation in schizophrenia. *Biological Psychiatry* 2000; 48(7):641-651.
- Jarskog LF, Mattioli MA, Perkins DO, **Lieberman JA**: First-episode psychosis in a managed care setting: Clinical management and research. *The American Journal of Psychiatry* 2000; 157(6):878-884.
- Javitt DC, Shelley AM, Silipo G, **Lieberman JA**: Deficits in auditory and visual processing in schizophrenia: Defining the pattern. *Archives of General Psychiatry* 2000; 57:1131-1137.
- Levy DL, Lajonchere CM, Dorogusker B, Seungwoo L, Min DK, Tartaglioni A., **Lieberman JA**, Mendell, NR: Quantitative characterization of eye tracking dysfunction in schizophrenia. *Schizophrenia Research* 2000; 5(42)(3):171-185.
- Lewis DA, **Lieberman JA**: Catching up on schizophrenia: Natural history and neurobiology. *Neuron* 2000; 28:325-334.
- Lieberman JA**, Fenton WS: Delayed detection of psychosis: Causes, consequences, and effect on public health. *American Journal of Psychiatry* 2000; 157:1727-1734.
- Lieberman JA**, Golden R, Stroup S, McEvoy J: Drugs of the psychopharmacological revolution in clinical psychiatry. *Psychiatric Services* 2000; 51(10):1254-1259.
- Lieberman JA**: Clinical research in the age of neuroscience. *Neuropsychopharmacology* 2000; 22(1): 1-3
- Marx CE, Duncan GE, Gilmore JH, **Lieberman JA**, Morrow AL: Olanzapine increases allopregnanolone in rat cerebral cortex. *Biological Psychiatry* 2000; 47(11):1000-1004.
- Marx CE, Jarskog LF, Lauder JM, Gilmore JH, **Lieberman JA**, Morrow AL: Neurosteroid modulation of embryonic neuronal survival in vitro following anoxia. *Brain Research* 2000; 871:104-112.
- Miyamoto S, Leipzig JN, **Lieberman JA**, Duncan GEL: Effects of ketamine, MK-801, and amphetamine on regional brain 2-deoxyglucose uptake in freely moving mice. *Neuropsychopharmacology* 2000; 22(4) 400-412.
- Overstreet DH, Moy SS, Lee RG, Lubin DA, **Lieberman JA**, Johns JM: Enduring effects of prenatal cocaine administration on emotional behavior in rats. *Physiol Behav* 2000; 70:149-156.
- Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, **Lieberman JA**: Characterizing and dating the onset of symptoms in psychotic illness: The symptom onset in schizophrenia (SOS) inventory. *Schizophrenia Research* 2000; 44(1):1-10.
- Sheitman BB, Murray MG, Snyder JA, Silva S, Goldman R, Chakos M, Volavka J, **Lieberman JA**: IQ scores of treatment-resistant schizophrenia patients before and after the onset of the illness. *Schizophrenia Research* 2000; 46:203-207.
- Vincent JB, Neves-Pereira ML, Paterson AD, Yamamoto E, Parikh SV, Macciardi F, Gurling HM, Potkin SG, Pato CN, Azevedo MH, Kovacs M, Davies M, **Lieberman JA**, Meltzer HY, Petronis A, Kennedy JL: An unstable trinucleotide repeat region on chromosome 13 implicated in spinocerebellar ataxia: A common expansion locus. *American Journal of Human Genetics* 2000; 66(3):819-829.

## 1999

- Basile VS, Masellis M, Badri F, Paterson AD, Meltzer HY, **Lieberman JA**, Potkin SG, Macciardi F, Kennedy JL: Association of MscI polymorphism of the dopamine D<sub>2</sub> receptor gene tardive dyskinesia in schizophrenia. *Neuropsychopharmacology* 1999; 21(1):17-27.
- Bilder RM, Wu H, Bogerts B, Ashtari M, Robinson D, Woerner M, **Lieberman JA**, Degreaf G: Cerebral asymmetries in schizophrenia and mood disorders: A quantitative MRI study. *International Journal of Psychophysiology* 1999; 34:197-205.

- Dawkins K, **Lieberman JA**, Lebowitz BD, Hsiao JK: NIMH Activities: Antipsychotics: Past and future: Proceedings of the NIMH Division of Services and Intervention Research Workshop. *Schizophrenia Bulletin* 1999; 25(2):395-405.
- Duncan GE, Zorn, Stevin, **Lieberman JA**: Mechanisms of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypofunction hypotheses of schizophrenia *Molecular Psychiatry* 1999; 4(5):418-428.
- Duncan, GE, Miyamoto S, Leipzig JN, **Lieberman, JA**: Subanesthetic doses of ketamine and MK-801 induce similar alterations in brain activity patterns: Support for NMDA receptor involvement in ketamine-induced psychosis. *Brain Research* 1999; 843:171-183.
- Duncan, GE, Sheitman BB. **Lieberman, JA**: An integrated view of pathophysiological models of schizophrenia. *Brain Research Reviews* 1999; 29(2-3):250-264.
- Hinrichsen GA, **Lieberman JA**: Family attitudes, coping and patient management strategies in first episode schizophrenia. *Acta Psychiatrica Scandinavica* 1999; 100(5):359-366.
- Keefe RS, Silva SG, Perkins DO, **Lieberman JA**: The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: A review and meta-analysis. *Schizophrenia Bulletin* 1999; 25(2):201-222.
- Leadbetter RA, Shutty MS, Elkashef AM, Kirch DG, Spraggins T, Cail WS, Wu H, Bilder RM, **Lieberman JA**, Wyatt RJ: MRI changes during water loading in patients with polydipsia and intermittent hyponatremia. *American Journal of Psychiatry* 1999; 156(6):958-960.
- Lee H., Tarazi FI, Chakos M., Wu H, Redmond M, Alvir J, Kinon BJ, Bilder R, Creese I, **Lieberman JA**: Effects of chronic treatment with typical and atypical antipsychotic drugs on the caudate nucleus in the rat. *Life Sciences* 1999; 64(18):1595-1602.
- Lieberman JA**, Aghajanian GK: Caveat Emptor: Researcher Beware. *Neuropsychopharmacology* 1999; 21(4):471-473 [Editorial].
- Lieberman JA**: Medical education and patients' psychosocial needs. *Journal of Family Practice* 1999; 48(9):675-676.
- Lieberman JA**: Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. *Biological Psychiatry* 1999; 46(6):729-739.
- Lieberman JA**: Pathophysiologic Mechanisms in the Pathogenesis and Clinical course of Schizophrenia. *The Journal of Clinical Psychiatry* 1999; 60(supplement 12):9-12.
- Lieberman JA**: Schizophrenia: Comments on genes, development, risk factors, phenotype and course. *Biological Psychiatry* 1999; 46(7):869-870 [Editorial].
- Lieberman JA**: Searching for the neuropathology of schizophrenia: Neuroimaging strategies and findings. *American Journal of Psychiatry* 1999; 156(8):1133-1136 [Editorial].
- Robinson DG, Woerner MG, Alvir JMa.J, Bilder R, Goldman R, Geisler S, Koreen A, Sheitman B, Chakos M, Mayerhoff D, **Lieberman JA**: Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. *Archives of General Psychiatry* 1999; 56(3):241-247.
- Robinson DG, Woerner MG, Alvir JMa.J, Geisler S. Koreen A, Sheitman B, Chakos M, Mayerhoff D, Bilder R, Goldman R, **Lieberman JA**: Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. *American Journal of Psychiatry* 1999; 156(4):544-549.
- Sanger TM, **Lieberman JA**, Tohen M, Grundy S, Beasley C, Tollefson GD: Olanzapine versus Haloperidol treatment in first-episode psychosis. *American Journal of Psychiatry* 1999; 156(1):79-87.
- Szeszko P, Bilder R, Dunlop J, Walder D, **Lieberman JA**: Longitudinal assessment of methylphenidate effects on oral word production and symptoms in first-episode schizophrenia at acute and stabilized phases. *Biological Psychiatry* 1999; (45):680-686.
- Szeszko PR, Bilder RM, Lencz T, Pollack S, Alvir JM, Ashtari M, Wu H, **Lieberman JA**: Investigation of frontal lobe subregions in first episode schizophrenia. *Psychiatry Research* 1999; 90(1):1-15.
- Tamminga CA, **Lieberman JA**: Schizophrenia research series: from molecule to public policy. *Biological Psychiatry* 1999; 46(1):3.
- Umbricht D, Javitt D, Novak G, Bates J, Pollack S, **Lieberman J**, Kane J: Effects of risperidone on auditory event-related potentials in schizophrenia. *International Journal of Neuropsychopharmacology* 1999; 2(4):299-304.

- Vincent JB, Petronis A, Strong E, Parikh SV, Meltzer HY, **Lieberman J**, Kennedy JL: Analysis of genome-wide CAG/CTG repeats, and at SEF2-1B and ERDA1 in schizophrenia and bipolar affective disorder. *Molecular Psychiatry* 1999; 4(3):229-234.
- Yui K, Goto K, Ikemoto S, Ishiguro T, Angrist B, Duncan GE, Sheitman BB, **Lieberman JA**, Brancha SH, Ali SF: Neurobiological basis of relapse prediction in stimulant-induced psychosis and schizophrenia: the role of sensitization. *Molecular Psychiatry* 1999; 4(6):512-523.

## 1998

- Andersson C, Chakos M, Mailman R, **Lieberman J**: Emerging roles for novel antipsychotic medications in the treatment of schizophrenia. *Psychiatr Clin North Am* 1998; 21(1):151-179.
- Bradford DW, Chakos MH, Sheitman BB, **Lieberman JA**: Atypical antipsychotic drugs in treatment-refractory schizophrenia. *Psychiatric Annals* 1998; 28(11):618-626.
- Chakos MH, Esposito S, Charles C, **Lieberman JA**: Clinical applications of Neuroimaging in psychiatry. *Magn Reson Imaging Clin N Am* 1998; 6(1):155-164.
- Chakos MH, Shirakawa O, **Lieberman JA**, Lee H, Bilder R, Tamminga CA: Striatal enlargement in rats chronically treated with neuroleptic. *Biological Psychiatry* 1998; 44(8):675-684.
- Duncan GE, Mailman RB, Leipzig JN, **Lieberman JA**: Differential effects of clozapine and haloperidol on ketamine-induced brain metabolic activation. *Brain Research* 1998; 812(1-2):65-75.
- Lieberman JA**, Mailman R: Decline of Dopamine: Effects of age and acute neuroleptic challenge. *American Journal of Psychiatry* 1998; 155(3):319-323.
- Lieberman JA**, Mailman RB, Duncan G, Sikich L, Chakos MH, Nichols DE, Kraus J: Serotonergic basis of antipsychotic drug effects in Schizophrenia. *Biological Psychiatry* 1998; 44(11):1099-1117.
- Lieberman JA**, Sheitman B, Chakos M, Robinson D, Schooler N, Keith S: The development of treatment resistance in patients with schizophrenia: A clinical and pathophysiological perspective. *Journal of Clinical Psychopharmacology* 1998; 18(2):20S-24S [Review].
- Lieberman JA**: Maximizing clozapine therapy: Managing side effects. *Journal of Clinical Psychiatry* 1998; 59(suppl 3):38-43.
- Lieberman JA**: Pathophysiology in the clinical course of schizophrenia. *Inter Clin Psychopharm* 1998; 13(suppl 1):S3-S6.
- Marx CE, **Lieberman JA**: Psychoneuroendocrinology of schizophrenia. *Psychiatr Clin North Am* 1998; 21(2):413-434.
- Masellis M, Basile V, Meltzer HY, **Lieberman JA**, Sevy S, Macciardi FM, Cola P, Howard A, Badri F, Nothen MM, Kalow W, Kennedy JL: Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. *Neuropsychopharmacology* 1998; 19(2):123-132.
- Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, **Lieberman JA**: The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. *Journal of Clinical Psychiatry* 1998; 59(2):69-75.
- Perkins DO, **Lieberman JA**: Medical complications and selectivity of therapeutic response to atypical antipsychotic drugs. *American Journal of Psychiatry* 1998; 155:272-276.
- Sheitman BB, **Lieberman JA**: The natural history and pathophysiology of treatment resistant schizophrenia. *Journal of Psychiatric Research* 1998; 132(3-4):143-150.
- Snyder P, Bogerts B, Wu H, Bilder R, Deoras K, **Lieberman JA**: Neuroimaging and behavior- absence of the adhesio interthalamica as a marker of early developmental neuropathology in schizophrenia: An MRI and postmortem histologic study. *Journal of Neuroimaging* 1998; 8(3):159-163.
- Umbricht D, Javitt D, Novak G, Bates J, Pollack S, **Lieberman JA**, Kane J: The effects of clozapine on auditory event-related potentials in schizophrenia. *Biological Psychiatry* 1998; 44(8):716-725.
- Woerner MG, Alvir JMJ, Saltz B, **Lieberman J**, Kane JM: Prospective study of tardive dyskinesia in the elderly: Rates and risk factors. *American Journal of Psychiatry* 1998; 155(11):1521-1528.

1997

- Barr WB, Ashtari M, Bilder RM, DeGreef G, **Lieberman JA**: Brain morphometric comparison of first-episode schizophrenia and temporal lobe epilepsy. *British Journal of Psychiatry* 1997; 170:515-519.
- Herz MI, Liberman RP, **Lieberman JA**, Marder SR, McGlashan TH, Wyatt RJ, Wang P: Practice guidelines for the treatment of patients with schizophrenia. *American Journal of Psychiatry* 1997; 154:4[suppl].
- Koreen A, **Lieberman JA**, Alvir J, Chakos M: The behavioral effect of m-chlorophenylpiperazine (mCPP) and methylphenidate in first-episode schizophrenia and normal controls. *Neuropsychopharmacology* 1997; 16(1):61-68.
- Lieberman JA**, Sheitman B, Kinon BJ: Neurochemical sensitization in the pathophysiology of schizophrenia: Deficits and dysfunction in neuronal regulation and plasticity. *Neuropsychopharmacology* 1997; 17(4):205-229.
- Schooler NR, Keith SJ, Severe JB, Matthews SM, Bellack AS, Glick ID, Hargreaves WA, Kane JM, Ninan PT, Frances A, Jacobs M, **Lieberman JA**, Mance R, Simpson GM, Woerner MG: Relapse and rehospitalization during maintenance treatment of schizophrenia: The effects of dose reduction and family treatment. *Archives of General Psychiatry* 1997; 54(5):453-463.
- Sheitman BB, Lee H, Strous R, **Lieberman JA**: The evaluation and treatment of first episode psychoses. *Schizophrenia Bulletin* 1997; 23(4):653-661.
- Turbay D, Alper CA, **Lieberman JA**, Delgado JC, Corzo D, Yunis JJ, Yunis EJ: Tumor necrosis factor constellation polymorphism and clozapine-induced agranulocytosis in two different ethnic groups. *Blood* 1997; 89(11):4167-4174.
- Volkow ND, Wang GJ, Fowler JS, Logan J, Angrist B, Hitzemann RJ, **Lieberman J**, Pappas NS: Effects of methylphenidate on regional brain glucose metabolism in humans: relationship to dopamine D2 receptors. *American Journal of Psychiatry* 1997; 154(1):50-55.
- Wang GJ, Volkow ND, Hitzemann RJ, Wong C, Angrist B, Burr Gail, Pascani K, Pappas N, Lu A, Cooper T, **Lieberman JA**: Behavioral and cardiovascular effects of intravenous methylphenidate in normal subjects and cocaine abusers. *European Addiction Research* 1997; 3:49-54.

1996

- Atkin K, Kendall F, Gould D, Freeman H, **Lieberman J**, O'Sullivan, D: Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. *British Journal of Psychiatry* 1996; 169:483-488.
- Chakos MH, Alvir MJ, Woerner MG, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane JM, Borenstein M, **Lieberman JA**: Incidence and correlates of tardive dyskinesia in first episode of schizophrenia. *Archives of General Psychiatry* 1996; 53(4):313-319.
- Kinon BJ, **Lieberman JA**: Mechanisms of action of atypical antipsychotic drugs: A critical analysis. *Psychopharmacology* 1996; 124(1/2):2-34.
- Lieberman JA**, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B, Woerner M: Psychobiologic correlates of treatment response in schizophrenia. *Neuropsychopharmacology* 1996; 14(3S):13S-21S.
- Lieberman JA**, Koreen A, Chakos M, Sheitman B, Woerner M, Alvir J, Bilder R: Factors influencing treatment response and outcome of first-episode schizophrenia: Implications for understanding the pathophysiology of schizophrenia. *Journal of Clinical Psychiatry* 1996; 57(8):5-9.
- Lieberman JA**, Rush AJ: Redefining the role of psychiatry in medicine. *American Journal of Psychiatry* 1996; 153(11):1388-1397.
- Lieberman JA**: Atypical antipsychotic drugs as a first-line treatment of schizophrenia: a rationale and hypothesis. *Journal of Clinical Psychiatry* 1996; 57[suppl] 11:68-71.
- Lieberman JA**: Ethical dilemmas in clinical research with human subjects: an investigator's perspective. *Psychopharmacology Bulletin* 1996; 32(1):19-25.

- Paterson AD, Ying D-J, Petronis A, Schoots O, **Lieberman JA**, Van Tol HHM, Kennedy JL: A PstI restriction fragment length polymorphism in the 5' untranslated region of DRD4 is not associated with schizophrenia. *Psychiatric Genetics* 1996; 6:191-193.
- Sasaki T, Billett E, Petronis A, Ying D, Parsons T, Macciardi FM, Meltzer HY, **Lieberman J**, Joffe RT, Ross CA, McInnis MG, Li SH, & Kennedy JL: Psychosis and genes with trinucleotide repeat polymorphism. *Human Genetics* 1996; 97:244-246.
- Sasaki T, Macciardi FM, Badri F, Verga M, Meltzer HY, **Lieberman J**, Howard A, Bean G, Joffe RT, Hudson CJ, Kennedy JL: No evidence for association of dopamine D2 receptor variant (ser311/cys311) with major psychosis. *American Journal of Medical Genetics* 1996; 67:415-417.
- Shelley AM, Grochowski S, **Lieberman JA**, Javitt DC: Premature disinhibition of P3 generation in schizophrenia. *Biological Psychiatry* 1996; 39: 714-719.
- Szymanski S, **Lieberman J**, Pollack S, Kane JM, Safferman A, Munne R, Umbricht D, Woerner M, Masiar S, Kronig M: Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. *Biological Psychiatry* 1996; 39:249-254.
- Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Ding YS, Logan J, Dewey SL, Hitzemann R, **Lieberman J**: Relationship between psychostimulant induced high and dopamine transporter occupancy. *Proceedings National Academy of Sciences* 1996; 93:10388-10392.
- Volkow ND, Wang GJ, Gatley SJ, Fowler JS, Ding YS, Hitzemann R, Logan J, Wong C, **Lieberman J**: Temporal relationships between the pharmacokinetics of methylphenidate in the human brain and its behavioral and cardiovascular effects. *Psychopharmacology* 1996; 123:26-33.
- Woerner MG, Sheitman BB, **Lieberman JA**, & Kane JM: Tardive dyskinesia induced by risperidone? [letter]. *American Journal of Psychiatry* 1996; 153:843.
- Zhu FY, Phillips MR, **Lieberman JA**: An investigation of tardive dyskinesia in long term institutionalized patients. *Shanghai Archives of Psychiatry* 1996; 8:128-132.

## 1995

- Alvir JMJ, **Lieberman JA**, Safferman AZ: Do white-cell count spikes predict agranulocytosis in clozapine recipients? *Psychopharmacology Bulletin* 1995; 31(2):311-314.
- Aronowitz JS, Safferman AZ, **Lieberman JA**: Management of clozapine-induced enuresis. *Am Journal of Psychiatry* 1995; 152(3):472.
- Bilder RM, Bogerts B, Ashtari M, Wu H, Alvir JM, Jody D, Reiter G, Bell L, **Lieberman JA**: Anterior hippocampal volume reductions predict frontal lobe dysfunction in first episode schizophrenia. *Schizophrenia Research* 1995; 17:47-58.
- Chakos MH, **Lieberman JA**, Alvir J, Bilder R, Ashtari M: Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. *The Lancet* 1995; 345(8947):456-457.
- Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Alvir J, **Lieberman JA**: Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesias in never medicated schizophrenic patients. *American Journal of Psychiatry* 1995; 152:1724-1729.
- Corzo D, Yunis JJ, Salazar M, **Lieberman JA**, Howard A, Awdeh Z, Alper CA, Yunis EJ: The major histocompatibility complex region marked by HSP70-1 and HSP70-2 variants is associated with clozapine-induced agranulocytosis in two different ethnic groups. *Blood* 1995; 86(10):3835-3840.
- Kennedy JL, Billett EA, Macciardi FM, Verga M, Parsons TJ, Meltzer HY, **Lieberman J**, Buchanan JA: Association study of dopamine D3 receptor gene and schizophrenia. *American Journal of Medical Genetics* 1995; 60:558-562.
- Koreen AR, **Lieberman JA**, Kronig M, Cooper TB: Cross-tapering clozapine and risperidone. *Am Journal of Psychiatry* 1995; 152(11):1690.
- Kronig MH, Munne RA, Szymanski S, Safferman AZ, Pollack S, Cooper T, Kane JM, **Lieberman JA**: Plasma clozapine levels and clinical response in treatment refractory schizophrenia patients. *American Journal of Psychiatry* 1995; 152:179-182.

- Lieberman J:** Signs and symptoms. What can they tell us about the clinical course and pathophysiologic processes of schizophrenia?. *Archives of General Psychiatry* 1995; 52:361-363.
- Lieberman JA:** Treatment of first-episode patients. *Journal of Clinical Psychiatry* 1995; 13(1):5-7.
- Linday LA, Pippenger CE, Howard A, **Lieberman JA:** Free radical scavenging enzyme activity and related trace metals in clozapine-induced agranulocytosis: A pilot study. *Journal of Clinical Psychopharmacology* 1995; 15(5):353-360.
- Masellis M, Paterson AD, Badri F, **Lieberman JA**, Meltzer HY, Cavazzoni P, Kennedy JL: Genetic variation of 5-HT<sub>2A</sub> receptor and response to clozapine. *The Lancet* 1995; 346(8992):1108.
- Mendelowitz AJ, **Lieberman JA**, Gerson SL, Alvir JMJ: Clozapine induced agranulocytosis: Risk factors, monitoring and management. *Drugs* 1995; 4(6):412-421.
- Mendelowitz AJ, **Lieberman JA:** New findings in the use of atypical antipsychotic drugs I: Focus on risperidone. *The Journal of Clinical Psychiatry* 1995; 2(1):1-12.
- Pollack S, **Lieberman JA**, Fleischhacker WW, Borenstein M, Safferman A, Hummer M, Kurtz M: A comparison of European and American dosing regimen of schizophrenic patients on clozapine: Efficacy and side effects. *Psychopharmacology Bulletin* 1995; 31(2):315-320.
- Snyder PJ, Bilder RM, Wu H, Bogerts B, **Lieberman JA:** Cerebellar volume asymmetries are related to handedness: A quantitative MRI study. *Neuropsychologia* 1995; 33(4):407-419.
- Szymanski S, **Lieberman J**, Pollack S, Safferman A, Munne R, Umbricht D, Kane J, Kronig M, Chakos M, Cooper T: Clozapine effects on neuroendocrine response to apomorphine challenge testing in chronic neuroleptic nonresponsive schizophrenia: preliminary findings. *Biological Psychiatry* 1995; 37:52-55.
- Szymanski S, **Lieberman JA**, Alvir JM, Mayerhoff D, Loebel A, Geisler S, Chakos M, Koreen A, Jody D, Kane J, Woerner M, Cooper T: Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. *American Journal of Psychiatry* 1995; 152:698-703.
- Umbricht D, Degreef G, Barr WB, **Lieberman JA**, Pollack S, Schaul N: Postictal and chronic psychoses in patients with temporal lobe epilepsy. *American Journal of Psychiatry* 1995; 152:224-231.
- Umbricht DG, **Lieberman JA**, Kane JM: The clinical efficacy of clozapine in the treatment of schizophrenia. *Reviews in Contemporary Pharmacotherapy* 1995; 6:165-186.
- Volkow ND, Ding U, Fowler JS, Wang GJ, Logan J, Gatley JS, Dewey SL, Ashby C, **Lieberman J**, Hitzemann R, Wolf AP: Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. *Archives of General Psychiatry* 1995; 52:456-463.
- Volkow ND, Ding Y-S, Fowler C, Wang G-J, Logan J, Gatley JS, Dewey S, Ashby C, **Lieberman J**, Hitzemann R, Wolf AP: Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in human brain. *Archives of General Psychiatry* 1995; 52(6):456-462.
- Woerner MG, Alvir JMJ, Kane JM, Saltz BL, **Lieberman JA:** Neuroleptic treatment of elderly patients. *Psychopharmacology Bulletin* 1995; 31:333-337.
- Yunis JJ, Corzo D, Salazar M, **Lieberman JA**, Howard A, Yunis EJ: HLA associations in clozapine-induced agranulocytosis. *Blood* 1995; 86(3):1177-1183.

## 1994

- Alvir JMJ, **Lieberman JA:** Agranulocytosis: Incidence and risk factors. *The Journal of Clinical Psychiatry* 1994; 55(9)[suppl B]:137-138.
- Bilder RM, Wu H, Bogerts B, Degreef G, Ashtari M, Alvir JMJ, Snyder PJ, **Lieberman JA:** Absence of regional hemispheric volume asymmetries in first episode schizophrenia. *American Journal of Psychiatry* 1994; 151(10):1437-1447.
- Bilder RM, Wu H, Chakos MH, Bogerts B, Pollack S, Aronowitz J, Ashtari M, Degreef G, Kane JM, **Lieberman JA:** Cerebral morphometry and clozapine treatment in schizophrenia. *The Journal of Clinical Psychiatry* 1994; 55(9)[suppl B]:53-56.

- Chakos MH, **Lieberman JA**, Bilder RM, Lerner G, Bogerts B, Degreef G, Wu H, Ashtari M: Increase in caudate nuclei volumes of first episode schizophrenic patients taking antipsychotic drugs. *American Journal of Psychiatry* 1994; 151(10):1430-1436.
- Corzo D, Yunis JJ, Yunis EJ, Howard A, **Lieberman JA**: HSP70-2 9.0 kb variant is in linkage disequilibrium with the HLA-B and DRB1\* alleles associated with clozapine- induced agranulocytosis. *Journal of Clinical Psychiatry* 1994; 55(9)[suppl B]:149-152.
- Fleischhacker WW, Hummer M, Kurz M, Kurzthaler I, **Lieberman JA**, Pollack S, Safferman AZ, Kane JM: Clozapine dose in the United States and Europe: Implications for therapeutic and adverse effects. *The Journal of Clinical Psychiatry* 1994; 55(9) [suppl B]:78-81.
- Jann MW, Jenike MA, **Lieberman JA**: The new psychopharmaceuticals. *Patient Care* 1994; 28(2):47-61.
- Kane JM, Safferman AZ, Pollack S, Johns C, Szymanski S, Kronig M, **Lieberman JA**: Clozapine, negative symptoms, and extrapyramidal side effects. *The Journal of Clinical Psychiatry* 1994; 55(9)[suppl B]: 74-77.
- Koreen A, **Lieberman J**, Alvir J, Chakos M, Loebel A, Cooper T, Kane J: Relation of plasma fluphenazine levels to treatment response and extrapyramidal side effects in first episode schizophrenic patients. *American Journal of Psychiatry* 1994; 151:35-39.
- Koreen AM, **Lieberman J**, Alvir J, Mayerhoff D, Loebel A, Chakos M, Amin F, Cooper T: Plasma homovanillic acid in first episode schizophrenia: Psychopathology and treatment response. *Archives of General Psychiatry* 1994; 51:132-138.
- Lieberman J**, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, Kronig M, Bookstein P, Kane J: Clinical effects of clozapine in chronic schizophrenia: Treatment response and predictors of outcome. *American Journal of Psychiatry* 1994; 151:1744-1752.
- Lieberman J**: Clinical biological studies of atypical antipsychotics: Focus on the serotonin/dopamine systems. *Journal of Clinical Psychiatry* 1994; 12(2):24-28.
- Lieberman JA**, Alvir J, Geisler S, Ramos-Lorenzi J, Woerner M, Novacenko H, Cooper T, Kane JM: Methylphenidate response, psychopathology and tardive dyskinesia as predictors of relapse in schizophrenia. *Neuropsychopharmacology* 1994; 11(2):107-118.
- Lieberman JA**, Kane JM, Safferman AZ, Pollack S, Howard A, Szymanski S, Masiar SJ, Kronig MH, Cooper T, Novacenko H: Predictors of response to clozapine. *The Journal of Clinical Psychiatry* 1994; 55(9) [suppl B]:126-128.
- Lieberman JA**, Sloan J: The moral imperatives of medical research in human subjects. *The Journal of the California Alliance for the Mentally Ill* 1994; 5(1):40-42.
- Mayerhoff DI, Loebel AD, Borenstein M, Szymanski SR, Geisler SH, Alvir JMJ, **Lieberman JA**: The deficit state in first-episode schizophrenia. *American Journal of Psychiatry* 1994; 151(10):1417-1422.
- Pollack S, Bruce P, Borenstein M, **Lieberman J**: The resampling method of statistical analysis. *Psychopharmacology Bulletin* 1994; 30(2):227-234.
- Safferman AZ, Kane JM, Aronowitz JS, Gordon MF, Pollack S, **Lieberman JA**: The use of clozapine in neurologic disorders. *The Journal of Clinical Psychiatry* 1994; 55(9) [suppl B]:98-101.
- Seeman P, Ulpian C, Chouinard G, Van Tol HHM, Dwosh H, **Lieberman JA**, Siminovitch K, Liu ISC, Wayne J, Voruganti P, Hudson C, Serjeant GR, Masibay AS, Seeman MV: Dopamine D4 receptor variant, D4<sup>GLYCINE194</sup>, in Africans but not in Caucasians: No association with schizophrenia. *American Journal of Medical Genetics (Neuropsychiatric Genetics)* 1994; 54:384-390.
- Szymanski S, Masiar S, Mayerhoff D, Loebel A, Geisler S, Gonzalez S, Pollack S, Kane J, and **Lieberman J**: Clozapine response in treatment-refractory first episode schizophrenia. *Biological Psychiatry* 1994; 35(4):278-280.
- Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, **Lieberman J**, Angrist B, Papas N, Mac Gregor R, Burr G, Cooper T, Wolf AP: Imaging endogenous dopamine competition with (<sup>11</sup>C) raclopride in the human brain. *Synapse* 1994; 16:255-262.
- Wang GJ, Volkow ND, Fowler JS, Ferrieri R, Schlyer D, Alexoff D, Pappas N, **Lieberman J**, King P, Warner D, Wong C, Hitzemann R, Wolf AP: Methylphenidate decreases regional cerebral blood flow in normal human subjects. *Life Sciences* 1994; 54:143-146.

- Alvir JMJ, **Lieberman JA**, Safferman AZ, Schwimmer JL, Schaaf JA: Clozapine induced agranulocytosis: Incidence and risk factors in the United States. *New England Journal of Medicine* 1993; 329:162-167
- Bogerts B, **Lieberman JA**, Ashtari M, Bilder R, Degreef G, Lerner G, Johns C, Masiar S: Hippocampus-amygdala volumes and psychopathology in chronic schizophrenia. *Biological Psychiatry* 1993; 33(4):236-246.
- Fleischhacker WW, Levine RA, **Lieberman JA**, Pollack S, Johns CA, Richardson MA: Neopterin and biopterin CSF levels in tardive dyskinesia after clozapine treatment. *Biological Psychiatry* 1993; 34:741-745.
- Fleischhacker WW, Miller CH, Barnas C, Bergmann K, Perovich R, Alvir JMJ, **Lieberman JA**, Kane JM: The effect of activation procedures on neuroleptic-induced akathisia. *British Journal of Psychiatry* 1993; 163:781-784.
- Kane JM, Woerner M, Pollack S, Safferman A, **Lieberman J**: Does clozapine cause tardive dyskinesia? *Journal of Clinical Psychiatry* 1993; 54:327-330.
- Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, **Lieberman J**: Depression in first episode schizophrenia. *American Journal of Psychiatry* 1993; 150:1643-1648.
- Levy DL, Valentino C, Smith M, Robinson D, Jody D, Lerner G, Alvir J, Geisler SH, Szymanski SR, Gonzalez A, Mayerhoff DI, Woerner MG, **Lieberman JA**, Mendell NR: Methylphenidate increases thought disorder in recent onset schizophrenics but not in normal controls. *Biological Psychiatry* 1993; 34(8):507-514.
- Lieberman J**, Jody D, Geisler S, Alvir J, Loebel A, Szymanski S, Woerner M, Borenstein M: Time course and biological correlates of treatment response in first episode schizophrenia. *Archives of General Psychiatry* 1993; 50:369-376.
- Lieberman JA**, Jody D, Alvir JMJ, Ashtari M, Levy D, Bogerts B, Degreef G, Mayerhoff D, Cooper T: Brain morphology, dopamine and eye tracking abnormalities in first episode schizophrenia: Prevalence and clinical correlates. *Archives of General Psychiatry* 1993; 50:357-368.
- Lieberman JA**, Koreen A: Neurochemistry and neuroendocrinology of schizophrenia. A selective review. *Schizophrenia Bulletin* 1993; 19(2):371-429.
- Lieberman JA**, Sobel S: Predictors of treatment response and course of schizophrenia. *Current Opinion in Psychiatry* 1993; 6:63-69.
- Lieberman JA**: Prediction of outcome in first-episode schizophrenia. *Journal of Clinical Psychiatry* 1993; 54(3)[suppl]:13-17.
- Lieberman JA**: Understanding the mechanism of atypical antipsychotic drugs: Review of compounds in use and development. *British Journal of Psychiatry* 1993; 163(suppl 22):7-18.
- Pollack S, **Lieberman J**, Kleiner D, Szymanski S, Kane J, Borenstein M, Cooper T: High plasma clozapine levels in tardive dyskinesia. *Psychopharmacology Bulletin* 1993; 29:257-262.
- Selzer JA, **Lieberman JA**: Schizophrenia and substance abuse. [Review] [56 refs]. *Psychiatric Clinics of North America* 1993; 16: 401-412.
- Szymanski S, **Lieberman J**, Pollack S, Munne R, Safferman A, Kane J, Kronig M, Cooper T: The dopamine-serotonin relationship in clozapine response. *Psychopharmacology* 1993; 112:S85-S89.
- Szymanski S, Munne R, Gordon MF, **Lieberman J**: A selective review of recent advances in the management of tardive dyskinesia. *Psychiatric Annals* 1993; 23(4):209-215.
- Umbricht DSG, Saltz B, Pollack S, Woerner M, Kane J, **Lieberman JA**: Polydipsia and tardive dyskinesia in chronic psychiatric patients - related disorders? *American Journal of Psychiatry* 1993; 150:1536-1538.
- Woerner MG, Saltz BL, Kane JM, **Lieberman JA**, Alvir JMJ: Diabetes and development of tardive dyskinesia. *The American Journal of Psychiatry* 1993; 150:966-968.



- Bilder RM, **Lieberman JA**, Kim Y, Alvir JMa, Reiter G: Methylphenidate and neuroleptic effects on oral word production in schizophrenia. *Journal of Neuropsychiatry, Neuropsychology and Behavioral Neurology* 1992; 5(4):262-271.
- Bilder RM, Turkel E, Lipschutz-Broch L, **Lieberman JA**: Antipsychotic medication effects on neuropsychological functions. *Psychopharm Bulletin* 1992; 28:353-366.
- Bogerts B, **Lieberman JA**, Bilder RM, Ashtari M, Degreef G, Lerner G, Johns C, Masiar S: A volumetric MRI study of limbic structures in chronic schizophrenia – relationship to psychopathology. *Clinical Neuropharmacology* 1992; 15 Suppl 1 PtA:112A-113A.
- Chakos MH, Mayerhoff DI, Loebel AD, Alvir JM, **Lieberman JA**: Incidence and correlates of acute extrapyramidal symptoms in first episode schizophrenia. *Psychopharmacology Bulletin* 1992; 28(1):81-86.
- Degreef G, Ashtari M, Bogerts B, Bilder RM, Jody DN, Alvir J M J, **Lieberman JA**: Volumes of ventricular system subdivisions measured from magnetic resonance images in first-episode schizophrenic patients. *Archives of General Psychiatry* 1992; 49:531-537.
- Degreef G, Bogerts B, Falkai P, Greve B, Lantos G, Ashtari M, **Lieberman J**: Increased prevalence of the cavum septum pellucidum in MRI scans and post mortem brains of schizophrenic patients. *Psychiatry Research: Neuroimaging* 1992; 45:1-13.
- Degreef G, Lantos G, Bogerts B, Ashtari M, **Lieberman J**: Abnormalities of the septum pellucidum on MRI scans in first episode schizophrenic patients. *American Journal of Neuroradiology* 1992; 13:835-840.
- Kirch DG, **Lieberman JA**, Mathews SM: First-episode psychosis: Part 1. Editors' introduction. *Schizophrenia Bull* 1992; 18(2): 177-178.
- Levy DL, Bogerts B, Degreef G, Drogusker B, Waternaux C, Ashtari M, Jody D, Geisler S, **Lieberman JA**: Normal eye tracking is associated with abnormal morphology of medial temporal lobe structures in schizophrenia. *Schizophrenia Research* 1992; 8:1-10.
- Lieberman J**, Bogerts B, Degreef G, Ashtari M, Alvir J: Qualitative assessment of brain morphology in acute and chronic schizophrenia. *American Journal of Psychiatry* 1992; 149(6):784-794.
- Lieberman JA**, Alvir JMJ, Woerner M, Degreef G, Bilder R, Ashtari M, Bogerts B, Mayerhoff DI, Loebel A, Levy D, Hinrichsen G, Szymanski S, Chakos M, Borenstein M, Kane JM: Prospective study of psychobiology in first episode schizophrenia at Hillside Hospital: Design, methodology and summary of findings. *Schizophrenia Bulletin* 1992; 18(3):351-371.
- Lieberman JA**, Alvir JMJ: A report of clozapine-induced agranulocytosis in the United States - Incidence and risk factors. *Drug Safety* 1992; 7[suppl.1]:1-2.
- Lieberman JA**, Mayerhoff DI: The psychobiology and treatment outcome of first-episode schizophrenia. *Resident & Staff Physician* 1992; 38(4):65-73.
- Lieberman JA**, Safferman AZ: Clinical profile of clozapine: Adverse reactions and agranulocytosis. *Psychiatric Quarterly* 1992; 63(1):51-70.
- Loebel AD, **Lieberman JA**, Alvir JMJ, Mayerhoff DI, Geisler SH, Szymanski SR: Duration of psychosis and outcome in first episode schizophrenia. *American Journal of Psychiatry* 1992; 149:1183-1188.
- Pisciotta AV, Konings SA, Ciesemier LL, **Lieberman JA**: Cytotoxic activity in serum of patients with clozapine-induced agranulocytosis. *Journal of Laboratory and Clinical Medicine* 1992; 119(3):254-266.
- Pisciotta AV, Konings SA, Ciesemier LL, Cronkite CE, **Lieberman JA**: On the possible mechanisms and predictability of clozapine-induced agranulocytosis. *Drug Saf* 1992; 7 Suppl 1:33-44.
- Yunis JJ, **Lieberman J**, Yunis EJ: Major histocompatibility complex associations with clozapine-induced agranulocytosis. *Drug Safety* 1992; 7[Suppl.1]:7-9.

- Degreef G, Ashtari M, Wu H, Borenstein M, Geisler S, **Lieberman J**: Follow-up MRI study in first episode schizophrenia. *Schizophrenia Research* 1991; 5:204-206.
- Lemus CZ, **Lieberman JA**, Johns CA, Mayerhoff DI, Pollack S, Cooper TB, Novacenko H: Hormonal Response to Fenfluramine Challenges in Clozapine Treated Schizophrenic Patients. *Biological Psychiatry* 1991; 29:691-694.
- Lemus CZ, Robinson DG, Kronig M, Cole K, **Lieberman JA**: Behavioral Responses to a Dopaminergic Challenge in Obsessive Compulsive Disorder. *Journal of Anxiety Disorders* 1991; 5:369-373
- Lieberman JA**, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J: The Effects of Clozapine on Tardive Dyskinesia. *British Journal of Psychiatry* 1991; 158:503-510.
- Robinson D, Mayerhoff D, Alvir J, Cooper T, **Lieberman J**: Mood Responses of Remitted Schizophrenics to Methylphenidate Infusion. *Psychopharmacology* 1991; 105:247-252.
- Safferman A, **Lieberman J**, Kane J, Szymanski S, Kinon B: Update on the Clinical Efficacy and Side Effects of Clozapine. *Schizophrenia Bulletin* 1991; 17(2): 247-261.
- Saltz BL, Woerner MG, Kane JM, **Lieberman JA**, Alvir MJ, Bergmann KJ, Blank K, Koblenzer J, Kahaner K: Prospective Study of Tardive Dyskinesia Incidence in the Elderly. *Journal of the American Medical Association* 1991; 266(17):2402-2406.
- Szymanski S, Kane JM, **Lieberman JA**: A Selective Review of Biological Markers in Schizophrenia. *Schizophrenia Bulletin* 1991; 17(1):99-111.
- Szymanski S, Lieberman J, Picou D, Masiar S, Cooper T: A case report of cimetidine-induced clozapine toxicity. *Journal of Clinical Psychiatry* 1991; 52:21-22.
- Szymanski S, Zito J, Ashtari M, **Lieberman J**: Gadolinium - DTPA Enhanced Gradient Echo Magnetic Resonance Scans in First Episode and Chronic Schizophrenic Patients. *Psychiatry Research* 1991; 40:203-207.
- Woerner MG, Kane JM, **Lieberman JA**, Alvir J, Bergmann K, Borenstein M, Schooler N, Mukherjee S, Rotrosen J, Rubenstein M, Basavaraju N: The Prevalence of Tardive Dyskinesia. *Journal of Clinical Psychopharmacology* 1991; 11:34-53.

## 1990

- Alvir JM, **Lieberman JA**, Borenstein MT: A single estimate of separate within individual correlations: Applications in psychopharmacology. *Psychopharmacology Bulletin* 1990; 26:203-206.
- Ashtari M, Zito JL, Gold B, **Lieberman JA**, Borenstein M, Herman PG: Computerized Volume Mensuration of Brain Structure. *Journal of Investigative Radiology* 1990; 27(7):798-805.
- Bogerts B, Ashtari M, Degreef G, Alvir JM, Bilder RM, **Lieberman JA**: Reduced Temporal Limbic Structure Volumes on Magnetic Resonance Images in First Episode Schizophrenia. *Psychiatry Research* 1990; 35:1-13.
- Halbreich U, Lemus CZ, **Lieberman JA**, Parry B, Schiavi RC: Gonadal Hormones, Sex and Behavior. *Psychopharmacology Bulletin* 1990; 26:297-301.
- Jody D, **Lieberman JA**, Geisler S, Szymanski S, Alvir MJ: Behavioral response to methylphenidate and treatment outcome in first episode schizophrenia. *Psychopharmacol Bulletin* 1990; 26:224-230.
- Lemus CZ, **Lieberman JA**, Johns CA, Pollack S, Bookstein P, Cooper TB: CSF 5-Hydroxyindoleacetic Acid Levels and Suicide Attempts in Schizophrenia. *Biological Psychiatry* 1990; 27:926-929.
- Lieberman J**, Kane J, Woerner M, Alvir J, Borenstein M, Novacenko H: Prediction of Relapse in Schizophrenia. *Clinical Neuropharmacology* 1990; 13:434-435.
- Lieberman JA**, Kinon BJ, Loebel AD: Dopaminergic Mechanisms of Idiopathic and Drug Induced Psychosis. *Schizophrenia Bulletin* 1990; 16(1):97-110.
- Lieberman JA**, Yunis J, Egea E, Kane JM, Yunis EJ: HLA-B38, DR4, DQW3 and Clozapine Induced Agranulocytosis in Jewish Patients with Schizophrenia. *Archives of General Psychiatry* 1990; 47:945-948.
- Lieberman JA**: Neuroleptic-induced Movement Disorders and Experience with Clozapine in Tardive Dyskinesia. *Journal of Clinical Psychiatry* 1990; 8(1):3-8.

Mayerhoff DI, **Lieberman JA**, Lemus CZ, Pollack S, Schneider BS: Growth Hormone Response to Growth Hormone Releasing Hormone in Schizophrenic Patients. *American Journal of Psychiatry* 1990; 147:1072-1074.

## 1989

- Fleischhacker WW, Bergmann KJ, Perovich R, Pestreich LK, Borenstein M, **Lieberman JA**, Kane JM: The Hillside Akathisia Scale: A New Rating Instrument for Neuroleptic-Induced Akathisia. *Psychopharmacology Bulletin* 1989; 25(2):222-226.
- Glick ID, Jacobs M, **Lieberman J**, Simpson G, Schooler NR: Prediction of Short Term Outcome in Schizophrenia: Depressive Symptoms, Negative Symptoms and Extrapyramidal Signs. *Psychopharmacology Bulletin* 1989; 25(3):344-347.
- Hinrichsen GA, **Lieberman JA**, Pollack S, Steinberg H: Depression in Hemodialysis Patients. *Psychosomatics* 1989; 30(3):284-289.
- Kendler KS, **Lieberman JA**, Walsh D: The Structured Interview for Schizotypy (SIS): A Preliminary Report. *Schizophrenia Bulletin* 1989; 15(4):559-571.
- Lemus CZ, **Lieberman JA**, Johns CA: Myoclonus during treatment with clozapine and lithium: the role of serotonin. *Hillside Journal of clinical Psychiatry* 1989; 11(2):127-130.
- Lieberman J**, Jody D, Geisler S, Vital-Herne J, Alvir J, Walsleben J, Woerner M: Treatment Outcome of First Episode Schizophrenia. *Psychopharmacology Bulletin* 1989; 25:92-96.
- Lieberman J**, Johns C, Cooper T, Pollack S, Kane J: Clozapine Pharmacology and Tardive Dyskinesia. *Psychopharmacology* 1989; 99(S):54-59.
- Lieberman J**, Kane J, Johns C: Clozapine: Guidelines for Clinical Management. *Journal of Clinical Psychiatry* 1989; 50:329-338.
- Lieberman J**: Dopamine Pathophysiology in Tardive Dyskinesia. *Psychiatric Annals* 1989; 19(6):289-296.
- Lieberman JA**, Alvir J, Mukherjee S, Kane JM: Treatment of Tardive Dyskinesia with Bromocriptine: A Test of the Receptor Modification Strategy. *Archives of General Psychiatry* 1989; 46:908-913.
- Lieberman JA**, Riefe R: Spastic Dysphonia and Denervation Signs in a Young Man with Tardive Dyskinesia. *British Journal of Psychiatry* 1989; 154:105-109.
- Lieberman JA**, Saltz BL, Johns CA, Pollack S, Kane J: Clozapine Effects on Tardive Dyskinesia. *Psychopharmacology Bulletin* 1989; 25(1):57-62.
- Perovich R, **Lieberman JA**, Fleischhacker WW, Alvir J: The Behavioral Toxicity of Bromocriptine in Patients with Psychiatric Illness. *Journal of Clinical Psychopharmacology* 1989; 9(6):417-422.
- Saltz BL, Kane JM, Woerner M, **Lieberman JA**, Alvir J, Blank K, Kahaner K, Foley C: Prospective Study of Tardive Dyskinesia in the Elderly. *Psychopharmacology Bulletin* 1989; 25(1):52-56.

## 1988

- Andreasen NC, Shore D, Burke JD Jr., Grove WM, **Lieberman JA**, Oltmanns TF, Pettegrew JW, Pulver AE, Siever LJ, Tsuang MT, et al: Clinical phenomenology. *Schizophrenia Bull* 1988; 14(3):345-363.
- Kane JM, Woerner M, **Lieberman J**: Epidemiological Aspects of Tardive Dyskinesia. *L'Encephale* 1988; 14 Spec No:191-194.
- Kane JM, Woerner M, **Lieberman J**: Tardive Dyskinesia: Prevalence, Incidence and Risk Factors. *Journal of Clinical Psychopharmacology* 1988; 8(4):52S-56S.
- Lieberman JA**, Johns C, Kane J, Rai K, Pisciotto AV, Howard A: Clozapine Induced Agranulocytosis: Non-Cross Reactivity With Other Psychotropic Drugs. *Journal of Clinical Psychiatry* 1988; 49(7):271-277.
- Lieberman JA**, Lesser M, Johns C, Pollack S, Saltz B, Kane JM: Pharmacologic Studies of Tardive Dyskinesia. *Journal of Clinical Psychopharmacology* 1988; 8(4):57S-63S.

**Lieberman JA, Pollack S, Lesser MS, Kane JM:** Pharmacologic Characterization of Tardive Dyskinesia. *Journal of Clinical Psychopharmacology* 1988; 8(4):254-260.

## 1987

**Lieberman JA, Kane JM, Sarantakos S, Galadeta D, Woerner M, Alvir J, Ramos-Lorenzi J:** Prediction of Relapse in Schizophrenia. *Archives of General Psychiatry* 1987; 44:597-603.

**Lieberman JA, Kane JM, Alvir J:** Provocative Tests with Psychostimulant Drugs in Schizophrenia. *Psychopharmacology* 1987; 91:415-433.

## 1986

**Kane JM, Woerner M, Borenstein M, Wegner J, Lieberman J:** Integrating Incidence and Prevalence of Tardive Dyskinesia. *Psychopharmacology Bulletin* 1986; 22:254-258.

**Kane JM, Woerner M, Lieberman J, Kinon B:** Tardive dyskinesias and drugs. *Drug Development Research* 1986; 9:41-51.

**Lieberman JA, Kane JM, Reife R:** Neuromuscular effects of monoamine oxidase inhibitors. *Advances in Neurology* 1986; 43:231-249.

**Lieberman JA, Kane J, Johns C, Vital-Herne V:** Clozapine: Clinical Evidence of Novel Effects. *Clinical Neuropharmacology* 1986; 9:140-141.

**Lieberman JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R, Kane JM:** Tricyclic Antidepressant Drug and Metabolite Levels in Chronic Renal Failure. *Annals of the New York Academy of Sciences* 1986; 463:304-306.

**Lieberman JA, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J:** Prediction of Relapse in Schizophrenia. *Psychopharmacology Bulletin* 1986; 22(3):845-853.

## 1985

**Kane JM, Woerner M, Lieberman JA:** Tardive dyskinesia: prevalence, incidence, and risk factors. *Psychopharmacology* 1985 Suppl; 2: 72-78.

**Kane J, Woerner M, Lieberman J, Weinhold P, Florio W, Rubenstein M, Rotrosen J, Kurucz J, Mukherjee S, Bergmann K, Schooler N:** The Prevalence of Tardive Dyskinesia. *Psychopharmacology Bulletin* 1985; 21:136-139.

**Lieberman J, Kane J, Gadaleta D, Ramos-Lorenzi J, Bergmann K, Wegner J, Novacenko H:** Methylphenidate Challenge Tests and Course of Schizophrenia. *Psychopharmacology Bulletin* 1985; 21:123-129.

**Lieberman J, Kane J, Reife R:** Neuromuscular effects of monoamine oxidase inhibitors. *Journal of Clinical Psychopharmacology* 1985; 5:221-228.

**Lieberman J, Kane J, Sarantakos S, Cole K, Howard A, Borenstein M, Novacenko H, Puig-Antich J:** Dexamethasone Suppression Tests in Patients With Obsessive-Compulsive Disorder. *American Journal of Psychiatry* 1985; 142:747-751.

**Lieberman JA, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R, Kane JM:** Tricyclic Antidepressant Drug and Metabolite Levels in Chronic Renal Failure. *Clinical Pharmacology and Therapeutics* 1985; 37:301-307.

**Wegner JT, Kane JM, Weinhold P, Woerner M, Kinon B, Lieberman J:** Cognitive Impairment in Tardive Dyskinesia. *Psychiatry Research* 1985; 16:331-333.

## 1984

- Kane J, **Lieberman J**: The Efficacy of Amoxapine, Maprotiline and Trazodone in Comparison to Imipramine and Amitriptyline: A Review of the Literature. *Psychopharmacology Bulletin* 1984; 20:240-249.
- Kane J, Woerner M, **Lieberman J**, Rabiner C: Studies on the Long-Term Treatment of Schizophrenia. *The Psychiatric Hospital* 1984; 15:179-183.
- Lieberman J**, Kane J, Gadaletta D, Brenner R, Lesser M, Kinon B: The use of Methylphenidate Challenge Test as a Predictor of Relapse in Schizophrenia. *American Journal of Psychiatry* 1984; 141:633-638.
- Lieberman J**, Kane J, Woerner M, Weinhold P, Basavaraju N, Kurucz J, Bergmann K: Prevalence of Tardive Dyskinesia in Elderly Samples. *Psychopharmacology Bulletin* 1984; 20:382-386.
- Lieberman J**, Kane J, Woerner M, Weinhold P: Prevalence of tardive dyskinesia in the elderly patients. *Psychopharmacology Bulletin* 1984; 20:22-26.
- Lieberman J**, Reife R, Lesser M: Acute antidepressant effect of lithium in unipolar depression. *Psychosomatics* 1984; 25:932-933.
- Lieberman J**: Evidence for a Biological Hypothesis of Obsessive-Compulsive Disorder. *Neuropsychobiology* 1984; 11:14-21.
- Lieberman JA**, Bradley RJ, Rubinstein M, Kane JM: Antibodies to acetylcholine receptors in tardive dyskinesia. *The Lancet* 1984; 1(8385):1066.
- Lieberman J**, Bradley R, Rubinstein M, Kane J: Antibodies to Acetylcholine Receptors in Patients with Tardive Dyskinesia. *Annals of the New York Academy of Science* 1984; 435:444-447.

## 1983

- Kane J, Woerner M, Weinhold P, Kinon B, **Lieberman J**, Wegner J: The epidemiology of tardive dyskinesia. *Clinical Neuropharmacology* 1983; 6:109-116.
- Lieberman J**, Brenner R, Lesser M, Coccaro E, Borenstein M, Kane J: Dexamethasone suppression tests in patients with panic disorder. *American Journal of Psychiatry* 1983; 140(7):917-919.

## 1982

- Brenner R, Cooper T, Yablonski M, Lesser M, **Lieberman J**, Siris S, Rifkin A: Measurement of lithium concentration in human tears. *American Journal of Psychiatry* 1982; 139:763-764.
- Siris S, Cooper T, Rifkin A, Brenner R, **Lieberman J**: Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate. *American Journal of Psychiatry* 1982; 139:104-106.

## 1980

- Lieberman J**, O'Connell RA: Clinical utility of tricyclic blood levels. *New York State Journal of Medicine* 1980; 80(13):1967-1969.

## 1978

- O'Connell R, **Lieberman J**: Parenteral loxapine in acute schizophrenia. *Journal of Current Therapeutic Research* 1978; 23:236-242.

## **LETTERS TO THE EDITOR AND COMMENTARY:**

- Krystal JH, Carter CS, Geschwind D, et al: It is time to take a stand for medical research and against terrorism targeting medical scientists. *Biological Psychiatry* 2008; 63(8):725-727.
- Keefe RSE, Sweeney JA, Gu H, Hammer RM, Perkins DO, McEvoy JP, **Lieberman JA**: Challenge to atypical antipsychotic drug effect on cognition. *American Journal of Psychiatry* 2007; 164:1911-1912.
- Stroup TS, Rosenheck RA, Essock SE, **Lieberman JA**: Pre-trial medication bias in randomized antipsychotic drug trials. *American Journal of Psychiatry*, 2007; 164:1266-1267.
- Rosenheck R, Swartz M, McEvoy J, Stroup TS, Davis S, Keefe R, Hsiao J, **Lieberman JA**: Perspectives on second generation antipsychotics: A review of the cost-effectiveness component of the Clinical Antipsychotic Trial of Intervention Effectiveness (CATIE) schizophrenia trial. *American Journal of Psychiatry*, 2007; 164:678-680 [Response to Law and Soumerai, et al.].
- Renou J, De Luca V, Zai CC, Bulgin N, Remington G, Meltzer HY, **Lieberman JA**, Le Foll B, Kennedy JL: Multiple variants of the DRD3, but not BDNF gene, influence age-at-onset of schizophrenia. *Molecular Psychiatry*, 2007; 12(12):1058-1060.
- Jarskog LF, **Lieberman JA**: Neuroprotection in Schizophrenia. *J Clin Psychiatry* 2006; 67(9):e09.
- Rosenheck RA, Swartz MS, **Lieberman JA**: Introduction to the Special Section on CATIE Baseline Data: Practical Clinical Trials in Psychiatry: Studies of Schizophrenia from the CATIE Network. *Psychiatr Serv* 2006; 57(8):1093.
- Lieberman, JA**: Comparative Effectiveness of Antipsychotic Drugs: A commentary on the cost utility of the latest antipsychotic drugs in schizophrenia study (CUTLASS 1) and clinical antipsychotic trials of intervention effectiveness (CATIE). *Archives of General Psychiatry* 2006; 63; 1069-1072.
- Lieberman JA**, Hsiao JK: Interpreting the results of the CATIE study. *Psychiatr Serv* 2006; 57(1):139.
- Lieberman JA**: What the CATIE Study Means for Clinical Practice. *Psychiatr Serv* 2006; 57(8):1075.
- Lieberman JA**: Recent advances in the clinical use of atypical antipsychotics. *CNS Spectrums* 2005; 10(8 Suppl 8):4.
- McClure RK, **Lieberman JA**: Neurodevelopmental and Neurodegenerative Hypotheses of Schizophrenia: A Review and Critique. *Current Opinion in Psychiatry* 2003; 16 [Suppl 2]:S15-28.
- Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, **Lieberman JA**, López-Ibor JJ, van Raay B, Tornquist E, Twomey E: The Usefulness and Use of Second-Generation Antipsychotic Medications – an Update. *Current Opinion in Psychiatry* 2003; [Suppl 1]16.
- Volavka J, Czobor P, Cooper TB, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy JP, **Lieberman JA**: Dr. Volavka and Colleagues Reply. *American Journal of Psychiatry* 2003; 160(3); 592-593.
- Spivak B, Alamy SS, Jarskog LF, Sheitman BB, **Lieberman JA**: Ziprasidone alternative for olanzapine-induced hyperglycemia. *American Journal of Psychiatry* 2002; 159(9):1.
- Sartorius N, Fleischhacker WW, Gjerris A, Kern U, Knapp M, Leonard BE, **Lieberman JA**, López-Ibor JJ, van Raay B, Twomey E: The Usefulness and Use of Second-Generation Antipsychotic Medications. *Current Opinion in Psychiatry* 2002; [Suppl 1]15 March.
- Lieberman Jeffrey A**: Our duty to Dix. *The Raleigh News & Observer*, April 1, 2001.
- Lieberman Jeffrey A**: Serious medicine can deter rampages. *The Raleigh News & Observer*, August 9, 1998.
- Lieberman Jeffrey A**: Society ignorant of mental illness. *The New York Times*, August 3, 1998.
- Lieberman Jeffrey A**: Health care debate touches a nerve. *The Chapel Hill News*, July 26, 1998.
- Lieberman Jeffrey A**: New requirements for pediatric drugs: Good idea, half baked policy. *Wall Street Journal*, August 18, 1997.
- Lieberman Jeffrey A**: A Misconception of Schizophrenia. *The Chapel Hill News*, December 3, 1997.
- Lieberman JA**: Managed care slows medical research. *New York Times*, July 20, 1997.
- Lieberman JA**: Helfgott: Flawed, but Triumphant. *Wall Street Journal*, April 14, 1997.
- Masellis M, Paterson Ad, Badri F, **Lieberman JA**, Meltzer HY, Cavazzoni P, Kennedy JL: Genetic variation of 5HT<sub>2A</sub> receptor and response to clozapine. *The Lancet* 1995; 346:1108.

- Chakos MH, **Lieberman JA**, Alvir J, Bilder R, Ashtari M: Caudate nuclei volumes in schizophrenic patients treated with typical antipsychotics or clozapine. *The Lancet* 1995; 345:456.
- Alvir JMJ, **Lieberman JA**: A reevaluation of the clinical characteristics of clozapine induced agranulocytosis in light of the U.S. experience. *Journal of Clinical Psychopharmacology* 1994; 14:87-89.
- Aronowitz JS, Chakos MH, Safferman AZ, **Lieberman JA**: Syncope associated with the combination of clozapine and enalapril. *Journal of Clinical Psychopharmacology* 1994; 14(6):439-430.
- Safferman AZ, **Lieberman JA**, Zeman D, Symanski S, Pisciotto AV, Rai K: Response to "Unrelated agranulocytosis in a patient taking clozapine." *Journal of Clinical Psychopharmacology* 1994; 14(3):211-212.
- Waddington JL, **Lieberman JA**: New insights into clinical issues in schizophrenia. *Journal of Psychopharmacology* 1994; 8:65-66.
- Safferman AZ, **Lieberman JA**, Pollack S, Kane JM: Akathisia and clozapine treatment. *Journal of Clinical Psychopharmacology* 1993; 13(4):286-287.
- Safferman AZ, **Lieberman JA**, Zeman D, Szymanski S, Pisciotto AV, Rai K: Unrelated agranulocytosis in a patient taking clozapine. *Journal of Clinical Psychopharmacology*, 1993; 13(3):218-219.
- Safferman AZ, **Lieberman JA**, Pollack S, Kane JM: Clozapine and akathisia. *Biological Psychiatry* 1992; 31:753-754.
- Safferman AZ, **Lieberman JA**, Alvir JMJ, Howard A: Rechallenge in patients with histories of clozapine induced agranulocytosis. *The Lancet* 1992; 339(5) 1296-1297.
- Bilder RM, Lipschutz-Broch L, Reiter G, Geisler S, Mayerhoff D, **Lieberman JA**: Neuropsychological deficits in the early course of first episode schizophrenia. *Schizophrenia Res* 1991; 5(3):198-199.
- Szymanski S, Jody D, Leipzig R, Masias S, **Lieberman J**: Anticholinergic delirium caused by re-treatment with clozapine. *American Journal of Psychiatry* 1991; 148(12):1752.
- Gerson SL, **Lieberman JA**, Friedenberg WR, Lee D, Marx, Jr. JJ, Meltzer H: Polypharmacy in fatal clozapine-associated agranulocytosis. *The Lancet* 1991; 338:262.
- Kane JM, **Lieberman JA**: Clozapine for Schizophrenia. *Medical Letter* 1990; 32(809):3-4.
- Lieberman JA**, Bowers MB, Jr.: Substance abuse comorbidity om schizophrenia: editors' introduction. *Schizophrenia Bull* 1990; 16(1):29-30.
- Lieberman J**, Kane JM, Sarantakos S, Gadaleta D, Woerner M, Alvir J, Ramos-Lorenzi J: Ethics of drug discontinuation studies in schizophrenia. *Archives of General Psychiatry* 1989; 46:387.
- Robinson D, Bailine S, **Lieberman J**: Dysphoria associated with methylphenidate infusion. *American Journal of Psychiatry* 1988; 145:1321-1322.
- Lieberman J**, Bradley R, Rubenstein M, Kane J: Antibodies to acetylcholine receptors in patients with tardive dyskinesia. *The Lancet* 1984; 1:1066.
- Lieberman J**, Lesser M, Brenner R: Is bromocriptine a dopamine antagonist treatment? *Archives of General Psychiatry* 1983; 40:469-470.
- Lieberman J**, Kane J: Questioning DST normalization as a guide to tricyclic discontinuation. *American Journal of Psychiatry* 1983; 140:263-264.
- Lieberman J**: Cholinergic rebound in neuroleptic withdrawal syndromes. *Journal of Clinical Psychiatry* 1981; 42(4):179.

## **BOOKS:**

### ***Pre-publication: In Preparation, Submitted, and In Press***

- Lieberman JA** (with Ogi Ogas): Shrinks the Untold Story of Psychiatry, Little, Brown and Company, New York, NY, *In Press*.
- Tasman A, Kay J, **Lieberman JA**, First MB, Maj M (eds.): Psychiatry, V2, 4<sup>th</sup> Edition, John Wiley & Sons, Ltd., West Sussex, UK, *In Prep*.
- Lieberman JA** (Executive Series Editor): American Psychiatry Library, Oxford University Press, New York, NY, USA, *In Press*.

### *Published*

- Lieberman JA**, Stroup TS, Perkins, DO (eds.): Fundamento Da Esquizofrenia. ABP Associação Brasileira de Psiquiatria (2012), Artmed, São Paulo, SP, Brazil, 2013.
- Lieberman JA**, Murray R (eds.): Comprehensive Care of Schizophrenia: A Textbook of Treatment, 2<sup>nd</sup> Edition, Oxford University Press, New York, NY, USA, 2012.
- Lieberman JA**, Stroup TS, Perkins, DO (eds.): Essentials of Schizophrenia, American Psychiatric Publishing, Inc., Washington, DC, USA, 2012.
- Stroup TS, **Lieberman JA** (eds.): Antipsychotic Trials of Schizophrenia: The CATIE Project, Cambridge University Press, Cambridge UK, 2010.
- Tasman A, Kay J, **Lieberman JA** First MB, Maj M (eds.): Psychiatry, V2, 3<sup>rd</sup> Edition, John Wiley & Sons, Ltd., West Sussex, UK, 2008.
- Lieberman JA**, Tasman A: Handbook of Psychiatric Drugs, John Wiley & Sons, Ltd., West Sussex, UK, 2006.
- Lieberman JA**, Stroup TS, Perkins DO (eds.): Textbook of Schizophrenia, American Psychiatric Publishing, Inc., Washington, DC, USA, 2006.
- Tasman A, Kay J, **Lieberman JA** (eds.): Psychiatry, V2, 2<sup>nd</sup> Edition, John Wiley & Sons, Ltd., West Sussex, UK, 2003.
- Lieberman JA**, Murray R (eds.): Comprehensive Care of Schizophrenia: A Textbook of Treatment, 1<sup>st</sup> Edition, Martin Dunitz and Co., London, UK, 2001.
- Lieberman JA**, Tasman A (eds.): Psychiatric Drugs, W.B. Saunders and Co., Philadelphia, PA, USA, 1999.
- Lieberman JA** (ed.): Re-integration of the Schizophrenic Patient, Science Press Limited, London, UK, 1998.
- Pincus HA, **Lieberman JA**, Ferris S (eds.): Ethical Issues in Psychiatric Research: A Resource Manual on Human Subjects Protection, American Psychiatric Press, Inc., Washington, DC, USA, 1998.
- Tasman A, Kay J, **Lieberman JA** (eds.): Psychiatry, 1<sup>st</sup> Edition, W. B. Saunders and Co., Philadelphia, PA USA. 1996.
- Kane JM, **Lieberman JA** (eds.): Adverse Effects of Psychotropic Drugs, Guilford Press, New York, NY, USA, 1992.
- Lieberman JA**, Kane JM (eds.): Predictors of Relapse in Schizophrenia, American Psychiatric Press, Inc., Washington, DC, USA, 1986.

### **BOOK CHAPTERS:**

#### *Pre-publication: In Preparation, Submitted, and In Press*

- Stroup TS, Lawrence RE, Abbas AI, Miller BR, Perkins DO, **Lieberman, JA**: Schizophrenia Spectrum and Other Psychotic Disorders. In: Hales RE, Yudofsky SC, Roberts L (eds.): Textbook of Psychiatry, 6<sup>th</sup> Edition, American Psychiatric publishing, Inc., Washington, DC, USA, *In Press*.
- Lieberman JA**, Schobel SA, Girgis RR: Biological Treatments of Psychosis. In: Murray R, Hill P, McGuffin P (eds.), The Essentials of Postgraduate Psychiatry, 4<sup>th</sup> Edition, Cambridge University Press, Cambridge, UK, *In Press*.
- Sharif Z, Miyamoto S, **Lieberman JA**: Pharmacotherapy of Schizophrenia. In: Sibley DR (ed.), Handbook of Contemporary Neuropsychiatry, *In Press*.
- Miyamoto S, Merrill DB, Jarskog, LF, **Lieberman JA**, Fleischhacker WW, Marder SR: Antipsychotic Drugs. In: Tasman A, Kay J, **Lieberman JA**, First MB, Maj M (eds.), Psychiatry, V2, 4<sup>th</sup> Edition, John Wiley & Sons, Ltd., West Sussex, UK, *In Prep*.
- Abbas A, **Lieberman JA**: Pharmacological Treatments for Schizophrenia. In: Nathan PE, Gorman JM (eds.), A Guide to Treatments that Work, 4<sup>th</sup> Edition, Oxford University Press, New York, *In Prep*.



*Published*

- Sharif Z, Cole YI, **Lieberman JA**: Aripiprazole. In: Schatzberg AF, Nemeroff CB (eds.): Essentials of Clinical Psychopharmacology, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 291-303.
- Ballon JS, **Lieberman JA**: Treatment Resistant Schizophrenia. In: Nemeroff CB (ed.), Management of Treatment-Resistant Major Psychiatric Disorders, Oxford University Press, New York, NY, USA, Pp. 225-244, 2012
- Miyamoto S, Fleischhacker W-W, **Lieberman JA**: Pharmacologic Treatment of Schizophrenia. **Lieberman JA**, Murray R (eds.): Comprehensive Care of Schizophrenia: A Textbook of Treatment, 2<sup>nd</sup> Edition, Oxford University Press, New York, NY, USA, Pp. 77-138, 2012.
- Perkins DO, **Lieberman JA**: Epidemiology and Natural History. In: **Lieberman JA**, Stroup TS, Perkins, DO (eds.): Essentials of Schizophrenia, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 1-10, 2012.
- Perkins DO, **Lieberman JA**: Prodrome and First Episode. **Lieberman JA**, Stroup TS, Perkins, DO (eds.): Essentials of Schizophrenia, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 57-72, 2012.
- Stroup TS, Marder SR, **Lieberman JA**: Pharmacotherapies. In: **Lieberman JA**, Stroup TS, Perkins, DO (eds.): Essentials of Schizophrenia, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 173-206, 2012.
- Geddes J, **Lieberman JA**: Evidence Based Treatment. In: Weinberger D, Harrison P (eds.), Schizophrenia, 3<sup>rd</sup> Edition, Blackwell Publishing (Wiley-Blackwell), Oxford, UK, Pp. 525-539, 2011.
- Ballon JS, Girgis RR, **Lieberman JA**: Personalized Medicine for Schizophrenia. In: Koslow SH, Gordon E (eds.): Integrative Neuroscience and Personalized Medicine, Oxford University Press, New York, NY, USA, Pp. 93-116, 2011.
- Stroup TS, McEvoy JP, **Lieberman JA**: Study Design and Protocol Development Process. In: Stroup TS, **Lieberman JA**, (eds.): Antipsychotic Trials of Schizophrenia: The CATIE Project, Cambridge University Press, Cambridge, UK, Pp. 1-21, 2010.
- McEvoy JP, Stroup TS, **Lieberman JA**: Effectiveness and Efficacy: Staying on Treatment and Symptom Reduction. In: Stroup TS, **Lieberman JA** (eds.): Antipsychotic Trials of Schizophrenia: The CATIE Project, Cambridge University Press, Cambridge, UK, Pp. 39-56, 2010.
- Stroup TS, **Lieberman JA**: Implications for Research Design and Study Implementation. In: Stroup TS, **Lieberman JA**, (eds.): Antipsychotic Trials of Schizophrenia: The CATIE Project, Cambridge University Press, Cambridge, UK, Pp. 281-287, 2010.
- Rosenheck RA, Stroup TS, **Lieberman JA**: Conclusion and Implications for Practice and Policy. In: Stroup TS, **Lieberman JA**, (eds.): Antipsychotic Trials of Schizophrenia: The CATIE Project, Cambridge University Press, Cambridge, UK, Pp. 288-306, 2010.
- Lieberman JA**: (Section Editor) Psychosis. In: Charney DS, Nestler EJ (eds.), Neurobiology of Mental Illness, 3<sup>rd</sup> Edition, Oxford University Press, New York, NY, USA, Pp. 240. 2009.
- Sharif Z, **Lieberman JA**: Aripiprazole. In: Schatzberg AF, Nemeroff CB (eds.), Textbook of Psychopharmacology, 4<sup>th</sup> Edition, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 613-626, 2009.
- Miyamoto S, Merrill DB, **Lieberman JA**, Fleischhacker WW, Marder SR: Antipsychotic Drugs. In: Tasman A, Kay J, **Lieberman JA**, First MB, Maj M (eds.), Psychiatry, V2, 3<sup>rd</sup> Edition, John Wiley & Sons, Ltd., West Sussex, UK, Pp. 2161-2193, 2008.
- Perkins DO, **Lieberman JA**, Lewis S: First Episode. In: **Lieberman JA**, Stroup TS, Perkins DO (eds.), Textbook of Schizophrenia, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 353-364, 2006.

- Marx CE, Grobin AC, Deutch AY, **Lieberman JA**: Atypical antipsychotic drugs and stress. In: Steckler et al. (eds.), Handbook of Stress and the Brain, Vol.15., Elsevier Science B.V., Pp. 1119-1131, 2005.
- Graham K, **Lieberman JA**: Late Bloomer. In: Spitzer RL, First MB, Gibbon M, Williams JBW (eds.), Treatment Companion to the DSM-IV-TR® Casebook, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 238-246, 2004.
- Miyamoto S, **Lieberman JA**, Fleischhacker WW, Aoba A, Marder SR: Antipsychotics Drugs. In: Tasman A, Kay J, **Lieberman JA** (eds.), Psychiatry V2, 2<sup>nd</sup> Edition, John Wiley & Sons, Ltd., London, UK, Pp.1928-1964, 2003.
- Lieberman JA**: Aripiprazole. In: Schatzberg A, Nemeroff CB (eds.), Textbook of Psychopharmacology, 3<sup>rd</sup> Edition, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 487-494, 2003.
- Lieberman JA**: Quetiapine. In: Schatzberg A, Nemeroff CB (eds.), Textbook of Psychopharmacology, 3<sup>rd</sup> Edition, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 473-486, 2003.
- Miyamoto S, Aoba A, Duncan GE, **Lieberman JA**: Acute Pharmacological Treatment of Schizophrenia. In: Schizophrenia, 2<sup>nd</sup> Edition, Blackwell Publishing, Oxford, UK, 2002.
- Miyamoto S, Duncan GE, Goff DC, **Lieberman JA**: Therapeutics of Schizophrenia, In: Neuropsychopharmacology The Fifth Generation of Progress. Lippincott Williams & Wilkins, Philadelphia, PA, USA, Pp. 775-807, 2002.
- Bradford D, Stroup S, **Lieberman JA**: Pharmacological Treatments for Schizophrenia. In: Nathan PE, Gorman JM (eds.), A Guide to Treatments that Work, 2<sup>nd</sup> Edition, Oxford University Press, New York, NY, Pp. 169-199, 2002.
- Zipursky RB, Schulz SC, **Lieberman JA**: Investigating the Early Stages of Schizophrenia: The Hillside Prospective Study of First-Episode Schizophrenia. In: The Early Stages of Schizophrenia, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp. 55-80, 2001.
- Miyamoto S, Duncan GE, **Lieberman JA**: Olanzapine. In: Breier A, Tran PV, Herrea JM, Tollefson GD, Bymaster FP (eds.), Current Issues in the Psychopharmacology of Schizophrenia. Lippincott Williams & Wilkins, Philadelphia, PA, USA, Pp. 235-249, 2001.
- Kraus J, Perkins DO, **Lieberman JA**: Pathophysiology of Schizophrenia: Neurodevelopmental and Neurodegenerative Processes. In: Early Intervention in Psychiatric Disorders. Kluwer Academic Publishers, Pp. 231-252, 2001.
- Siegfried SL, Fleischhacker W, **Lieberman JA**: Pharmacological Treatment of Schizophrenia. In: **Lieberman JA** and Murray R (eds.), Comprehensive Care of Schizophrenia: A Textbook of Treatment, Martin Dunitz and Co., London, UK, Pp. 59-94, 2001.
- Lieberman JA**, Duncan G: What makes Olanzapine an Atypical Antipsychotic? In: Tran, Bymaster, Tye, Herrera, Breier and Tollefson (eds.), Olanzapine (Zyprexa®): A Novel Antipsychotic, Lippincott Williams & Wilkins, Philadelphia, PA, USA, Pp. xxiii-xxvii, 2000.
- Miyamoto S, Duncan GE, Mailman RB, **Lieberman JA**: Developing Novel Antipsychotic Drugs: Strategies and Goals. In: Central and Peripheral Nervous System Investigational Drugs, PharmaPress Ltd., London, UK, Pp. 35-39, 2000.
- Perkins DO, Stroup TS, **Lieberman JA**: Assessment of Psychotic Disorders. In: Rush AJ, Pincus HA, First MB, et al., (eds.), American Psychiatric Association Handbook of Psychiatric Measures, American Psychiatric Association Press, Washington, DC, USA, Pp. 485-513, 2000.
- Chatterjee A, **Lieberman JA**: Studies of First Episode Schizophrenia: A Comprehensive Review. In: McGorry P, Jackson (eds.), The Recognition and Management of Early Psychosis, Cambridge University Press, Cambridge, UK, Pp. 115-154, 1999.
- Jaraskog LE, Perkins DO, **Lieberman JA**: The course and outcome of schizophrenia. In: **Lieberman JA** (ed.), Re-integration of the Schizophrenic Patient, Science Press Limited, London, UK, Pp. 1-10, 1998.
- Flaum M, Amador X, Gorman J, Bracha HS, Edel W, McGlashan T, Pandurangi A, Kendler K, Robinson D, **Lieberman JA**, Ontiveros A, Tohen M, McGorry P, Tyrrell G, Arndt S, Andreasen N: DSM-IV Field Trial for Schizophrenia and Other Psychotic Disorders. In: Widiger TA, Frances AJ, Pincus HA, Ross R, First MB, Davis W, Kline M (eds.), DSM-IV Sourcebook Volume 4, American Psychiatric Association Press, Washington, DC, USA, 1998.

- Sheitman BB, Kinon BJ, Ridgway BA, **Lieberman JA**: Pharmacological Treatments of Schizophrenia. In: Nathan PE, Gorman JM (eds.), A Guide to Treatments that Work, 1<sup>st</sup> Edition, Oxford University Press, New York, NY, USA, Pp 167-189, 1998.
- Koreen AR, Sheitman B, **Lieberman JA**: Biological predictors of antipsychotic treatment response. In: Csernansky (ed.), Handbook of experimental pharmacology, Antipsychotics. Springer-Verlag, New York, NY, USA, Pp. 389-444, 1996.
- Lieberman JA**: Treatment effects on the course of schizophrenia: potential benefits of atypical antipsychotics in first episode patients. In: Brunello N, et al. (eds.), Critical Issues in the Treatment of Schizophrenia. Vol.10, International Academy for Biomedical and Drug Research, Basel, Switzerland, Pp. 106-114, 1995.
- Safferman AZ, **Lieberman JA**, Kane JM, Szymanski S, Kinon BJ: Clozapine in treatment refractory schizophrenia: Clinical efficacy and side effects. In: Shiriqui, Nasrallah (eds) Contemporary Issues in the Treatment of Schizophrenia, American Psychiatric Press, Washington, DC, USA, Pp. 329-368, 1995.
- Lieberman JA**: Predictors of outcome in schizophrenia: The concept of time. In: Gaebel, Awad (eds.), Prediction of neuroleptic treatment outcome in schizophrenia - Concepts and methods, Springer-Verlag Wien, New York, NY, USA, Pp 43-49, 1994.
- Lieberman JA**, Brown AS, Gorman J: Schizophrenia. In: Oldham, Riba (eds.), Review of Psychiatry, Vol. 13, American Psychiatric Publishing, Inc., Washington, DC, USA, Pp 133-170, 1994.
- Szymanski S, Kane J, **Lieberman JA**: Trait Markers in Schizophrenia: Are They Diagnostic? In: Widiger et al., (eds.), DSM-IV Source Book, American Psychiatric Association, Washington, DC, USA, Pp 477-490, 1994.
- Bogerts B, **Lieberman JA**: Neuropathology in the study of psychiatric disease. In: Costa e Silva, Nadelson (eds.), International Review of Psychiatry, American Psychiatric Press, Washington DC, USA, Pp 515-545, 1993.
- Lieberman JA**, Saltz BL: Tardive Tourette's: TD formfruste or a distinct clinical syndrome? In: Joseph A (ed.), Disorders of Movement in Psychiatry and Neurology. Blackwell Scientific Publications, Cambridge, MA, USA, Pp 134-138, 1992.
- Saltz BL, **Lieberman JA**: Spontaneous and drug induced disorders of movement in the elderly. In: Joseph A (ed.), Disorders of Movement in Psychiatry and Neurology, Blackwell Scientific Publications, Cambridge, MA, USA, Pp 155-166, 1992.
- Lemus CZ, **Lieberman JA**: Antidepressant induced myoclonus. In: Joseph A (ed.), Disorders of Movement in Psychiatry and Neurology, Blackwell Scientific Publications, Cambridge, MA, USA, Pp 146-154, 1992.
- Lieberman JA**, Safferman A: Clinical profile of clozapine: Adverse reactions and agranulocytosis. In: Lapiere Y, Jones B (eds.), Clozapine in treatment resistant schizophrenia: A scientific update, Royal Society of Medicine Services Limited, London, UK, Pp 3-14, 1992.
- Mayerhoff DI, **Lieberman JA**: Behavioral Effects of Neuroleptics. In: Kane JM, **Lieberman JA** (eds.), Adverse Effects of Psychotropic Drugs, The Guilford Press, New York, NY, USA, Pp. 128-138, 1992.
- Lemus CZ, **Lieberman JA**: Neuromuscular Effects of Antidepressants and Lithium. In: Kane JM, **Lieberman JA** (eds.), Adverse Effects of Psychotropic Drugs, The Guilford Press, New York, NY, USA, Pp. 165-174, 1992.
- Kane JM, **Lieberman JA**: Tardive Dyskinesia. In: Kane JM, **Lieberman JA** (eds.), Adverse Effects of Psychotropic Drugs, The Guilford Press, New York, New York, USA, Pp. 235-245, 1992.
- Lieberman JA**, Jody D, Alvir J, Borenstein M, Mayerhoff D: Negative Symptoms in Schizophrenia: Relationship to Positive Symptoms and Outcome. In: Marneros A, Tsuang M, Andreasen N (eds.), Negative versus Positive Schizophrenia, Springer-Verlag, Berlin, Germany, Pp 109-125, 1991.
- Bogerts B, Falkai P, Degreaf G, **Lieberman JA**: Neuropathological and Brain Imaging Studies in Positive and Negative Schizophrenia. In: Maneros A, Tsuang M, Andreasen N (eds.), Negative versus Positive Schizophrenia, Springer-Verlag, Berlin, Germany, Pp 292-316, 1991.
- Robinson D, Jody D, **Lieberman JA**: Provocative Tests with Methylphenidate in Schizophrenia and Schizophrenia Spectrum Disorders. In: Greenhill LL, Osman BB (eds.), Ritalin theory and patient management, Mary Ann Liebert, Inc., New York, NY, USA, Pp 309-320, 1991.

- Lieberman JA** Johns C, Pollack S, Masiar S, Bookstein P, Cooper T, Iadorola M, Kane J: Biochemical Effects of Clozapine in Cerebrospinal Fluid of Patients with Schizophrenia. In: Schulz SC and Tamminga CA (eds.), Schizophrenia Research - Advances in Neuropsychiatry and Psychopharmacology, Vol.1, Raven Press, New York, NY, USA, Pp 341-349, 1991.
- Bogerts B, Falkai P, Degreef G, Ashtari M, **Lieberman JA**: Postmortale und kernspintomographische Untersuchungen an schizophrenen Patienten - Korrelation mit schizophrener Plus- und Minussymptomatik. In: H.-J. Möller-E. Pelzer (Hrsg.) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer-Verlag, Heidelberg, Germany, Pp 103-113, 1990.
- Johns CA, Mayerhoff DI, **Lieberman JA**, Kane JM: Schizophrenia: Alternative Neuroleptic Strategies. In: Angrist B and Schulz SC (eds) The Neuroleptic Nonresponsive Patient: Characterization and Treatment. APA Press, Washington, DC, USA, Pp 51-66, 1990.
- Kane JM, **Lieberman JA**, Johns CA: Clozapine in Refractory Schizophrenia. In: Angrist B and Schulz SC (eds) The Neuroleptic Nonresponsive Patient: Characterization and Treatment. APA Press, Washington, DC, USA, Pp 153-164, 1990.
- Kane J, **Lieberman JA**, Woerner M, Borenstein M, Alvir J: Tardive dyskinesia: New research. In: Schulz SC, Tamminga CA (eds.), Schizophrenia: Scientific Progress. Oxford University Press, New York, NY, USA, Pp. 381-386, 1989.
- Lieberman JA**, Alvir J: Dopamine Receptor Function in Tardive Dyskinesia. In: Belmaker RH, Sandler M, Bahlstrom A (eds.), Progress in Catecholamine Research. Part C: Clinical Aspects, Alan R. Liss, New York, NY, USA, Pp 5-8, 1988.
- Kane JM, **Lieberman JA**: Maintenance pharmacotherapy in schizophrenia. In: Meltzer HY (ed.), Psychopharmacology, The Third Generation of Progress: The Emergence of Molecular Biology and Biological Psychiatry, Raven Press, New York, NY, USA, Pp. 1103-1109, 1987.
- Kane JM, Woerner M, Sarantakos S, Kinon B, **Lieberman JA**: Do low-dose neuroleptics prevent or ameliorate tardive dyskinesia? In: Casey DE, Gardose G (eds.), Neuroleptics and Tardive Dyskinesia: From Dogma to Reason, American Psychiatric Press, New York, NY, USA, Pp. 99-108, 1986.
- Lieberman JA**, Cooper TB, Suckow RF, Steinberg H, Borenstein M, Brenner R, Kane JM: Tricyclic antidepressant and metabolite levels in chronic renal failure. In: Pfeifer, Siegfried (ed.), Pharmacokinetics, An Abstracts Collection, Vol.1, No. 4, Pp 268, 1986.
- Lieberman JA**, Kane JM, Gadaleta D, Ramos-Lorenzi J, Bergmann K, Wegner J, Novacenko H: Methylphenidate challenge tests and course of schizophrenia. In: Burrows GH, Norman TR, Dennerstein L (eds.), Clinical and Pharmacological Studies in Psychiatric Disorders, John Libbey Ltd., London, UK, Pp 189-195, 1985.
- Kane J, Woerner M, **Lieberman JA**: Tardive Dyskinesia: Prevalence, Incidence, and Risk Factors. In: T Chase, D Casey, J Gerlach, and V Christensen (eds.), Dyskinesia - Research and Treatment. Springer-Verlag, Heidelberg, Germany, Pp 72-77, 1985.
- Kane J, Woerner M, **Lieberman JA**, Kinon B: Tardive Dyskinesia. In: Jeste DV, Wyatt RJ (eds.), Neuropsychiatric Movement Disorders, American Psychiatric Press, Inc., Washington, DC, USA, Pp 97-118, 1984.
- Kane J, Woerner M, Weinhold P, Kinon B, **Lieberman J**, Borenstein M: Incidence and severity of tardive dyskinesia in affective illness. In: Gardos G, Casey D (eds.), Tardive Dyskinesia and Affective Disorders, American Psychiatric Press, Washington, DC, USA, Pp 21-28, 1983.